<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/251605-substituted-thiophenes-as-glucagon-receptor-antagonists by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:49:43 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 251605:SUBSTITUTED THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">SUBSTITUTED THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A compound structurally represented by Formula 1 or a pharmaceutically acceptable salt thereof as glucagon receptor antagonists.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>This patent application claims the benefit of United States Provisional Patent<br>
Application No. 60/65249 filed February 11,2005.<br>
This invention relates to compounds that are antagonists of the action of glucagon<br>
on the glucagon receptor, or inverse agonists of the glucagon receptor, and to<br>
pharmaceutical compositions thereof, and to the uses of these compounds and<br>
compositions in the treatment of the human or animal body. The invention also relates to<br>
intermediates and methods of making the glucagon antagonists, inverse agonists, and<br>
pharmaceutical compositions thereof. The present compounds show a high affinity and<br>
selective binding for the glucagon receptor, and as such are useful in the treatment of<br>
disorders responsive to the modulation of glucagon receptors, such as diabetic and other<br>
glucagon related metabolic disorders, and the like.<br>
Glucagon is a key hormonal agent that, in cooperation with insulin, mediates<br>
homeostatic regulation of blood glucose. Glucagon primarily acts by stimulating certain<br>
cells (important among these are liver cells) to release glucose when blood glucose levels<br>
fall. The action of glucagon is opposite to that of insulin, which stimulates cells to take<br>
up and store glucose whenever blood glucose levels rise. Both glucagon and insulin are<br>
peptide hormones. Native glucagon is a 29 amino acid peptide and is produced in the<br>
alpha islet cells of the pancreas and insulin is produced in the beta islet cells. Glucagon<br>
exerts its action by binding to and activating its receptor, which is a member of the<br>
Glucagon-Secretin branch of the 7-transmembrane G-protein coupled receptor family.<br>
The receptor functions by activating the adenylyl cyclase second messenger system<br>
resulting in an increase in cAMP levels. The glucagon receptor, or naturally occurring<br>
variants of the receptor, may possess intrinsic constitutive activity, in vitro as well as<br>
in vivo (i.e. activity in the absence of an agonist). Compounds acting as inverse agonists<br>
can inhibit this activity.<br>
Diabetes mellitus is a common disorder of glucose metabolism. The disease is<br>
characterized by hyperglycemia and may be classified as type 1 diabetes, the insulin-<br>
dependent form, or type 2 diabetes, which is non-insulin-dependent in character. Subjects<br>
with type 1 diabetes are hyperglycemic and hypoinsulinemic, and the conventional<br>
treatment for this form of the disease is to provide insulin. However, in some patients<br>
with type 1 or type 2 diabetes, absolute or relative elevated glucagon levels have been<br>
shown to contribute to the hyperglycemic state. Both in healthy control animals as well as<br>
in animal models of type 1 and type 2 diabetes, removal of circulating glucagon with<br>
selective and specific antibodies has resulted in reduction of the glycemic level. Mice<br>
with a homozygous deletion of the glucagon receptor exhibit increased glucose tolerance.<br>
Also, inhibition of glucagon receptor expression using antisense oligonucleotides<br>
ameliorates diabetic syndrome in db/db mice. These studies suggest that glucagon<br>
suppression or an action that antagonizes glucagon could be a useful adjunct to<br>
conventional treatment of hyperglycemia in diabetic patients. The action of glucagon can<br>
be suppressed by providing an antagonist or an inverse agonist, i.e. substances that<br>
prevent or inhibit constituitive, or glucagon-induced, glucagon receptor mediated<br>
responses.<br>
Several publications disclose peptides that are stated to act as glucagon<br>
antagonists. Probably, the most thoroughly characterized antagonist is DesHis'fGlu9]-<br>
glucagon amide (Unson et al., Peptides 10,1171 (1989); Post et al., Proc. Natl. Acad. Sci.<br>
USA 90,1662 (1993)). Other antagonists are DesHis1, Phe6[Glu9]-glucagon amide<br>
(Azizh et al., Bioorganic &amp; Medicinal Chem. Lett. 16,1849 (1995)) and NLeu9,Ala11,16-<br>
glucagon amide (Unson et al., J. Biol. Chem. 269 (17), 12548 (1994)). Peptide<br>
antagonists of peptide hormones are often potent, however they are generally known not<br>
to be orally available because of degradation by physiological enzymes, and poor<br>
distribution in vivo. Therefore, orally available non-peptide antagonists of peptide<br>
hormones are generally preferred.<br>
A number of publications have appeared in recent years reporting non-peptide<br>
agents that act at the glucagon receptor. In spite of the number of treatments for diseases<br>
that involve glucagon, the current therapies suffer from one or more inadequacies,<br>
including poor or incomplete efficacy, unacceptable side effects, and contraindications for<br>
certain patient populations. Thus there remains a need for improved treatments using<br>
alternative or improved pharmaceutical agents mat modulate glucagon receptor activity<br>
and treat the diseases that could benefit from glucagon receptor modulation. The present<br>
invention provides such a contribution to the art based on the finding that a novel class of<br>
compounds has a high affinity, selective, and potent inhibitory activity at the glucagon<br>
receptor. The present invention is distinct in the particular structures and their activities.<br>
SUMMARY OF THE INVENTION<br>
The present invention provides a compound structurally represented by Formula I:<br><br>
or a pharmaceutivally acceptable salt thereof wherein:<br>
Y is -O-, -S-, or-O-CH2-;<br>
Q, D, X and T independently represent carbon or nitrogen, provided that no more than<br>
two of Q, D, X and T are nitrogen;<br>
Rl is -hydrogen, -OH, or -halogen;<br>
R2 is -hydrogen, or -(C1-C3) alkyl;<br>
R3 and R4 are independently at each occurrence -hydrogen, -halogen, -CN, -(C1-C7)<br>
alkoxy, -(C1-C7) alkyl, or -(C2-C7) alkenyl;<br>
R5 and R14 are independently<br>
-hydrogen, -(C1-C12) alkyl, -(C3-C12)cycloalkyl, -(C3-C12)cycloalkyl-(C1-C12) alkyl, -<br>
phenyl, -phenyl-phenyl-(C1-C12)alkyl, -phenyl-(C3-C12)cycloalkyl, -aryl, -aryl-(C1-<br>
C12)alkyl, -heteroaryl, -heteroaryl-(C1-C12)alkyl, -(C2-C12)alkenyl, -(C3-<br>
C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-C12)alkyl, -aryl-(C2-<br>
C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C8-C12)cycloalkynyl, -<br>
aryl-( C2-C12)alkynyl, or -heteroaryl-( C2-C12)alkynyl,<br>
wherein -(C1-C12)alkyl, -(C3-C12)cycloalkyl, -phenyl, -phenyl-pheny(C1-<br>
C12)alkyl, -phenyl-(C3-C12)cycloalkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -<br>
heteroaryl-(C1-C12)alkyl, -heterocycloalkyl, -heterocycloalkyl-(C1-C12)alkyl, -<br>
(C2-C12)alkenyl, -(C3-C12)cycloaIkenyl, -aryl-(C2-C,0)alkenyl, -heteroaryl-(C2-<br>
C10)alkenyl, -(C2-C12)alkynyl, -(C8-C12) cycloalkynyl, -aryl-(C2-C12)alkynyl, or -<br>
heteroaryl-(C2-C12)alkynyl are each optionally substituted with from one to three<br>
substituents each independently selected from the group consisting of -hydrogen, -<br>
hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl, -(C1-C7)alkyl-COOR12, -(C1-<br>
C7)alkoxy, -(C3-C7)cycloalkyl, -aryloxy, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl,-<br>
heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -<br>
NR12C(O)R12, -NR12S02R12, -SR12, -S(O)R12, -S(O)2R12, and<br>
-S(O)2N(R12)2;<br>
wherein optionally R5 and R14 may form a four, five, or six membered ring with<br>
the atom to which they are attached, and the ring so formed may optionally<br>
include one or two double bonds, and optionally may be substituted with up to .<br>
four halogens.<br>
R6 and R7 are independently<br>
-hydrogen, -halogen, -hydroxy, -CN, -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl,<br>
-aryl, -heteroaryl, -(C3-C7)cycloalkyl, or -(C3-C7)heterocycloalkyl,<br>
wherein -(C2-C7)alkenyl, -(C1-C7)alkyl, -(Q-C7) alkoxy, -aryl; -heteroaryl, -(C3-<br>
C7)cycloalkyl, -(C3-C7)heterocycloalkyl, are each optionally substituted with from<br>
one to three substituents independently selected from the group consisting of -<br>
hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl, -(C1-C7)alkyl-<br>
COOR12, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryloxy, -aryl, -aryl-(C1-C7)alkyl,<br>
-heteroaryl, -heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -<br>
N(R12)2, -NR12C(O)R12, -C(O)NR12R12, -NR12S02R12, -SR12, -S(O)R12, -<br>
S(O)2R12, and -S(O)2N(R12)2;<br>
provided however that wherein D is nitrogen, men R6 or R7 are not attached to D,<br>
and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and<br>
provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and<br>
provided that wherein X is nitrogen, then R6 or R7 are not attached to X;<br>
and wherein R6 and R7 may optionally form a six membered ring with the atoms<br>
to which they are attached, and the ring so formed may optionally contain up to<br>
two oxygens, and further the ring so formed may optionally be substituted with up<br>
to four halogens;<br>
R8 and R9 are independently at each occurrence<br>
-hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl, -CF3, -(C1-C7)alkoxy, -(C3-<br>
C7)cycIoalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -<br>
aryloxy, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)<br>
R12, -N R12S02 R12, -SR12, -S(O)R12, -S(O)2 R12, or -S(O)2N(R12)2;<br>
wherein -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-<br>
C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, are each optionally<br>
substituted with from one to three substituents independently selected from the<br>
group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-<br>
C7)alkyl, -(C1-C7)alkyl-COOR12, -(C1-C7)alkoxyl, -(C3-C7)cycloalkyl, -aryloxy, -<br>
aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heterocycloalkyl, -C(O)R12, -COOR12, -<br>
OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -C(O)NR12R12, -NR12SO2<br>
R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2;<br>
R10 is independently<br>
-hydrogen, -halogen, -(C1-C12)alkyl, -cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl,<br>
-heteroaryl -(C1-C7)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl,<br>
-aryl-(C2-Cl0)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl,<br>
-(C8-C12)cycloalkynyl, -aryl-(C2-C12)alkynyl, or -heteroaryl-(C2-C12)alkynyl,<br>
wherein -(C1-C12)alkyl, -cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl,<br>
-heteroaryl -(C1-C7)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl,<br>
-aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl,<br>
-(C8-C12)cycloalkynyl, -aryl-(C2-C12)alkynyl,-heteroaryl-(C2-C12)alkynyl,<br>
are each optionally substituted with from one to three substituents each<br>
independently selected from the group consisting of -hydrogen, -hydroxy, -cyano,<br>
-nitro, -halo, -oxo, -(C1-C7)alkyl, -(C1-C7)alkyl-COOR12, -(C1-C7)alkoxyl, -(C3-<br>
C7)cycloalkyl, -aryloxy, -aryl, -aryl-Cj-C? alkyl, -heteroaryl, -heterocycloalkyl, -<br>
C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -<br>
NR12S02 R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2;<br>
R11 is independently at each occurrence<br>
-hydrogen;<br>
, wherein the zig-zag mark represents the point of<br><br>
attachment to the Rl 1 position in formula I,<br>
wherein A, G, and E independently represent carbon or nitrogen, provided that no<br>
more than two of A, G, and E are nitrogen;<br>
provided however that wherein A is nitrogen, then R8 or R9 are not attached to A,<br>
and provided that wherein G is nitrogen, then R8 or R9 are not attached to G, and<br>
provided that wherein E is nitrogen, then R8 or R9 are not attached to E;<br>
 , wherein the zig-zag mark represents the point of<br>
attachment to the R11 position in formula I, wherein m is an integer of 0,1,2, or<br>
3, and when m is 0 then (CH2)m is a bond,<br>
provided however that wherein D is nitrogen, then Rl 1 is not attached to D, and<br>
provided that wherein T is nitrogen, then R11 is not attached to T, and provided<br>
that wherein Q is nitrogen, then Rl 1 is not attached to Q, and provided that<br>
wherein X is nitrogen, then Rl 1 is not attached to X;<br>
R12 is independently at each occurrence -hydrogen or -(C1-C7) alkyl;<br>
R13 is independently at each occurrence -hydrogen, -halogen, -(C1-C7) alkyl, -CF3, -<br>
OCF3, or -(C2-C7)alkenyl<br>
wherein -(C1-C7) alkyl, -(C2-C7)alkenyl are each optionally substituted once with<br>
substituents independently selected from the group consisting of -CF3, -OCF3.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
The present invention provides compounds and pharmaceutical compositions that<br>
are useful as glucagon receptor antagonists or inverse agonists. In another aspect the<br>
present invention provides compounds that are selective antagonists or inverse agonists of<br>
the glucagon receptor over the GLP-1 receptor. In yet another aspect, the present<br>
invention provides compounds, pharmaceutical compositions, and methods useful in the<br>
treatment of diabetic and other glucagon related metabolic disorders, and other disorders<br>
associated with glucagon receptor. In another aspect the present invention provides novel<br>
intermediates useful in preparation of the glucagon receptor antagonists of the invention.<br>
In one embodiment, the present invention provides compounds of Formula I as<br>
described in detail herein. While all of the compounds of the present invention are useful,<br>
certain of the compounds are particularly interesting and are preferred. The following<br>
listing sets out several groups of preferred compounds. It will be understood that each of<br>
the listings may be combined with other listings to create additional groups of preferred<br>
embodiments as indicated herein.<br>
In a preferred embodiment, the present invention provides a compound<br>
structurally represented by Formula la:<br><br>
or a pharmaceutically acceptable salt thereof wherein:<br>
Yis-O, -S-,or-O-CH2-;<br>
Q, D, and T independently represent carbon or nitrogen, provided that no more than two<br>
of Q, D, and T are nitrogen;<br>
Rl is -hydrogen, or -OH;<br>
,R2 is-hydrogen;<br>
R3 and R4 are independently at each occurrence -hydrogen, or -halogen;<br>
R5 and R14 are independently<br>
-hydrogen, -(C1-C12) alkyl, -(C3-C12)cycloalkyl, -(C3-C12)cycloalkyl-(C1-C12) alkyl,<br>
-(C2-C12)alkenyl, -(C3-C12)cycIoalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-<br>
C12)alkyl, -(C2-C12)alkynyl, or -(C8-C12)cycloaIkynyl;<br>
wherein -(C1-C12) alkyl, -(C3-C12)cycloalkyl, -(C3-C12)cycloalkyl-(C1-C12) alkyl,<br>
-(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-<br>
C12)alkyl, -(C2-C12)alkynyl, or -(C8-C12)cycloalkynyl are each optionally<br>
substituted with one to three halogens;<br>
wherein optionally R5 and R14 may form a four, five, or six membered ring with<br>
the atom to which they are attached, and the ring so formed may optionally<br>
include one or two double bonds, and optionally may be substituted with up to<br>
three halogens.<br>
R6 and R7 are independently<br>
-hydrogen, -halogen, -hydroxy, -CN, -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl,<br>
-(C3-C7)cycloalkyl, or -(C3-C7)heterocycloalkyl,<br>
wherein -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl, -(C3-C7)cycloalkyl, or<br>
-(C3-C7)heterocycloalkyl, are each optionally substituted with one to three<br>
halogens;<br>
provided however that wherein D is nitrogen, then R6 or R7 are not attached to D,<br>
and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and<br>
provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and<br>
wherein R6 and R7 may optionally form a six membered ring with the atoms to<br>
which they are attached, and the ring so formed may optionally contain up to two<br>
oxygens, and further the ring so formed may optionally be substituted with up to<br>
four halogens;<br>
R8 and R9 are independently at each occurrence<br>
-hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl, -CF3, -(C1-C7)alkoxy, -(C3-<br>
C7)cycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -<br>
NR12C(O) R12, -N R12SO2 R12, -SR12, -S(O)R12, -S(O)2 R12, or -S(O)2N(R12)2;<br>
wherein -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, are each optionally<br>
substituted with from one to three halogens;<br>
R10 is independently -hydrogen;<br>
Rl 1 is independently at each occurrence<br>
-hydrogen;<br>
 , wherein the zig-zag mark represents the point of<br>
attachment to the Rl 1 position in formula I;<br>
wherein A, G, and E independently represent carbon or nitrogen, provided that no<br>
more than two of A, G, and E are nitrogen;<br>
provided however that wherein A is nitrogen, then R8 or R9 are not attached to A,<br>
and provided that wherein G is nitrogen, then R8 or R9 are not attached to G, and<br>
provided that wherein E is nitrogen, then R8 or R9 are not attached to E; and<br>
R12 is independently at each occurrence -hydrogen or -(C1-C7) alkyl.<br>
In another preferred embodiment, the present invention provides a compound<br>
structurally represented by Formula lb:<br><br>
or a pharmaceutically acceptable salt thereof wherein:<br>
Yis-O-,-S-, or-O-CH2-;<br>
Q, D, and T independently represent carbon or nitrogen, provided that no more than two<br>
of Q, D, and T are nitrogen;<br>
Rl is -hydrogen, or -OH;<br>
R2 is -hydrogen;<br>
R3 and R4 are -hydrogen;<br>
R5 and R14 are independently<br>
-hydrogen, -(C1-C12) alkyl, -(C3-C12)cycloalkyl, -(C3-C12)cycloalkyl-(C1-C12) alkyl,<br>
-(C2-:C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-<br>
C12)alkyl, -(C2-C12)alkynyl, or -(C8-C12)cycloaIkynyl;<br>
wherein -(C1-C12) alkyl, -(C3-C12)cycloalkyl, -(C3-C12)cycloalkyl-(C,-C12) alkyl,<br>
-(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalky(C1-<br>
C12)alkyl, -(C2-C12)alkynyl, or -(C8-C12)cycloalkynyl are each optionally<br>
substituted with one to three halogens;<br>
wherein optionally R5 and R14 may form a four, five, or six membered ring with<br>
the atom to which they are attached, and the ring so formed may optionally<br>
include one or two double bonds, and optionally may be substituted with up to<br>
three halogens.<br>
R6 and R7 are independently<br>
-hydrogen, -halogen, -hydroxy, -CN, -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl,<br>
-(C37C7)cycloalkyl, or -(C3-C7)heterocycloalkyl,<br>
wherein -(C1-C7)a]koxy, -(C2-C7)alkenyl, -(C1-C7)alkyl, -(C3-C7)cycloalkyl, or<br>
-(C3-C7)heterocycloalkyl, are each optionally substituted with one to three<br>
halogens;<br>
provided however that wherein D is nitrogen, then R6 or R7 are not attached to D,<br>
and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and<br>
provided that wherein Q is nitrogen, men R6 or R7 are not attached to Q, and<br>
wherein R6 and R7 may optionally form a six membered ring with the atoms to<br>
which they are attached, and the ring so formed may optionally contain up to two<br>
oxygens, and further the ring so formed may optionally be substituted with up to<br>
four halogens;<br>
R8 and R9 are independently at each occurrence<br>
-hydrogen,- -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl, -CF3, -(C1-C7)alkoxy, -(C3-<br>
C7)cyclpalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -<br>
NR12C(O) R12, -N R12S02 R12, -SR12, -S(O)R12, -S(O)2 R12, or -S(O)2N(R12)2;<br>
wherein -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyI, are each optionally<br>
substituted with from one to three halogens;<br>
R10 is independently -hydrogen;<br>
Rl 1 is independently at each occurrence<br>
-hydrogen;<br>
 , wherein the zig-zag mark represents the point of<br>
attachment to the R11 position in formula I;<br>
wherein A, G, and E independently represent carbon or nitrogen, provided that no<br>
more than two of A, G, and E are nitrogen;<br>
provided however that wherein A is nitrogen, then R8 or R9 are not attached to A,<br>
and provided that wherein G is nitrogen, then R8 or R9 are not attached to G, and<br>
provided that wherein E is nitrogen, then R8 or R9 are not attached to E; and<br>
R12 is independently at each occurrence -hydrogen or -(C1-C7) alkyl.<br>
In another preferred embodiment, the present invention provides a compound<br>
structurally represented by Formula Ic;<br><br>
or a pharmaceutically acceptable salt thereof wherein:<br>
Y is -O-, -S-, or-O-CH2-;<br>
Q, D, and T are carbon;<br>
Rl is -hydrogen;<br>
R2 is -hydrogen;<br>
R3 and R4 are -hydrogen;<br>
R5 is hydrogen;<br>
R14 is<br>
-(C1-C12) alkyl, -(C3-C12)cycloalkyl, -(C3-C12)cycloalkyl-(C1-C12) alkyl, -(C2-<br>
C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-<br>
C12)alkyl, -(C2-C12)a]kynyl) or -(C8-C12)cycloalkynyl;<br>
wherein -(C1-C12) alkyl, -(C3-C12)cycloalkyl, -(C3-C12)cycloalkyl-(C1-C12) alkyl,<br>
-(C2-C12)alkenyl, -(C3-.C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-<br>
C12)alkyl, -(C2-C12)alkynyl, or -(C8-C12)cycloalkynyl are each optionally<br>
substituted with one to three halogens;<br>
R6 and R7 are independently<br>
-hydrogen, -halogen, -hydroxy, -CN, -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl,<br>
-(C3-C7)cycloalkyl, or-(C3-C7)heterocycloalkyl,<br>
wherein -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl, -(C3-C7)cycloalkyl, or<br>
-(C3-C7)heterocycloalkyl, are each optionally substituted with one to three<br>
halogens;<br>
provided however that wherein D is nitrogen, then R6 or R7 are not attached to D,<br>
and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and<br>
provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and<br>
wherein R6 and R7 may optionally form a six membered ring with the atoms to<br>
which they are attached, and the ring so formed may optionally contain up to two<br>
oxygens, and further the ring so formed may optionally be substituted with up to<br>
four halogens;<br>
R8 and R9 are independently at each occurrence<br>
-hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl, -CF3, -(C1-C7)alkoxy, -(C3-<br>
C7)cycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -<br>
NR12C(O) R12, -N R12S02 R12, -SR12, -S(O)R12, -S(O)2 R12, or -S(O)2N(R12)2;<br>
wherein -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycIoalkyl, are each optionally<br>
substituted with from one to three halogens;<br>
R10 is independently -hydrogen;<br>
Rl 1 is independently at each occurrence<br>
 , wherein the zig-zag mark represents the point of attachment<br>
to the Rl I position in formula I;<br>
wherein A, G, and E independently represent carbon or nitrogen, provided that no<br>
more than two of A, G, and E are nitrogen;<br>
provided however that wherein A is nitrogen, then R8 or R9 are not attached to A,<br>
and provided that wherein G is nitrogen, then R8 or R9 are not attached to G, and<br>
provided that wherein E is nitrogen, then R8 or R9 are not attached to E; and<br>
R12 is independently at each occurrence -hydrogen or -(C1-C7) alkyl.<br>
Other embodiments of the invention are provided wherein each of the<br>
embodiments described herein above is further narrowed as described in the following<br>
preferences. Specifically, each of the preferences below is independently combined with<br>
each of die embodiments above, and the particular combination provides another<br>
embodiment in which the variable indicated in the preference is narrowed according to<br>
the preference.<br>
Preferably Y is -O-. Preferably Y is -S-. Preferably Y is -O-CH2-. Preferably<br>
Q, D, X, and T independently represent carbon. Preferably X is carbon and Rl 1 is<br>
attached to X. Preferably one of are nitrogen. Preferably T is nitrogen. Preferably two of<br>
Q, D, and T are nitrogen.<br>
Preferably Rl is -hydrogen, or -OH. Preferably Rl is -hydrogen. Preferably Rl is<br>
-OH. Preferably R2 is -hydrogen. Preferably R3 and R4 are -hydrogen. Preferably R3<br>
halogen and R4 is -hydrogen.<br>
Preferably R5 is -(C1-C8) alkyl(optionally substituted with 1 to 3 halogens).<br>
Preferably R5 is ethyl, propyl, isopropyl, butyl, tertbutyl, 3-methyl-butyl, pentyl, hexyl,<br>
heptyl, octyl, 3,3-dimethylbutyl, 2-methylpropyl, 4-methylpentyl, 2,2-dimethylpropyl,<br>
3,3,3-trifluoropropyl, or 4,4,4-trifluorbutyl. Preferably R5 is isopropyl, butyl, tertbutyl, 3-<br>
methyl-butyl, pentyl, 3,3-dimethylbutyl, 2-methylpropyl, 4-methylpentyl, 2,2-<br>
dimethylpropyl, 3-trifluoropropyl, or 4,4,4-trifluorbutyl. Preferably R5 is isopropyl, 3-<br>
methyl-butyl, trifluoropropyl, or 4,4,4-trifluorbutyl.<br>
Preferably R5 is -(C3-C7)cycloalkyl. Preferably R5 is cyclopropyl, cyclobutyl,<br>
cyclopentyl, or cyclohexyl. Preferably R5 is cyclopropyl. Preferably R5 is cyclobutyl.<br>
Preferably R5 is cyclopentyl. Preferably R5 is cyclohexyl.<br>
Preferably R5 is -(C1-C6)alkyl-(C3-C7)cycloalkyl. Preferably R5 is<br>
-(C1-C3)alkyl-(C3-C6)cycloalkyl. Preferably R5 is -(C1-C3)alkyl-cyclopropyl. Preferably<br>
R5 is -(C1-C3)alkyl-cyclobutyl. Preferably R5 is -(C1-C3)alkyl-cyclopentyl. Preferably R5<br>
is -(C1-C3)alkyl-cyclohexyl.<br>
Preferably R5 is -(C3-C7)cycloalkyl-(C1-C6)alkyl(optionally substituted with 1 to 3<br>
halogens). Preferably R5 is -cyclopropyl-(C1-C6)alkyl(optionally substituted with 1 to 3<br>
halogens). Preferably R5 is -cyclobutyl-(C1-C6)alkyl(optionally substituted with 1 to 3<br>
halogens). Preferably R5 is -cycIopentyl-(C1-C6)alkyl(optionally substituted with 1 to 3<br>
halogens). Preferably R5 is -cyclohexyl-(C1-C6)alkyl(optionalIy substituted with 1 to 3<br>
halogens).<br>
Preferably R6 is -H, -halogen, -hydroxy, hydroxymethyl, or -(C1-C6)alkyl<br>
(optionally substituted with 1 to 3 halogens). Preferably R6 is -H, -halogen, or<br>
-(C1-C3)alkyl (optionally substituted with 1 to 3 halogens). Preferably R6 is -H, -halogen,<br>
or -CHa. Preferably R6 is -H. Preferably R6 is fluorine, chlorine, or bromine. Preferably<br>
R6is-CH3.<br>
Preferably R7 is -H, -halogen, -hydroxy, hydroxymethyl, or -(C1-C6) alkyl<br>
(optionally substituted with 1 to 3 halogens). Preferably R7 is -H, -halogen, or<br>
-(C1-C3)alkyl (optionally substituted with 1 to 3 halogens). Preferably R7 is -H, -halogen,<br>
or -CH3. Preferably R7 is -H. Preferably R7 is fluorine, chlorine, or bromine. Preferably<br>
R7 is -CH3.<br>
Preferably R6 and R7 are -H. Preferably R6 is halogen and R7 is -H. Preferably<br>
R6 is -H and R7 is -CH3. Preferably R6 and R7 are -CH3. Preferably R6 and R7 are CH3<br>
and are attached to D and T respectively.<br>
Preferably Rl 1 is vherein the zig-zag mark represents the<br>
point of attachment to the R11 position in formula I; wherein A, G, and E are carbon.<br>
Preferably R8 is -halogen, -(C1-C6)alkyl(optionally substituted with 1 to 3<br>
halogens), or -(C1-C6)alkoxy. Preferably R8 is -H or -halogen. Preferably R8 is -H.<br>
Preferably R9 is -(C1-C6) alkyl (optionally substituted with 1 to 3 halogens). Preferably<br>
R9 is methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, trifluoromethyl, 3-methyl-butyI,<br>
pentyl, hexyl, 3,3-dimethylbutyl, 2-methylpropyl, 4-methylpentyl, 2,2-dimethylpropyl, 3-<br>
trifluoropropyl, or 4-trifluorbutyl. Preferably R9 is isopropyl, tertbutyl, or trifluoromethyl.<br>
Preferably R8 is -H, and R9 is isopropyl, tertbutyl, or trifluoromethyl;<br>
 Preferably R14 is -(C1-C8) alkyl(optionally substituted with 1 to 3 halogens).<br>
Preferably R14 is ethyl, propyl, isopropyl, butyl, tertbutyl, 3-methyl-butyl, pentyl, hexyl,<br>
heptyl, octyl, 3,3-dimethylbutyl, 2-methylpropyl, 4-methylpentyl, 2,2-dimethylpropyl,<br>
3,3,3-trifluoropropyl, or 4,4,4-trifluorbutyl. Preferably R14 is isopropyl, butyl, tertbutyl,<br>
3-methyl-butyl, pentyl, 3,3-dimethylbutyl, 2-methylpropyl, 4-methylpentyl, 2,2-<br>
dimethylpropyl, 3-trifluoropropyl, or 4,4,4-trifluorbutyl. Preferably R14 is isopropyl, 3-<br>
methyl-butyl, trifluoropropyl, or 4,4,4-trifluorbutyl.<br>
Preferably R14 is -(C3-C7)cycloalkyl. Preferably R14 is cyclopropyl, cyclobutyl,<br>
cyclopentyl, or cyclohexyl. Preferably R14 is cyclopropyl. Preferably R14 is cyclobutyl.<br>
Preferably R14 is cyclopentyl. Preferably R14 is cyclohexyl.<br>
Preferably R14 is -(C1-C6)alkyl-(C3-C7)cycloalkyl. Preferably R14 is<br>
-(C1-C3)alkyl-(C3-C6)cycloalkyl. Preferably R14 is -(C1-C3)alkyl-cyclopropyl. Preferably<br>
R14 is -(C1-C3)alkyl-cyclobutyl. Preferably R14 is -(C1-C3)alkyl-cyclopentyl. Preferably<br>
R14 is -(C1-C3)alkyl-cyclohexyl.<br>
Preferably R14 is -(C3-C7)cycloalkyl-(C1-C6)alkyl(optionally substituted with 1 to<br>
3 halogens). Preferably R14 is -cyclopropyl-(C1-C6) alkyl(optionally substituted with 1 to<br>
3 halogens). Preferably R14 is -cyclobutyl-(C1-C6)alkyl(optionally substituted with 1 to 3<br>
halogens). Preferably R14 is -cyclopentyl-(C|-C6)alkyl(optionally substituted with 1 to 3<br>
halogens). Preferably R14 is -cyclohexyl-(C1-C6)alkyl(optionally substituted with 1 to 3<br>
halogens).<br>
Embodiments of the invention include compounds represented by formulae XI to<br>
X126 in Table 1, and phannaceutically acceptable salts thereof.<br>
Table 1;<br><br>
The following listing sets out several groups of preferred compounds. It will be<br>
understood that each of the listings may be combined with other listings to create<br>
additional groups of preferred embodiments. Other embodiments are,<br>
1. A compound of Formula (II)<br><br>
or a pharmaceutivally acceptable salt thereof wheren Q, D, X, T and R1-R14 are<br>
defined as herein described.<br>
2. A compound of Formula (III)<br><br>
or a pharmaceutically acceptable salt thereof wherein Q, D, X, T and R1-R14 are<br>
defined as herein described.<br>
3. A compound of Formula (TV)<br><br>
or a pharmaceutically acceptable salt thereof wherein Q, D, X, T and R1-R14 are<br>
defined as herein described<br>
Other Embodiments include compounds of formulae I-IV as follows;<br>
4. wherein Y is -O-.<br>
5. wherein Y is -S-.<br>
6. wherein Y is -O-CHr-<br>
7. wherein Rl is -hydrogen, -OH, or -halogen.<br>
8. wherein Rl is hydrogen.<br>
9. wherein Rl is-OH.<br>
10. wherein Rl is halogen.<br>
11. wherein R2 is -hydrogen, or -(C i -C3) alkyl.<br>
12. wherein R2 is hydrogen.<br>
13. wherein R2 is -(C1-C3) alkyl.<br>
14. wherein R3 is -hydrogen, -halogen, -CN, -(C1-C7) alkoxy, -(Q-C7) alkyl, or -(C2-<br>
C7) alkenyl.<br>
15. wherein R3 is -hydrogen or -halogen.<br>
16. wherein R4 is -hydrogen, -halogen, -CN, -(C1-C7) alkoxy, -(C1-C7) alkyl, or -(C2-<br>
C7) alkenyl.<br>
17. wherein R4 is -hydrogen or -halogen.<br>
18. wherein R5 and R14 are independently -hydrogen, -(C1-C12) alkyl, -(C3-<br>
C12)cycloalkyl, -(C3-C12)cycloalkyl-(C1-C12) alkyl, -phenyl, -phenyl-phenyl-(C1-<br>
C12)alkyl, -phenyl-(C3-C12)cycloalkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -<br>
heteroaryl-(C1-C12)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -<br>
heterocycloalkyl, -heterocycloalkyl-(C1-C12)alkyl, -aryl-(C2-C10)alkenyl, -<br>
heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C8-C12)cycloalkynyl, -aryl-( C2-<br>
C12)alkynyl, -heteroaryl-( C2-C12)alkynyl, wherein -(C1-Cu)alkyl, -(C3-<br>
C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -phenyl-(C3-<br>
C12)cycloalkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -heteroaryl-( Ci-C12)alkyl,<br>
-heterocycloalkyl, -heterocycloalkyl-(C1-C12)alkyl, -(C2-Cu)alkenyl, -(C3-<br>
C12)cycloalkenyl, -aryl-(C2-C)0)alkenyl, -heteroaryl-(C2-CI0)alkenyl, -(C2-<br>
C12)alkynyl, -(C8-C12) cycloalkynyl, -aryl-(C2-C12)alkynyl, or -heteroaryl-(C2-<br>
C12)alkynyl are each optionally substituted with from one to three substituents<br>
each independently selected from the group consisting of-hydrogen, -hydroxy, -<br>
cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl, -(C1-C7)alkyl-COOR12, -(C1-C7)alkoxy,<br>
-(C3-C7)cycloalkyl, -aryloxy, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl,-<br>
heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -<br>
NR12C(O)R12, -NR12S02R12, -SR12, -S(O)R12, -S(O)2R12, and -<br>
S(O)2N(R12)2;<br>
19. wherein R5 and R14 are independently -hydrogen, -(C1-C12) alkyl, -(C3-<br>
C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -phenyl-(C3-<br>
C12)cycloalkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -heteroaryl-(C1-C12)alkyl, -<br>
(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-<br>
C12)alkyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2-CJ0)alkenyl, -(C2-C12)alkynyl, -<br>
(Cs-C12)cycloalkynyl, -aryl-( C2-C12)alkynyl, or -heteroaryl-( C2-C12)alkynyl<br>
wherein optionally R5 and R14 may form a four, five, or six membered ring with<br>
the atom to which they are attached, and the ring so formed may optionally<br>
include one or two double bonds, and optionally may be substituted with up to<br>
four halogens.<br>
20. wherein R5 and R14 are independently -(C1-C12) alkyl, -(C3-C12)cycloalkyl, -<br>
phenyl, -phenyl-phenyl-(Ci -Cu)alkyl, -phenyl-(C3-C12)cycloalkyl,-(C2-<br>
C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C1-<br>
C12)alkyl, -(C2-C12)alkynyl, or -(C8-C12)cycloalkynyl wherein optionally R5 and<br>
R14 may form a four, five, or six membered ring with the atom to which they are<br>
attached, and the ring so formed may optionally include one or two double<br>
bonds, and optionally may be substituted with up to four halogens.<br>
21. wherein R5 and R14 are independently -(C1-C12) alkyl, -(C3-C12)cycloalkyl, ,-<br>
(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -heterocycloalkyl-(C|-<br>
C12)alkyl, -(C2-C12)alkynyl, or -(C8-C12)cycloalkynyl wherein optionally R5 and<br>
R14 may form a four, five, or six membered ring with the atom to which they are<br>
attached, and the ring so formed may optionally include one or two double<br>
bonds, and optionally may be substituted with up to four halogens.<br>
22. wherein R6 and R7 are independently at each occurrence -hydrogen, -halogen, -<br>
hydroxy, -CN, -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl, -aryl, -heteroaryl,<br>
-(C3-C7)cycIoalkyl, -(C3-C7)heterocycloalkyl, wherein -(C2-C7)alkenyl, -(C1-<br>
C7)alkyl, -(C1-C7) alkoxy, -aryl, -heteroaryl, -(C3-C7)cycloalkyl, -(C3-<br>
C7)heterocycloalkyI, are each optionally substituted with from one to three<br>
substituents independently selected from the group consisting of -hydrogen, -<br>
hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl, -(C1-C7)alkyl-COOR12, -(C2-<br>
C7&gt;alkoxy, -(C3-C7)cycloalkyl, -aryloxy, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl,-<br>
heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2Rl2, -N(R12&gt;2, -<br>
NR12C(O)R12, -C(O)NR12R12, -NR12S02R12, -SR12, -S(O)R12, -S(O)2R12,<br>
and -S(O)2N(R12)2; provided however that wherein D is nitrogen, then R6 or R7<br>
are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are<br>
not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not<br>
attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not<br>
attached to X; and wherein R6 and R7 may optionally form a six membered ring<br>
with the atoms to which they are attached, and the ring so formed may optionally<br>
contain up to two oxygens, and further the ring so formed may optionally be<br>
substituted with up to four halogens.<br>
23. wherein R6 and R7 are independently at each occurrence -halogen, -hydroxy, -<br>
CN, -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl, -aryl, -heteroaryl, -(C3-<br>
C7)cycloalkyl, -(C3-C7)heterocycloalkyl, wherein -<c2-c7></c2-c7>
-(C1-C7) alkoxy, -aryl, -heteroaryl, -(C3-C7)cycloalkyl, -(C3-C7)heterocycloalkyl,<br>
are each optionally substituted with from one to three substituents independently<br>
selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo,<br>
-oxo, -(C,-C7)alkyl, -(C1-C7)alkyl-COOR12, -(C,-C7)alkoxy, -(C3-C7)cycloalkyl,<br>
-heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -<br>
NR12C(O)R12, -C(O)NR12R12, -NR12S02R12, -SR12, -S(O)R12, -S(O)2R12,<br>
and -S(O)2N(R12)2; provided however that wherein D is nitrogen, then R6 or R7<br>
are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are<br>
not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not<br>
attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not<br>
attached to X; and wherein R6 and R7 may optionally form a six membered ring<br>
with the atoms to which they are attached, and the ring so formed may optionally<br>
contain up to two oxygens, and further the ring so formed may optionally be<br>
substituted with up to four halogens.<br>
24. wherein R6 and R7 are independently at each occurrence -hydrogen, -halogen, -<br>
hydroxy, -CN, -(C1-C7)alkoxy, -(C2-C7)alkenyl, -(C1-C7)alkyl, wherein -(C2-<br>
C7&gt;alkenyl, -(C1-C7)alkyl, -(C1-C7) alkoxy, -aryl, -heteroaryl, -(C3-<br>
C7)cycloalkyl, -(C3-C7)heterocycloalkyl, provided however that wherein D is<br>
nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is<br>
nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is<br>
nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is<br>
nitrogen, then R6 or R7 are not attached to X.<br>
25. wherein R8 and R9 are independently at each occurrence -hydrogen, -hydroxy, -<br>
CN, -nitro, -halo, -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-<br>
(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)aIkyl, -aryloxy, -C(O)R12, -<br>
COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O) R12, -N RI2SO2<br>
R12, -SR12, -S(O)R12, -S(O)2 R12, and -S(O)2N(R12)2; and wherein -(C1-<br>
C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -<br>
heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, are each optionally substituted<br>
with from one to three substituents independently selected from the group<br>
consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl, -<br>
(C1-C7)alkyl-COOR12, -(C1-C7)alkoxyl, -(C3-C7)cycloalkyl, -aryloxy, -aryl, -<br>
aryl-(C1-C7)alkyl, -heteroaryl, -heterocycloalkyl, -C(O)R12, -COOR12, -<br>
OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -C(O)NR12R12, -<br>
NR12S02 R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2.<br>
26. wherein R8 and R9 are independently at each occurrence -hydrogen, -hydroxy, -<br>
CN, -nitro, -halo, -(C1-C7)alkyl, -(C1-C7)aIkoxy, -(C3-C7)cycloalkyt, -C(O)R12,<br>
-COOR12, -OC(O)R12, -08(O)^12, -N(R12)a, -NR12C(O) R12, -N R12S02<br>
R12, -SR12, -S(O)R12, -S(O)2 R12, and -S(O)2N(R12)2; and wherein -(Ct-<br>
C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, are each optionally substituted with<br>
from one to three substituents independently selected from the group consisting<br>
of-hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl, -(C1-C7)alkyl-<br>
COOR12, -(Ci -C7)alkoxyl, -(C3-C7)cycloalkyl, -heterocycloalkyl, -C(O)R12, -<br>
C0QR12, -0C(O)R12, -OS(O)2R12, -N(R12)t., -NR12C(O)R12, -<br>
C(O)NR12R12, -NR12S02 R12, -SR12, -S(O)R12, -8(O)^12, and -<br>
S(O)2N(R12)2.<br>
27. wherein R8 and R9 are independently at each occurrence -hydrogen, -hydroxy, -<br>
CN, -nitro, -halo, -(C1-C7)alkyl, -CF3, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -<br>
C(O)R12, -C00R12, -0C(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O) R12, -N<br>
R12S02 R12, -SR12, -S(O)R12, -S(O)2 R12, and -S(O)2N{R12)2.<br>
28. wherein R10 is independently -hydrogen, -halogen, -(C1-C12)alkyl, -cycloalkyl, -<br>
aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl -(C1-C7)alkyl, -(C2-C12)alkenyl, -<br>
(C3-C12)cycloalkenyl, -aryl-(C2-Ci0)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-<br>
C12)alkynyl, -(C8-C12)cycloalkynyl, -aryl-(C2-C12)alkynyl, -heteroaryl-(C2-<br>
C12)alkynyl, and wherein -(C1-C12)alkyl, -cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -<br>
heteroaryl, -heteroaryl -(C1-C7)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyI, -<br>
aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C]o)alkenyl, -(C2-C12)alkynyl, -(Cs-<br>
C12)cycloalkynyl, -aryl-(C2-C12)alkynyl, -heteroaryl-(C2-C12)alkynyl, are each<br>
optionally substituted with from one to three substituents each independently<br>
selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo,<br>
-oxo, -(C1-C7)alkyl, -(C1-C7)alkyl-COOR12, -(C1-C7)alkoxyl, -(C3-<br>
C7)cycloalkyl, -aryloxy, -aryl, -aryl-Ci-C7 alkyl, -heteroaryl, -heterocycloalkyl, -<br>
C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -<br>
NR12S02 R12, -SR12, -S(O)R12, -8(O)^12, and -S(O)2N(R12)2.<br>
29. wherein R10 is -hydrogen, -halogen, -(C1-C12)alkyl, -cycloalkyl -(C2-<br>
C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2-Ci0)alkenyl, -(C2-C12)alkynyl, -(C8-<br>
C12)cycloalkynyl.<br>
30. wherein R10 is -hydrogen, -halogen, -(Q-C12)alkyl.<br>
31. wherein R10 is -H.<br>
32. wherein Rl 1 is independently at each occurrence -H or<br>
, wherein the zig-zag mark represents the point of attachment<br>
to the Rll position in formulae I-IV, wherein A, G, and E independently<br>
represent carbon or nitrogen, provided that no more than two of A, G, and E are<br>
nitrogen; provided however mat wherein A is nitrogen, then R8 or R9 are not<br>
attached to A, and provided that wherein G is nitrogen, then R8 or R9 are not<br>
attached to G, and provided that wherein E is nitrogen, then R8 or R9 are not<br>
attached to E; or<br>
 , wherein the zig-zag mark represents the point of<br>
attachment to the Rl 1 position in formulae I-IV, wherein m is an integer of 0,1,<br>
2, or 3, and when m is 0 then (CH2)m is a bond, provided however that wherein D<br>
is nitrogen, then Rl 1 is not attached to D, and provided that wherein T is<br>
nitrogen, then Rll is not attached to T, and provided that wherein Q is nitrogen,<br>
then Rll is not attached to Q, and provided that wherein X is nitrogen, then Rll<br>
is not attached to X;<br>
33. wherein A, G, and E are carbon.<br>
34. wherein one of A, G, or E is nitrogen.<br>
35. wherein two of A, G, or E are nitrogen.<br>
36. wherein R12 is independently at each occurrence -hydrogen, -(C1-C7) alkyl.<br>
37. wherein R13 is independently at each occurrence -hydrogen, -halogen, -(C1-C7)<br>
alkyl, -CF3i -OCF3, -(C2-C7)alkenyl, wherein -(C1-C7) alkyl, -(C2-C7)alkenyl are<br>
each optionally substituted once with substituents independently selected from<br>
the group consisting of -CF3, -OCF3.<br>
38. wherein Q, D, X and T independently represent carbon or nitrogen, provided that<br>
no more than two of Q, D, X and T are nitrogen.<br>
39. Wherein D, Q, X and T are carbon.<br>
40. wherein X is carbon and Rll is attached to X.<br>
41. wherein D is carbon and Rll is attached to D.<br>
42. wherein X is carbon and Rll is attached to X and Rl 1 is selected from die group<br>
consisting o , wherein the zig-zag mark represents the point<br>
of attachment to the Rl 1 position in formula I, II, III, or IV, and wherein A, G,<br>
and E independently represent carbon or nitrogen, provided that no more than<br>
two of A, G, and E are nitrogen.<br>
43. wherein X is carbon and Rl 1 is attached to X and R11 is selected from the group<br>
consisting of , wherein the zig-zag mark represents the point<br>
of attachment to the Rl 1 position in formula I, n, IE, or IV, and wherein A, G,<br>
and E independently represent carbon or nitrogen, provided that no more than<br>
two of A, G, and E are nitrogen, and R8 and R9 are independently at each<br>
occurrence selected from the group consisting of -hydrogen, -hydroxy, -CN, - .<br>
nitro, -halo, -(C1-C7)alkyl, -(C1-C7)alkoxy, -(Cs-Cpjcycloalkyl, -aryl, -aryl-(C1-<br>
C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, -C(O)R12, -COOR12, -<br>
OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -N R12S02 R12, -SR12, -<br>
S(O)R12, -S(O)2 R12, and -S(O)2N(R12)2.<br>
44. wherein X is carbon and Rl 1 is attached to X and Rl 1 is selected from the group<br>
consisting of , wherein the zig-zag mark represents the point<br>
of attachment to the Rl 1 position in formula I, n, III, or IV, and wherein A, G,<br>
and E independently represent carbon or nitrogen, provided that no more than<br>
two of A, G, and E are nitrogen, and R8 and R9 are independently at each<br>
occurrence selected from the group consisting of -hydrogen, -hydroxy, -CN, -<br>
nitro, -halo, -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl.<br>
45. wherein X is carbon and Rl 1 is attached to X and Rl 1 is selected from the group<br>
consisting of , wherein the zig-zag mark represents the point<br>
of attachment to the Rl 1 position in formula I, II, III, or IV and wherein A, G,<br>
and E are carbon.<br>
46. wherein X is carbon and Rl 1 is attached to X and Rl 1 is selected from the group<br>
consisting oi wherein the zig-zag mark represents the point<br>
of attachment to the Rl 1 position in formula I, II, III, or IV, and wherein A, G,<br>
and E are carbon, and R8 and R9 are independently at each occurrence selected<br>
from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-<br>
C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -<br>
heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, -C(O)R12, -COOR12, -<br>
OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -N R12S02 R12, -SR12, -<br>
S(O)R12, -S(O)2 R12, and -S(O)aN(R12)2.<br>
47. wherein X is carbon and Rl 1 is attached to X and Rl 1 is selected from the group<br>
consisting of wherein the zig-zag mark represents the point<br>
of attachment to the Rl 1 position in formula I, II, in, or IV, and wherein A, G,<br>
and E are carbon, and R8 and R9 are independently at each occurrence selected<br>
from the group consisting of -hydrogen, -hydroxy, -CNF, -nitro, -halo, -(C1-<br>
C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl.<br>
48. wherein one of D, X, Q or T is nitrogen.<br>
49. wherein D is nitrogen.<br>
50. wherein X is nitrogen.<br>
51. wherein Q is nitrogen.<br>
52. wherein T is nitrogen.<br>
53. wherein two of D.X.Q and Tare nitrogen.<br>
54. wherein D and T are nitrogen.<br>
55. wherein Q and X are nitrogen.<br>
56. wherein m is 0,1,2, or 3.<br>
57. wherein (CH2)m is a bond.<br>
58. wherein (CH2)m is -CH2-.<br>
Due to their interaction with the glucagon receptor, the present compounds are<br>
useful in the treatment of a wide range of conditions and disorders in which an interaction<br>
with the glucagon receptor is beneficial. These disorders and conditions are defined<br>
herein as "diabetic and other glucagon related metabolic disorders". One of skill in the art<br>
is able to identify "diabetic and other glucagon related metabolic disorders" by the<br>
involvement of glucagon receptor mediated signaling either in the pathophysiology of the<br>
disorder, or in the homeostatic response to the disorder. Thus, the compounds may find<br>
use for example to prevent, treat, or alleviate, diseases or conditions or associated<br>
^pyfaptoms or sequelae, of the endocrinological system, the central nervous system, the<br>
peripheral nervous system, the cardiovascular system, the pulmonary system, and the<br>
gastrointestinal system, while reducing and or eliminating one or more of the unwanted<br>
side effects associated with the current treatments. "Diabetic and other glucagon related<br>
metabolic disorders" include, but are not limited to, diabetes, hyperglycemia, hyper<br>
insulinemia, beta-cell rest, improved beta-cell function by restoring first phase response,<br>
prandial hyperglycemia, preventing apoptosis, impaired fasting glucose (IFG), metabolic<br>
syndrome, hypoglycemia, hyper-/hypokalemia, normalizing glucagon levels, improved<br>
LDL/HDL ratio, reducing snacking, eating disorders, weight loss, polycystic ovarian<br>
syndrome (PCOS), obesity as a consequence of diabetes, latent autoimmune diabetes in<br>
adults (LADA), insulitis, islet transplantation, pediatric diabetes, gestational diabetes,<br>
diabetic late complications, micro-/macroalbuminuria, nephropathy, retinopathy,<br>
neuropathy, diabetic foot ulcers, reduced intestinal motility due to glucagon<br>
administration, short bowel syndrome, antidiarrheic, increasing gastric secretion,<br>
decreased blood flow, erectile dysfunction, glaucoma, post surgical stress, ameliorating<br>
organ tissue injury caused by reperfusion of blood flow after ischemia, ischemic heart<br>
damage, heart insufficiency, congestive heart failure, stroke, myocardial infarction,<br>
arrhythmia, premature death, anti-apoptosis, wound healing, impaired glucose tolerance<br>
(IGT), insulin resistance syndromes, syndrome X, type 1 diabetes, type 2 diabetes,<br>
hyperlipidemia, dyslipidemia, hypertriglyceridemia, hyperlipoproteinemia,<br>
hypercholesterolemia, arteriosclerosis including atherosclerosis, glucagpnomas, acute<br>
pancreatitis, cardiovascular diseases, hypertension, cardiac hypertrophy, gastrointestinal<br>
disorders, obesity, diabetes as a consequence of obesity, diabetic dyslipidemia, etc.<br>
In addition, the present invention relates to a compound of Formulae I-IV, or a<br>
pharmaceutical salt thereof; for use in inhibiting the glucagon receptor; for use in<br>
inhibiting a glucagon receptor mediated cellular response in a mammal; for use in<br>
reducing the glycemic level in a mammal; for use in treating a disease arising from<br>
excessive glucagon; for use in diabetic and other glucagon related metabolic disorders in<br>
a mammal; and for use in treating diabetes, obesity, hyperglycemia, atherosclerosis,<br>
ischemic heart disease, stroke, neuropathy, and wound healing. Thus, the uses and<br>
methods of this invention encompass a prophylactic and therapeutic administration of a<br>
compound of Formulae I-IV.<br>
The present invention is further related to the use of a compound of Formulae I-<br>
IV, or a pharmaceutical salt thereof; for the manufacture of a medicament for inhibiting<br>
the glucagon receptor; for the manufacture of a medicament for inhibiting a glucagon<br>
receptor mediated cellular response in a mammal; for the manufacture of a medicament<br>
for reducing the glycemic level in a mammal; for the manufacture of a medicament for<br>
treating a disease arising from excessive glucagon; for the manufacture of a medicament<br>
for treating diabetic and other glucagon related metabolic disorders in a mammal; and for<br>
the manufacture of a medicament for treating diabetes, obesity, hyperglycemia,<br>
atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing.<br>
The present invention further provides; a method of treating conditions resulting<br>
from excessive glucagon in a mammal; a method of inhibiting the glucagon receptor in a<br>
mammal; a method of inhibiting a glucagon receptor mediated cellular response in a<br>
mammal; a method of reducing the glycemic level in a mammal; a method of treating<br>
diabetic and other glucagon related metabolic disorders in a mammal; a method of<br>
treating diabetes, obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke,<br>
neuropathy, and wound healing; comprising administering to a mammal in need of such<br>
treatment a glucagon receptor-inhibiting amount of a compound of Formulae I-IV or a<br>
pharmaceutically acceptable salt thereof.<br>
The present invention provides a pharmaceutical composition which comprises a<br>
compound of Formulae I-IV, or a pharmaceutical salt thereof, and a pharmaceutically<br>
acceptable carrier, diluent, or excipient.<br>
In addition, the present invention relates to a pharmaceutical composition which<br>
comprises a compound of Formulae I-IV, or a pharmaceutical salt thereof, and a<br>
pharmaceutically acceptable carrier, diluent, or excipient; adapted for use in inhibiting the<br>
glucagon receptor; adapted for use in inhibiting glucagon receptor mediated cellular<br>
responses; adapted for use in reducing the glycemic level in a mammal; adapted for use in<br>
treating diabetic and other glucagon related metabolic disorders in a mammal; adapted for<br>
use in preventing or treating diabetes, obesity, hyperglycemia, atherosclerosis, ischemic<br>
heart disease, stroke, neuropathy, and wound healing.<br>
The present invention relates to a pharmaceutical composition comprising a compound or<br>
pharmaceutically acceptable salt of solvent thereof of the present invention, along with a<br>
pharmaceutically acceptable diluent or carrier, is found to show surprising properties.<br>
The pharmaceutical composition of the present invention, therefore, is synergistic.<br>
The present invention is further related to the use of a pharmaceutical composition<br>
which comprises a compound of Formulae I-IV, or a pharmaceutical salt thereof.<br>
medicament for inhibiting the glucagon receptor; for the manufacture of a medicament for<br>
inhibiting glucagon receptor mediated cellular responses; for the manufacture of a<br>
medicament for reducing the glycemic level in a mammal; for the manufacture of a<br>
medicament for treating diabetic and other glucagon related metabolic disorders in a<br>
mammal; and for the manufacture of a medicament for treating diabetes, obesity,.<br>
hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound<br>
healing.<br>
The present invention further provides a method of treating conditions resulting<br>
from excessive glucagon in a mammal comprising administering to a mammal in need of<br>
such treatment a glucagon receptor inhibiting amount of a pharmaceutical composition<br>
which comprises a compound of Formulae I-IV, or a pharmaceutical salt thereof, and a<br>
pharmaceutically acceptable carrier, diluent, or excipient.<br>
The present invention also provides; a method of selectively reducing the<br>
glycemic level in a mammal; a method of inhibiting hyperglycemia in a mammal; a<br>
method of treating diabetic and other glucagon related metabolic disorders in a mammal<br>
comprising administering to a mammal comprising administering to a mammal in need of<br>
such treatment a glucagon receptor inhibiting amount of a pharmaceutical composition<br>
which comprises a compound of Formulae I-IV, or a pharmaceutical salt thereof, and a<br>
pharmaceutically acceptable carrier, diluent, or excipient. Furthermore, a compound of<br>
Formulae I-IV may be applicable as diagnostic agents for identifying patients having a<br>
defect in the glucagon receptor, as a therapy to increase gastric acid secretions and to<br>
reverse intestinal hypomobility due to glucagon administration.<br>
In addition, a pharmaceutical composition of Formulae I-IV can be useful in the<br>
treatment or prevention of a disorder or disease in which modulation of glucagon receptor<br>
activity has a beneficial effect. The present invention further provides an antagonist or<br>
inverse agonist of Formulae I-IV which is characterized by having greater affinity for the<br>
glucagon receptor as compared to the affinity for the GLP-1 receptor.<br>
The present compounds are effective in lowering the blood glucose, both in the<br>
fasting and the postprandial stage. In still another embodiment of the invention the<br>
present compounds are used for the preparation of a pharmaceutical composition for the<br>
treatment of IGT. In a further embodiment of the invention the present compounds are<br>
used for the preparation of a pharmaceutical composition for the treatment of type 2<br>
diabetes. In yet a further embodiment of the invention the present compounds are used for<br>
the preparation of a pharmaceutical composition for the delaying or prevention of the<br>
progression from IGT to type 2 diabetes. In yet another embodiment of the invention the<br>
present compounds are used for the preparation of a pharmaceutical composition for the<br>
delaying or prevention of the progression from non-insulin requiring type 2 diabetes to<br>
insulin requiring type 2 diabetes. In a further embodiment of the invention the present<br>
compounds are used for the preparation of a pharmaceutical composition for the treatment<br>
of type 1 diabetes. Such treatment is normally accompanied by insulin therapy. In yet a<br>
further embodiment of the invention the present compounds are used for the preparation<br>
of a pharmaceutical composition for the treatment of obesity. In still a further ....<br>
embodiment of the invention the present compounds are used for the preparation of a<br>
pharmaceutical composition for the treatment of disorders of the lipid metabolism. In still<br>
another embodiment of the invention the present compounds are used for the preparation<br>
of a pharmaceutical composition for the treatment of an appetite regulation or energy<br>
expenditure disorder. In a further embodiment of the invention, treatment of a patient<br>
with the present compounds is combined with diet and/or exercise.<br>
General terms used in the description of compounds, compositions, and methods<br>
herein described, bear their usual meanings. Throughout the instant application, the<br>
following terms have the indicated meanings:<br>
"GLP-1" means glucagon-like peptide 1. The term "glucagon receptor" means one<br>
or more receptors that interact specifically with glucagon to result in a biological signal.<br>
The term "GLP-1 receptor" means one or more receptors that interact specifically with<br>
glucagon-like peptide 1 to result in a biological signal.<br>
The term "glucagon receptor antagonist" is defined as a compound of the present<br>
invention with the ability of to block cAMP production in response glucagon.<br>
The term "glucagon receptor inverse agonist" is defined as a compound of the present<br>
invention with the ability of to inhibit the constitutive activity of glucagon receptor. The<br>
term "selective" antagonist or inverse agonist means a compound having greater affinity<br>
for the glucagon receptor as compared to the affinity for the GLP-1 receptor.<br>
In the general formulae of the present document, the general chemical terms have<br>
their usual meanings. For example;<br>
"Halogen" or "halo" means fluoro, chloro, bromo and iodo.<br>
The term "alkyl," unless otherwise indicated, refers to those alkyl groups of a<br>
designated number of carbon atoms of either a straight or branched saturated<br>
configuration. "(Q-C3) alkyl" are one to three carbon atoms, such as methyl, ethyl,<br>
propyl, n-propyl, isopropyl, and the like and branched or isomeric forms thereof, and<br>
optionally may be substituted with one to three halogens or a designated number of<br>
substituents as set forth in the embodiments recited herein, "(C1-C7) alkyl" are one to<br>
seven carbon atoms such as methyl, ethyl, propyl, n-propyl, isopropyl, n-butyl, isobutyl,<br>
sec-butyl and tert-butyl, pentyl, isopentyl, hexyl, heptyl, and the like, and branched or<br>
isomeric forms thereof, and optionally may be substituted with one to three halogens or a<br>
designated number of substituents as set forth in the embodiments recited herein, and<br>
"(Q-C10) alkyl" are one to ten carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl,<br>
hexyl, heptyl, nonyl, decyl, and the like, and branched or isomeric forms thereof, and<br>
optionally may be substituted with one to three halogens or a designated number of<br>
substituents as set forth in the embodiments recited herein. "(C1-C12) alkyl" are one to<br>
twelve carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, nonyl,<br>
decyl, and the like, and branched or isomeric forms thereof, and optionally may be<br>
substituted with one to three halogens or a designated number of substituents as set forth<br>
in the embodiments recited herein.<br>
The term "(C3-C12) cycloalkyl" refers to a saturated or partially saturated<br>
carbocycle containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7<br>
carbon atoms optionally substituted with up to three halogens. Examples of (C3-C12)<br>
cycloalkyl include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl<br>
and cycloheptyl, and the like. "(C3-C7) cycloalkyl" means a ring with three to seven<br>
carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, cycloheptyl,<br>
and the like, optionally substituted with up to three halogens.<br>
The term " (C1-C7) alkoxy" represents an alkyl group of one to seven carbon<br>
atoms attached through an oxygen bridge, such as methoxy, ethoxy, propoxy, isopropoxy,<br>
butoxy, tert-butoxy, pentoxy, and the like, and may be optionally substituted with three<br>
halogens or a designated number of substituents as set forth in the embodiments recited<br>
herein.<br>
The terms "(C2-C7) alkenyl", "(C2-Ci0) alkenyl", "(C2-C10) alkylenyl", "(C2-C12)<br>
alkenyl", or "(C2-C12) alkylenyl" means hydrocarbon chains of the indicated number of<br>
carbon atoms, of either a straight or branched configuration, having at least one carbon-<br>
carbon double bond which may occur at any point along the chain, such as ethenyl,<br>
propenyl, butenyl, pentenyl, vinyl, alkyl, 2-butenyl and the like, and may be optionally<br>
substituted with one to three halogens or a designated number of substituents as set forth<br>
in the embodiments recited herein.<br>
The term "(C3-C12) cycloalkenyl" refers to a partially saturated carbocycle<br>
containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7 carbon atoms<br>
optionally substituted with up to three halogens.<br>
The term "(C2-C12) alkynyl" means hydrocarbon chain of two to twelve carbon<br>
atoms of either a straight or branched configuration and having at least one carbon-carbon<br>
triple bond, which may occur at any point along the chain. Example of alkynyl is<br>
acetylene. Alkynyl as defined above may be optionally substituted with up to three<br>
halogens or the designated number of substituents as set forth in the embodiments recited<br>
herein.<br>
The term "(Cs-Cu) cycloalkynyl" refers to a carbocycle containing one or more<br>
rings of from 8 to 12 carbon atoms, having at least one carbon-carbon triple bond which<br>
may occur at any point along the chain or ring, optionally substituted with up to three<br>
halogens. Cycloalkynyl as defined above may be optionally substituted with up to three<br>
halogens or the designated number of substituents as set forth in the embodiments recited<br>
herein.<br>
As used herein, the terms "Aryl" or "aryl" include carbocyclic aromatic ring<br>
systems (e.g. phenyl), fused polycyclic aromatic ring systems (e.g. naphthyl and<br>
anthracenyl) and aromatic ring systems fused to carbocyclic non-aromatic ring systems<br>
(e.g., 1,2,3,4-tetrahydronaphthyl), which may contain one or more fused or non-fused<br>
phenyl rings, and includes, for example, phenyl, biphenyl, 1- or 2-naphthyl, 1,2-<br>
dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like. In addition, the aryl group<br>
may be unsubstituted or may be optionally substituted with a designated number of<br>
substituents as set forth in the embodiments recited herein.<br>
The term "aryloxy" refers to an aryl group that is linked to the parent molecule<br>
through an oxygen bridge. The term "aryloxy" includes, but is not limited to carbocyclic<br>
aromatic ring systems (e.g. phenyl), fused polycyclic aromatic ring systems (e.g. naphthyl<br>
and anthracenyl) and aromatic ring systems fused to carbocyclic non-aromatic ring<br>
systems (e.g., 1,2,3,4-tetrahydronaphthyl), which may contain one or more fused or non-<br>
fused phenyl rings, and includes, for example, phenyl, biphenyl, 1- or 2-naphthyl, 1,2-<br>
dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like linked to the parent molecule<br>
through an oxygen bridge.<br>
The term "heteroaryl" group, as used herein, is an aryl ring system having at least<br>
one heteroatom such as nitrogen, sulfur or oxygen and includes monocyclic, bicyclic or<br>
tricyclic aromatic rings of 5- to 14-carbon atoms containing one or more heteroatoms<br>
selected from the group consisting of O, N, and S. The "heteroaryl" as defined above<br>
may be optionally substituted with a designated number of substituents as set forth in the<br>
embodiments recited herein. Examples of heteroaryl are, but are not limited to, furanyl,<br>
indolyl, thienyl (also referred to herein as "thiophenyl") thiazolyl, imidazolyl, isoxazoyl,<br>
oxazoyl, pyrazoyl, pyirolyl, pyrazinyl, pyridyl, pyrimidyl, pyrimidinyl and purinyl,<br>
cinnolinyl, benzofuranyl, benzothienyl, benzotriazolyl, benzoxazolyl, quinoline,<br>
isoxazolyl, isoquinoline and the like. The term "heteroaryl" also includes, but is not<br>
limited to the following:<br><br>
represents the point of attachment to the position indicated for heteroaryl in the parent<br>
molecule.<br>
The term "arylalkyl" refers to an aryl alkyl group which is linked to the parent<br>
molecule through the alkyl group, which may be further optionally substituted with a<br>
designated number of substituents as set forth in the embodiment recited herein.<br>
Likewise, arylheteroalkyl means an aryl group linked to the parent molecule through the<br>
heteroalkyl group.<br>
The term "acyl" refers to alkylcarbonyl species.<br>
The term "heterocycloalkyl" refers to a non-aromatic ring which contains one or<br>
more oxygen, nitrogen or sulfur and includes a monocyclic, bicyclic or tricyclic non-<br>
aromatic ring of 3 to 14 carbon atoms containing one or more heteroatoms selected from<br>
O, N, or S. "-(C3-C7) heterocycloalkyl" refers to a non-aromatic ring which contains one<br>
or more oxygen, nitrogen or sulfur and includes a monocyclic, bicyclic or tricyclic non-<br>
aromatic ring of 3 to 7 carbon atoms containing one or more heteroatoms selected from<br>
O.N.orS.<br>
The term "optionally substituted" as used herein means that the groups in question<br>
are either unsubstituted or substituted with one or more of the substituents specified.<br>
When the groups in question are substituted with more than one substituent, the<br>
substituents may be the same or different.<br>
/ Furthermore, when using the terms "independently", "independently are" and<br>
"independently selected from" it should be understood that the groups in question may be<br>
the same or different.<br>
The term "patient" includes human and non-human animals, such as companion<br>
animals (dogs and cats and the like) and livestock animals. Livestock animals are .<br>
animals raised for food production. Ruminants or "cud-chewing" animals such as cows,<br>
bulls, heifers, steers, sheep, buffalo, bison, goats and antelopes are examples of livestock.<br>
Other examples of livestock include pigs and avians (poultry) such as chickens, ducks,<br>
turkeys and geese. Yet other examples of livestock include fish, shellfish and crustaceans<br>
raised in aquaculture. Also included are exotic animals used in food production such as<br>
alligators, water buffalo and ratites (e.g., emu, rheas or ostriches). The patient to be<br>
treated is preferably a mammal, in particular a human being.<br>
The term "a glucagon receptor mediated cellular response" includes various<br>
responses by mammalian cells to glucagon stimulation or glucagon receptor activity. For<br>
example "glucagon receptor mediated cellular responses" include but are not limited to<br>
release of glucose from liver, or other cells, in response to glucagon stimulation or<br>
glucagon receptor activity. One of ordinary skill in the art can readily identify other<br>
cellular responses mediated by glucagon receptor activity, for example by observing a<br>
change in the responsive cellular endpoint after contacting the cell with an effective dose<br>
of glucagon.<br>
The terms "treatment", "treating" and "treat", as used herein, include their<br>
generally accepted meanings, i.e., the management and care of a patient for the purpose of<br>
preventing, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, delaying,<br>
or reversing the progression or severity of a disease, disorder, or pathological condition,<br>
described herein, including the alleviation or relief of symptoms or complications, or the<br>
cure or elimination of the disease, disorder, or condition.<br>
"Composition" means a pharmaceutical composition and is intended to encompass<br>
a pharmaceutical product comprising the active ingredient(s) including compound(s) of<br>
Formulae I-IV and the inert ingredients) that make up the carrier. Accordingly, the<br>
pharmaceutical compositions of the present invention encompass any composition made<br>
by admixing a compound of the present invention and a pharmaceutically acceptable<br>
carrier.<br>
The term "suitable solvent" refers to any solvent, or mixture of solvents, inert to<br>
the ongoing reaction that sufficiently solubilizes the reactants to afford a medium within<br>
which to effect the desired reaction.<br>
The term "unit dosage form" means physically discrete units suitable as unitary<br>
dosages for human subjects and other non-human animals, each unit containing a<br>
predetermined quantity of active material calculated to produce the desired therapeutic<br>
effect, in association with a suitable pharmaceutical carrier.<br>
Certain of the above defined terms may occur more than once in the structural<br>
formulae, and upon such occurrence each term shall be defined independently of the<br>
other.<br>
As used herein, the term "stereoisomer" refers to a compound made up of the<br>
same atoms bonded by the same bonds but having different three-dimensional structures<br>
which are not interchangeable. The three-dimensional structures are called<br>
configurations. As used herein, the term "enantiomer" refers to two stereoisomers whose<br>
molecules are nonsuperimposable mirror images of one another. The term "chiral center"<br>
refers to a carbon atom to which four different groups are attached. As used herein, the<br>
term "diastereomers" refers to stereoisomers which are not enantiomers. In addition, two<br>
diastereomers which have a different configuration at only one chiral center are referred<br>
to herein as "epimers." The terms "racemate," "racemic mixture" or "racemic<br>
modification" refer to a mixture of equal parts of enantiomers.<br>
The compounds of the present invention may be chiral, and it is intended that any<br>
enantiomers, as separated, pure or partially purified enantiomers or racemic mixtures<br>
mereof are included within the scope of the invention. Furthermore, when a double bond<br>
or a fully or partially saturated ring system or more than one center of asymmetry or a<br>
bond with restricted rotatability is present in the molecule diastereomers may be formed.<br>
It is intended that any diastereomers, as separated, pure or partially purified diastereomers<br>
or mixtures thereof are included within the scope of the invention. Furthermore, some of<br>
the compounds of the present invention may exist in different tautomeric forms and it is<br>
intended that any tautomeric forms, which the compounds are able to form, are included<br>
within the scope of the present invention. Thus, as one skilled in the art knows, certain<br>
aryls may exist in tautomeric forms. The invention also includes tautomers, enantiomers<br>
and other stereoisomers of the compounds of Formulae I-IV. Such variations are<br>
contemplated to be within the scope of the invention.<br>
The terms "R" and "S" are used herein as commonly used in organic chemistry to<br>
denote specific configuration of a chiral center. The term "R" (rectus) refers to that<br>
configuration of a chiral center with a clockwise relationship of group priorities (highest<br>
to second lowest) when viewed along the bond toward the lowest priority group. The<br>
term "S" (sinister) refers to that configuration of a chiral center with a counterclockwise<br>
relationship of group priorities (highest to second lowest) when viewed along the bond<br>
toward the lowest priority group. The priority of groups is based upon their atomic<br>
number (in order of decreasing atomic number). A partial list of priorities and a<br>
discussion of stereochemistry is contained in "Nomenclature of Organic Compounds:<br>
Principles and Practice", (J.H. Fletcher, et al eds., 1974) at pages 103-120.<br>
The designation " ~"""" " refers to a bond that protrudes forward out of the plane<br>
of the page. The designation......'" " refers to a bond that protrudes backward out of the<br>
plane of the page. The designation " "^^ " refers to a bond wherein the stereochemistry<br>
is not defined.<br>
The compounds of Formulae I-IV, when existing as a diastereomeric mixture,<br>
may be separated into diastereomeric pairs of enantiomers by, for example, fractional<br>
crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture<br>
thereof. The pair of enantiomers thus obtained may be separated into individual<br>
stereoisomers by conventional means, for example by the use of an optically active acid<br>
as a resolving agent. Alternatively, any enantiomer of a compound of Formulae I-IV may<br>
be obtained by stereospecific synthesis using optically pure starting materials or reagents<br>
of known configuration or through enantioselective synthesis.<br>
The term "enantiomeric enrichment" as used herein refers to the increase in the<br>
amount of one enantiomer as compared to the other. A convenient method of expressing<br>
the enantiomeric enrichment achieved is the concept of enantiomeric excess, or "ee," .<br>
which is found using the following equation:<br><br>
wherein E1 is the amount of the first enantiomer and E2 is the amount of me<br>
second enantiomer. Thus, if the initial ratio of the two enantiomers is 50:50, such as is<br>
present in a racemic mixture, and an enantiomeric enrichment sufficient to produce a final<br>
ratio of 70:30 is achieved, the ee with respect to the first enantiomer is 40%. However, if<br>
the final ratio is 90:10, the ee with respect to the first enantiomer is 80%. An ee of<br>
greater than 90% is preferred, an ee of greater than 95% is most preferred and an ee of<br>
greater than 99% is most especially preferred. Enantiomeric enrichment is readily<br>
determined by one of ordinary skill in the art using standard techniques and procedures,<br>
such as gas or high performance liquid chromatography with a chiral column. Choice of<br>
the appropriate chiral column, eluent and conditions necessary to effect separation of the<br>
enantiomeric pair is well within the knowledge of one of ordinary skill in the art. In<br>
addition, the specific stereoisomers and enantiomers of compounds of Formulae I-IV can<br>
be prepared by one of ordinary skill in the art utilizing well known techniques and<br>
processes, such as those disclosed by J. Jacques, et al., "Enantiomers, Racemates, and<br>
Resolutions." John Wiley and Sons, Inc., 1981, and EX. Eliel and S.H. Wilen,"<br>
Stereochemistry of Organic Compounds." (Wiley-Interscience 1994), and European<br>
Patent Application No. EP-A-838448, published April 29,1998. Examples of resolutions<br>
include recrystallization techniques or chiral chromatography.<br>
In general, the term "pharmaceutical" when used as an adjective means<br>
substantially non-toxic to living organisms. For example, the term "pharmaceutical salt"<br>
as used herein, refers to salts of the compounds of Formulae I-IV which are substantially<br>
non-toxic to living organisms. See, e.g,, Berge, S.M, Bighley, L.D., and Monkhouse,<br>
D.C., "Pharmaceutical Salts," J. Pharm. Sci., 66:1,1977. The present invention also<br>
encompasses pharmaceutically acceptable salts of the present compounds. Such salts<br>
include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable<br>
metal salts, ammonium and alkylated ammonium salts. Also intended as pharmaceutically<br>
acceptable acid addition salts are any hydrates that the present compounds are able to<br>
form. Furthermore, the pharmaceutically acceptable salts comprise basic amino acid salts<br>
such as lysine, arginine and ornithine. Typical pharmaceutical salts include those salts<br>
prepared by reaction of the compounds of Formulae I-IV with an inorganic or organic<br>
acid or base. Such salts are known as acid addition or base addition salts respectively.<br>
These pharmaceutical salts frequently have enhanced solubility characteristics compared<br>
to the compound from which they are derived, and thus are often more amenable to<br>
formulation as liquids or emulsions.<br>
/ The term "acid addition salt" refers to a salt of a compound of Formulae I-IV<br>
prepared by reaction of a compound of Formulae I-IV with a mineral or organic acid. For<br>
exemplification of pharmaceutical acid addition salts see, e.g., Berge, S.M, Bighley, L.D.,<br>
and Monkhouse, D.C., /. Pharm. Sci., 66:1,1977. Since compounds of this invention can<br>
be basic in nature, they accordingly react with any of a number of inorganic and organic<br>
acids to form pharmaceutical acid addition salts.<br>
The acid addition salts may be obtained as the direct products of compound<br>
synthesis. In the alternative, the free base may be dissolved in a suitable solvent<br>
containing the appropriate acid, and the salt isolated by evaporating the solvent or<br>
otherwise separating the salt and solvent<br>
Acids commonly employed to form acid addition salts are inorganic acids such as<br>
hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and<br>
the like, and organic acids, such as p-toluenesulfonic acid, ethanesulfonic acid,<br>
methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic<br>
acid, citric acid, tartaric acid, benzoic acid, acetic acid and the like. Preferred<br>
pharmaceutical acid addition salts are those formed with mineral acids such as<br>
hydrochloric acid, hydrobromic acid, and sulfuric acid, and tiiose formed with organic<br>
acids such as maleic acid, tartaric acid, and methanesulfonic acid. Examples of such<br>
pharmaceutivally acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite,<br>
bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate,<br>
pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate,<br>
acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate,<br>
succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate,<br>
benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate,<br>
methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate,<br>
phenylbutyrate, citrate, lactate, (3-hydroxybutyrate, glycollate, tartrate, methanesulfonate,<br>
propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the<br>
like.<br>
The skilled artisan would appreciate that some compounds of Formulae I-IV may<br>
be acidic in nature and accordingly react with any of a number of inorganic and organic<br>
bases to form pharmaceutical base addition salts. The term "base addition salt" refers to a<br>
salt of a compound of Formulae I-IV prepared by reaction of a compound of Formula I,<br>
H, or IE with a mineral or organic base. For exemplification of pharmaceutical base<br>
addition salts see, eg., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., J. Pharm. ScL,<br>
66:1,1977. Bases commonly employed to form pharmaceutical base addition salts are<br>
inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides,<br>
carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this<br>
invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide,<br>
potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate,<br>
calcium hydroxide, calcium carbonate, and the like. Examples of pharmaceutical base<br>
addition salts are the ammonium, lithium, potassium, sodium, calcium, magnesium,<br>
methylamino, diethylamino, ethylene diamino, cyclohexylamino, and ethanolamino salts,<br>
and the like of a compound of Formulae I-IV. The potassium and sodium salt forms are<br>
particularly preferred. The present invention also contemplates pharmaceutical base<br>
addition salts of compounds of Formulae I-IV.<br>
The pharmaceutical salts of the invention are typically formed by reacting a<br>
compound of Formulae I-IV with an equiraolar or excess amount of acid or base. The<br>
reactants are generally combined in a mutual solvent such as diethylether,<br>
tetrahydrofuran, methanol, ethanol, isopropanol, benzene, and the like for acid addition<br>
salts, or water, an alcohol or a chlorinated solvent such as dichloromethane for base<br>
addition salts. The salts normally precipitate out of solution within about one hour to<br>
about ten days and can be isolated by filtration or other conventional methods.<br>
It should be recognized that the particular counterion forming a part of any salt of<br>
this invention is not of a critical nature, so long as the salt as a whole is<br>
pharmacologically acceptable and as long as the counterion does not contribute undesired<br>
qualities to the salt as a whole.<br>
The compounds of the present invention may form solvates with standard low<br>
molecular weight solvents using methods well known to the person skilled in the art.<br>
Such solvates are also contemplated as being within the scope of the present invention.<br>
The invention also encompasses prodrugs of the present compounds, which on<br>
administration undergo chemical conversion by metabolic processes before becoming<br>
pharmacologically active substances. In general, such prodrugs will be functional<br>
derivatives of present compounds, which are readily convertible in vivo into a compound<br>
of the present invention. Conventional procedures for the selection and preparation of<br>
Amiable prodrug derivatives are described, for example in "Design of Prodrugs", ed. H.<br>
Bundgaard, Elsevier, 1985.<br>
In a further aspect of the invention the present compounds are administered in<br>
combination with one or more further active substances in any suitable ratios. Such<br>
further active substances may for example be selected from antidiabetics, antiobesity<br>
agents, antihypertensive agents, agents for die treatment of complications resulting from<br>
or associated with diabetes and agents for the treatment of complications and disorders<br>
resulting from or associated with obesity. The following listing sets out several groups of<br>
combinations. It will be understood that each of the agents named may be combined with<br>
other agents named to create additional combinations.<br>
Thus, in a further embodiment of the invention the present compounds may be<br>
administered in combination with one or more antidiabetics.<br>
Suitable antidiabetic agents include insulin, insulin analogues and derivatives such<br>
as those disclosed in EP 792 290 (Novo Nordisk A/S), for example N^'-tetradecanoyl<br>
des (B30) human insulin, EP 214 826 and EP 705 275 (Novo Nordisk A/S), for example<br>
Asp828 human insulin, US 5,504,188 (Eli Lilly), for example LysB28 Pro829 human insulin,<br>
EP 368 187 (Aventis), for example Lantus, which are all incorporated herein by<br>
reference, GLP-1 and GLP-1 derivatives such as those disclosed in WO 98/08871 (Novo<br>
Nordisk A/S), which is incorporated herein by reference, as well as orally active<br>
hypoglycemic agents.<br>
The orally active hypoglycemic agents preferably comprise imidazolines,<br>
sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones,<br>
insulin sensitizers, insulin secretagogues, such as glimepiride, o-glucosidase inhibitors,<br>
agents acting on the ATP-dependent potassium channel of the P-cells for example<br>
potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and<br>
WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by reference, or<br>
mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon<br>
antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk<br>
A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference,<br>
GLP-1 antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, PTPase (protein tyrosine<br>
phosphatase) inhibitors, inhibitors of hepatic enzymes involved in stimulation of<br>
gluconeogenesis and/or glycogenolysis, glucose uptake modulators, activators of<br>
glucokinase (GK) such as those disclosed in WO 00/58293, WO 01/44216, WO<br>
01/83465, WO 01/83478, WO 01/85706, WO 01/85707, and WO 02/08209 (Hoffman-La<br>
Roche) or those disclosed in WO 03/00262, WO 03/00267 and WO 03/15774<br>
(AstraZeneca), which are incorporated herein by reference, GSK-3 (glycogen synthase<br>
kinase-3) inhibitors, compounds modifying the lipid metabolism such as antilipidemic<br>
agents such as HMG CoA inhibitors (statins), compounds lowering food intake, PPAR<br>
(Peroxisome proliferator-activated receptor) ligands including the PPAR-alpha, PPAR-<br>
gamma and PPAR-delta substypes, and RXR (retinoid X receptor) agonists, such as<br>
ALRT-268, LG-1268 or LG-1069.<br>
In another embodiment, the present compounds are administered in combination<br>
with insulin or an insulin analogue or derivative, such as N^^-tetradecanoyl des (B30)<br>
human insulin, Asp028 human insulin, LysB28 ProB29 human insulin, Lantus, or a mix-<br>
preparation comprising one or more of these.<br>
In a further embodiment of the invention the present compounds are administered<br>
in combination with a sulphonylurea such as glibenclamide, glipizide, tolbautamide,<br>
chloropamidem, tolazamide, glimepride, glicazide and glyburide.<br>
In another embodiment of the invention the present compounds are administered<br>
in combination with a biguanide for example metformin.<br>
In yet another embodiment of the invention the present compounds are<br>
administered in combination with a meglitinide for example repaglinide or nateglinide.<br>
In still another embodiment of the invention the present compounds are<br>
administered in combination with a thiazolidinedione insulin sensitizer for example<br>
troglitazone, ciglitazone, piolitazone, rosiglitazone, isaglitazone, darglitazone,<br>
englitazone, CS-011/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO<br>
97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research<br>
Foundation), which are incorporated herein by reference.<br>
In still another embodiment of the invention the present compounds may be<br>
administered in combination with an insulin sensitizer for example such as GI262570,<br>
YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR-<br>
H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in<br>
WO 99/19313, WO 00/50414, WO 00/63191, WO 00/63192, WO 00/63193 such as<br>
ragaglitazar (NN 622 or (-)DRF 2725) (Dr. Reddy's Research Foundation) and WO<br>
j)0/23425, WO 00/23415, WO 00/23451, WO 00/23445, WO 00/23417, WO 00/23416,<br>
WO 00/63153, WO 63196, WO 00/63209, WO 00/63190 and WO 00/63189 (Novo<br>
Nordisk A/S), which are incorporated herein by reference.<br>
In a further embodiment of the invention the present compounds are administered<br>
in combination with an a-glucosidase inhibitor for example voglibose, emiglitate, miglitol<br>
or acarbose.<br>
In another embodiment of the invention the present compounds are administered<br>
in combination with an agent acting on the ATP-dependent potassium channel of the (}-<br>
cells for example tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or<br>
repaglinide.<br>
In yet another embodiment of the invention the present compounds may be<br>
administered in combination with nateglinide.<br>
In still another embodiment of the invention the present compounds are<br>
administered in combination with an antilipidemic agent or antihyperlipidemic agent for<br>
example cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin,<br>
simvastatin, pitavastatin, rosuvastatin, probucol, dextrothyroxine, fenofibrate or<br>
atorvastin.<br>
In still another embodiment of the invention the present compounds are<br>
administered in combination with compounds lowering food intake.<br>
In another embodiment of the invention, the present compounds are administered<br>
in combination with more than one of the above-mentioned compounds for example in<br>
combination with metformin and a sulphonylurea such as glyburide; a sulphonylurea and<br>
acarbose; nateglinide and metformin; repaglinide and metformin, acarbose and<br>
metformin; a sulfonylurea, metformin and troglitazone; insulin and a sulfonylurea; insulin<br>
and metformin; insulin, metformin and a sulfonylurea; insulin and troglitazone; insulin<br>
and lovastatin; etc.<br>
In a further embodiment of the invention the present compounds may be<br>
administered in combination with one or more antiobesity agents or appetite regulating<br>
agents.<br>
Such agents may be selected from the group consisting of CART (cocaine<br>
amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4<br>
(melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF<br>
(tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP<br>
(corticotropin releasing factor binding protein) antagonists, urocortin agonists, p3<br>
adrenergic agonists such as CL-316243, AJ-9677, GW-0604, LY362884, LY377267 or<br>
AZ-40140 MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-<br>
concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake<br>
inhibitors such as fluoxetine, seroxat or citaloprani, serotonin and noradrenaline re-uptake<br>
inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists,<br>
bombesin agonists, galanin antagonists, growth hormone, growth factors such as prolactin<br>
or placental lactogen, growth hormone releasing compounds, TRH (thyrotropin releasing<br>
hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists,<br>
DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR (peroxisome<br>
proliferator-activated receptor) modulators, RXR (retinoid X receptor) modulators, TR P<br>
agonists, AGRP (Agouti related protein) inhibitors, H3 histamine antagonists, opioid<br>
antagonists (such as naltrexone), exendin-4, GLP-1 and ciliary neurotrophic factor (such<br>
as axokine), cannaboid receptor antagonist for example CB-1 (such as rimonabant).<br>
In another embodiment the antiobesity agent is dexamphetamine or amphetamine.<br>
In another embodiment the antiobesity agent is leptin.<br>
In another embodiment the antiobesity agent is fenfluramine or exfenfluramine.<br>
In still another embodiment the antiobesity agent is sibutramine.<br>
In a further embodiment the antiobesity agent is orlistat.<br>
In another embodiment the antiobesity agent is mazindol or phentermine.<br>
In still another embodiment the antiobesity agent is phendimetrazine,<br>
diethylpropion, fluoxetine, bupropion, topiramate or ecopipam.<br>
Furthermore, the present compounds may be administered in combination with<br>
one or more antihypertensive agents. Examples of antihypertensive agents are -blockers<br>
such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, SCE<br>
(angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril,<br>
fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine,<br>
felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and a-blockers<br>
such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to<br>
Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack<br>
Publishing Co., Easton, PA, 1995.<br>
The compounds of the present invention may be administered in combination with<br>
FAS inhibitors.<br>
The compounds of the present invention may also be administered in combination<br>
with chemical uncouplers, hormone sensitive lipase inhibitor, imidazolines, 11--<br>
hydroxysteroid dehydrogenase inhibitors, lipoprotein lipase activator, AMPK activators,<br>
immunosuppresive drugs, nicotinamide, ASIS, anti-androgens or carboxypeptidase<br>
inhibitors.<br>
It should be understood that any suitable combination of the compounds according<br>
to the invention with diet and/or exercise, one or more of the above-mentioned<br>
compounds and optionally one or more other active substances are considered to be<br>
within the scope of the present invention.<br>
The compounds of Formulae I-IV can be prepared by one of ordinary skill in the<br>
art following a variety of procedures, some of which are illustrated in the procedures and<br>
schemes set forth below. The particular order of steps required to produce the compounds<br>
of Formulae I-IV is dependent upon the particular compound being synthesized, the<br>
starting compound, and the relative liability of the substituted moieties. The reagents or<br>
starting materials are readily available to one of skill in the art, and to the extent not<br>
commercially available, are readily synthesized by one of ordinary skill in the art<br>
following standard procedures commonly employed in the art, along with the various<br>
procedures and schemes set forth below.<br>
The following Schemes, Preparations, Examples and Procedures are provided to<br>
better elucidate the practice of the present invention and should not be interpreted in any<br>
way as to limit the scope of the same. Those skilled in the art will recognize that various<br>
modifications may be made while not departing from the spirit and scope of the<br>
invention. All publications mentioned in the specification are indicative of the level of<br>
those skilled in the art to which this invention pertains.<br>
The optimal time for performing the reactions of the Schemes, Preparations,<br>
Examples and Procedures can be determined by monitoring the progress of the reaction<br>
via conventional chromatographic techniques. Furthermore, it is preferred to conduct the<br>
reactions of the invention under an inert atmosphere, such as, for example, argon, or,<br>
particularly, nitrogen. Choice of solvent is generally not critical so long as the solvent<br>
employed is inert to the ongoing reaction and sufficiently solubilizes the reactants to<br>
effect the desired reaction. The compounds are preferably isolated and purified before<br>
their use in subsequent reactions. Some compounds may crystallize out of the reaction<br>
solution during their formation and then collected by filtration, or the reaction solvent<br>
may be removed by extraction, evaporation, or decantation. The intermediates and final<br>
products of Formulae I-IV may be further purified, if desired by common techniques such<br>
as recrystallization or chromatography over solid supports such as silica gel or alumina.<br>
The skilled artisan will appreciate that not all substituents are compatible with all<br>
reaction conditions. These compounds may be protected or modified at a convenient point<br>
in the synthesis by methods well known in the art.<br>
The terms and abbreviations used in the instant Schemes, Preparations, Examples<br>
and Procedures have their normal meanings unless otherwise designated. For example, as<br>
used herein, the following terms have the meanings indicated: "eq" refers to equivalents;<br>
"N" refers to normal or normality, "M" refers to molar or molarity, "g" refers to gram or<br>
grams, "mg" refers to milligrams; "L" refers to liters; "mL" refers to milliliters; "L"<br>
refers to microliters; "mol" refers to moles; "mmol" refers to millimoles; "psi" refers to<br>
pounds per square inch; "min" refers to minutes; "h" or "hr" refers to hours; "C" refers<br>
to degrees Celsius; "TLC" refers to thin layer chromatography; "HPLC" refers to high<br>
performance liquid chromatography; "Rf" refers to retention factor; "Rt" refers to<br>
retention time; "5"refers to part per million down-field from tetramethylsilane; "MS"<br>
refers to mass spectrometry, Observed Mass indicates (M+ 1) unless indicated otherwise.<br>
"MS(FD)" refers to field desorption mass spectrometry, "MS(IS)" refers to ion spray<br>
mass spectrometry, "MS(FIA)" refers to flow injection analysis mass spectrometry,<br>
"MS(FAB)" refers to fast atom bombardment mass spectrometry, "MS(EI)M refers to<br>
electron impact mass spectrometry, "MS(ES)" refers to electron spray mass spectrometry,<br>
"UV" refers to ultraviolet spectrometry, 'aH NMR" refers to proton nuclear magnetic<br>
resonance spectrometry. In addition, "IR" refers to infra red spectrometry, and the<br>
absorption maxima listed for the IR spectra are only those of interest and not all of the<br>
maxima observed. "RT" refers to room temperature.<br>
Infrared spectra are recorded on a Perkin Elmer 781 spectrometer. 1H NMR<br>
spectra are recorded on a Varian 400 MHz spectrometer at ambient temperature. Data are<br>
reported as follows; chemical shift in ppm from internal standard tetramethylsilane on the<br>
8 scale, multiplicity (b = broad, s = singlet, d = doublet, t = triplet, q = quartet, qn =<br>
quintet and m = multiplet), integration, coupling constant (Hz) and assignment. 13C NMR<br>
are recorded on a Varian 400 MHz spectrometer at ambient temperature. Chemical shifts<br>
are reported in ppm from tetramethylsilane on the 8 scale, with the solvent resonance<br>
employed as the internal standard (CDCI3 at 77.0 ppm and DMSO-q"s at 39.5 ppm).<br>
Combustion analyses are performed by Eli Lilly &amp; Company Microanalytical Laboratory.<br>
High resolution mass spectra are obtained on VG ZAB 3F or VG 70 SE spectrometers.<br>
Analytical thin layer chromatography is performed on EM Reagent 0.25 mm silica gel 60-<br>
F plates. Visualization is accomplished with UV light.<br>
GENERAL SCHEMES<br>
Compounds of the present invention have been formed as specifically described in<br>
the examples. Furthermore, many compounds are prepared more generally using a)<br>
alkylation of an alcohol, phenol or thiophenol with a halide, b) a Mitsunobu protocol (O.<br>
Mitsunobu, 1981 Synthesis, p1), and c) other methods known to the skilled artisan.<br>
Alternative synthesis methods may also be effective and known to the skilled artisan.<br>
For example, an intermediate like A is alkylated with an alkylating agent B in the<br>
presence of a base (e.g. NaH, K2CO3, CS2CO3 etc.). Hydrolysis in the presence of aqueous<br>
NaOH or LiOH gives the acid product.<br>
Scheme GZ1<br><br>
The enantiomeric pure products are prepared either through A) chiral<br>
chromatography or B) Mitsunobu coupling between a phenol or thiophenol and a chiral<br>
alcohol that can be prepared using the methods known to the art<br>
PREPARATIONS AND EXAMPLES<br>
The Examples provided herein are illustrative of the invention and are not<br>
intended to limit the scope of the claimed invention in any way.<br>
Preparation 1<br>
(R3)-5-(l-Hydroxy-ethyl)-thiophene-2-carboxylic acid methyl ester<br>
Step A <br>
S-Acetyl-thiophene-2-carboxylic acid methyl ester<br>
A solution of 5-acetyl-thiophene-2-carboxylic acid (1 g, 5.88 mmol) in DMF (24 mL) is<br>
treated with potassium carbonate (813 mg, 5.88 mmol), then iodomethane (0.368 mL,<br>
5.88 mmol), and stirred for 60 h at it. The reaction mixture is acidified and extracted into<br>
emyl acetate twice. The combined organic layers are washed with brine, dried, filtered,<br>
and concentrated, then taken up in ethyl acetate, washed with saturated aqueous<br>
^assium carbonate, dried, filtered and concentrated to give 5-acetyl-thiophene-2-<br>
carboxylic acid methyl ester (653 mg).<br>
Step B<br>
(R,S)-5-(l-Hydroxy-ethyI)-thiophene-2-carboxylic acid methyl ester<br>
A solution of 5-acetyl-thiophene-2-carboxylic acid methyl ester (650 mg, 3.53 mmol) in<br>
THF (35 mL) is cooled to 0 C under N2, treated with sodium borohydride (54 mg, 1.44<br>
mmol), wanned to rt, and stirred overnight. The reaction is quenched with aqueous<br>
buffer (pH = 7), and extracted into ethyl acetate twice. Combined organic layers are<br>
washed with brine, dried, filtered, and concentrated. The crude product is applied to<br>
silica gel and eluted using hexanes with an ethyl acetate gradient from 0% to 60% to give<br>
the tide compound (535 mg).<br>
Preparation 2<br>
(R,S)-5-(l-Hydroxy-propyl)-thiophene-2-carboxylic acid ethyl ester<br>
Step A <br>
5-FormyI-thiophene-2-carboxylic acid ethyl ester<br>
A solution of diisopropylamine (0.588 mL, 60 mmol) in THF (20 mL) under N2 is cooled<br>
to -78 C and treated with n-butyllithium (2.5 M in hexanes, 1.66 mL). The mixture is<br>
then warmed to 0 C for 10 min, cooled back to -78 C, treated dropwise with a solution<br>
of thiophene-2-carboxylic acid ethyl ester (0.5 g, 3.2 mmol) in THF (12 mL), and stirred<br>
5 min. N,N-dimethylformarnide (0.324 mL, 4.16 mmol) is then added, arid the reaction is<br>
allowed to warm to rt, while stirring overnight. Aqueous buffer (pH = 7) is added, and<br>
the product is extracted into ethyl acetate (3x). Combined organic layers are dried,<br>
filtered, and concentrated. The resulting residue is applied to silica gel and eluted using<br>
hexanes with an ethyl acetate gradient from 0% to 40% to give 5-formyl-thiophene-2-<br>
carboxylic acid ethyl ester (325 mg).<br>
Step B<br>
(R,S)-5-(l-Hydroxy-propyl)-thiophene-2-carboxylic acid ethyl ester<br>
A solution of 5-formyl-thiophene-2-carboxylic acid ethyl ester (136 mg, 0.739 mmol) in<br>
THF (7.4 mL) under N2 is cooled to 0 C, treated with ethylmagnesium bromide (3.0 M<br>
in Et20,0.271 mL, 0.813 mmol), allowed to warm to rt, and stirred overnight. The<br>
reaction is then acidified, extracted into ethyl acetate (2x), dried, filtered, and<br>
concentrated. The resulting residue is applied to silica gel and eluted using hexanes with<br>
an ethyl acetate gradient from 0% to 40% to give the title compound (81 mg).<br>
The following compounds are made in a substantially similar manner:<br>
Preparation 3<br>
(R,S)-5-(l-Hydroxy-butyJ)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 2 using 5-<br>
formyl-thiophene-2-carboxylic acid ethyl ester and n-propyl magnesium bromide as the<br>
starting materials.<br>
Preparation 4<br>
(R,S)-5-(l-Hydroxy-hexyI)-thiophene-2-carboxyIic add ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 2 using 5-<br>
formyl-thiophene-2-carboxylic acid ethyl ester and n-pentyl magnesium bromide as the<br>
starting materials.<br>
Preparation 5<br>
(R^S)-5-(CydohexyI-hydroxy-methyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 2 using 5-<br>
formyl-thiophene-2-carboxyhc acid ethyl ester and cyclohexyl magnesium bromide as the<br>
starting materials.<br>
Preparation 6<br>
(RyS)-5-(l-Hydroxy-2^-dimethyl-propyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 2 using 5-<br>
formyl-thiophene-2-carboxylic acid ethyl ester and (-butyl magnesium chloride as the<br>
starting materials.<br>
Preparation 7<br>
(R^S)-S-(l-Hydroxy-3^-dimethyl-butyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 2 using 5-<br>
formyl-thiophene-2-carboxylic acid ethyl ester and neo-pentyl magnesium chloride as the<br>
starting materials.<br>
Preparation 8<br>
5-Hydroxymethyl-thiophene-2-carboxylic acid ethyl ester<br><br>
This material is the byproduct of Preparation 2, Step B.<br>
Preparation 9<br>
(R,S)-5-(l-Hydroxy-3-methyl-butyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
A solution of diisopropylamine (8.55 mL, 60 mmol) in THF (350 mL) under N2 is cooled<br>
to -78 C and treated with n-butyllithium (2.5 M in hexanes, 24 mL). The mixture is then<br>
warmed to 0 C for 10 min, cooled back to -78 C, treated dropwise with a solution of<br>
thiophene-2-carboxylic acid ethyl ester (7.8 g, 50 mmol) in THF (150 mL), and stirred 5<br>
min. 3-Methyl-butyraldehyde (6.48 mL, 60 mmol) is then added, and me reaction is<br>
allowed to warm to rt, while stirring overnight Aqueous buffer (pH = 7) is added, and<br>
the product is extracted into ethyl acetate (3x). Combined organic layers are dried,<br>
filtered, and concentrated. The resulting residue is applied to silica gel and eluted using<br>
hexanes with an ethyl acetate gradient from 0% to 60% to give the title compound (8.03<br>
gj-<br>
Preparation 10<br>
5-(l-Hydroxy-l-methyl-ethyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made substantially as described for Preparation 9.<br>
Preparation 11<br>
(R)-5-(l-Hydroxy-4-methyl-pentyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
A solution of 5-formyl-thiophene-2-carboxylic acid ethyl ester (444 mg, 2.61 mmol) in<br>
THF (26 mL) under N2 is cooled to -10 C, treated with boron trifhioride diethyl etherate<br>
(0.033 mL, 0.26 mmol) and 3-methylbutylzinc bromide (0.5 M solution in THF, 2.87<br>
mmol, 5.73 mL), allowed to warm to rt, and stirred overnight The reaction is then<br>
acidified, extracted into ethyl acetate (2x), dried, filtered, and concentrated. The resulting<br>
residue is applied to silica gel and eluted using hexanes with an ethyl acetate gradient<br>
from 0% to 50% to give the title compound (204 mg).<br>
Preparation 12<br>
(R,S)-5-(l-Hydroxy-2-methyl-propyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
A solution of i-Pr2NH (1.26 mL, 9.20 mmol) in THF (35 mL) at -78 C is treated with n-<br>
BuLi (5.6 mL, 1.6M, 9.0 mmol) over the course of 3 minutes. The solution is warmed to<br>
rt for 10 min., then recooled to 78 C. Ethyl 2-thiophene carboxylate (1.00 mL, 7.44<br>
mol) is added dropwise and the resulting solution is stirred for 15 min., then<br>
isobutyraldehyde (0.81 mL, 9.14 mmol) is added and the reaction is wanned to rt and<br>
stirred overnight. The resulting solution is quenched with saturated NH4CI (25 mL) and<br>
extracted with EtOAc (2 x 50 mL). Combined extracts are washed with H2O, brine, dried<br>
over MgS04, filtered, and concentrated. The residue is loaded onto silica gel and eluted<br>
with hexanes using a gradient of 0% to 30% EtOAc giving 5-(l-hydroxy-2-methyl-<br>
propyl)-thiophene-2-carboxylic acid ethyl ester (1.25 g, 73%) as a yellow oil. MS (ES):<br>
211.1 [M+H-H2Of.<br>
The following compounds are made in a substantially similar manner:<br>
Preparation 13<br>
(R,S)-5-(l-Hylroxy-ethyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 11 using<br>
acetaldehyde as the starting material. (10.98 g, 85% yield). MS (ES): 201.0 [M+H]+.<br>
Preparation 14<br>
(R,S)-5-(l-Hydroxy-butyi)-thiophene-2-carboxyHc acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 11 using<br>
butyraldehyde as the starting material. (9.92 g, 68% yield). MS (ES): 229.2 [M+HJ+.<br>
Preparation 15<br>
(R,S)-5-(l-Hydroxy-3-methyl-butyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 11 using 3-<br>
methyl-butyraldehyde as the starting material. (0.373 g, 21% yield). MS (ES): 225.1<br>
[M+H-H2Of.<br>
Preparation 16<br>
(R,S)-5-(l-Hydroxy-pentyI)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 11 using<br>
pentanal as the starting material. (10.65 g, 69% yield). MS (ES): 243.1 [M+H]+.<br>
Preparation 17<br>
(R,S)-5-(l-Hydroxy-octyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 11 using<br>
octanal as the starting material. (0.467 g, 22% yield). MS (ES): 268.1 [M+H-H20]+.<br>
Preparation 18<br>
(R,S)-3-Chloro-5-(l-hydroxy-propyl)-thiophene-2-carboxylic add ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 11 using 3-<br>
chloro-thiophene-2-carboxylic acid ethyl ester and propibnaldehyde as the starting<br>
materials. (0.499 g, 37% yield).<br>
Preparation 19<br>
(R,S)-5-(l-Hydroxy-2^2-dimethyl-propyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
Preparation 20<br>
(R,S)-5-(l-Hydroxy-3,3-dimethyl-butyl)-thiophene-2-carboxyIic acid ethyl ester<br><br>
Preparation 21<br>
(R)-5-(l-Hydroxy-3,3-dimethyl-butyI)-thiophene-3-carboxylic acid methyl ester<br><br>
A solution of 5-formyl-thiophene-3-carboxylic acid methyl ester (0.504 g, 2.96 mmol) in<br>
Et20 (30 mL) at 0 C is treated with neopentyl magnesium chloride (7.1 mL, 0.5 M in<br>
Et20, 3.6 mmol) and stirred for 15 min. Solution warmed to rt and additional Et20 (10<br>
mL) added. The reaction mixture is stirred overnight at rt. after which it is poured into<br>
H2O (30 mL) and extracted with EtOAc (3 x 50 mL). Combined extracts washed with<br>
brine, dried over MgSCU, filtered, and concentrated. The residue is loaded onto silica gel<br>
and eluted using hexanes with an ethyl acetate gradient from 0% to 50%. The resulting<br>
mixture is then loaded onto Cis and eluted using H20 and a MeCN gradient from 15% to<br>
100% giving ()-5-(l-hydroxy-3,3-dimethyl-butyl)-thiophene-3-carboxylic acid mediyl<br>
ester (0.316 g, 44%) as a light yellow syrup.<br>
Preparation 22<br>
(R^)-4-Chloro-5-(l-hydroxy-propy])-thiophene-2-carboxylic acid methyl ester<br><br>
Step A<br>
4&gt;5-Dichloro-thiophene-2-carboxylicacid<br>
a solution of i'-Pr2NH (1.80 mL, 12.9 mmol) in THF (65 mL) at -78 C is treated with n-<br>
BuLi (7.8 mL, 1.6M, 12.5 mmol). The solution is warmed to 0 C for 10 min., then<br>
recooled to -78 C. A solution of 2,3-dichlorothiophene (2.00 g, 13.1 mmol) in THF (3.0<br>
mL) is added dropwise and the resulting solution is stirred for 40 min, then anhydrous<br>
CO2 (^ is bubbled through the solution for 8 min. The reaction is warmed to rt and<br>
acidified with 1 N HC1 (25 mL) and extracted with EtOAc (2 x 50 mL). Combined<br>
extracts are dried over MgSC&gt;4, filtered, and concentrated giving 4,5-dichloro-thiophene-<br>
2-carboxylic acid (1.94 g, 75%) as a white solid. MS (ES): 197.0 [M+Hf.<br>
StepB<br>
4-Chloro-5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid methyl ester<br>
A solution of 4,5-dichloro-thiophene-2-carboxylic acid in THF (25 mL) at -53 C is<br>
treated with LiHMDS (2.5 mL, 1M THF) and then cooled to -78 C for 10 min. Tert-<br>
butyl lithium (3.2 mL, 1.7 M Pentane, 5.4 mmol) is added dropwise for 12 min., then<br>
treated with propanal (0.25 mL, 3.4 mmol). After 5 min. the reaction is warmed to rt and.<br>
stirred overnight. The reaction mixture is then acidified with 1 N HC1 (10 mL) and<br>
extracted with EtOAc (3 x 25 mL). Combined organic extracts are dried over MgSC^,<br>
filtered, and concentrated to provide crude 4-chloro-5-(l-hydroxy-propyl)-thiophene-2-<br>
carboxylic acid as a brown syrup (0.280 g), which is used in the next step without further<br>
purification.<br>
A solution of crude 4-chloro-5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid (0.262 g)<br>
in dimethylformamide (6.0 mL) is treated with K2CO3 (0.502 g, 3.63 mmol) and<br>
iodomethane (0.17 mL, 2.73 mmol) and stirred overnight The reaction mixture is then<br>
poured into H2O (15 mL) and extracted with EtOAc (3 x 10 mL). Combined organic<br>
extracts are washed with brine (lx), dried over MgSCU, filtered, and concentrated. The<br>
residue is loaded onto silica gel and eluted with hexanes using a gradient of 0% to 50%<br>
EtOAc to provide 4-chloro-5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid methyl<br>
ester (87.6 mg, 15% - 2 steps) as a yellow syrup. MS (ES): 216.9 [M+H]+.<br>
Preparation 23<br>
5-(l-Ethyl-l-hydroxymethyl-propyl)-thiophene-2-carboxylic acid methyl ester<br><br>
Step A<br>
2-Ethyl-2-thiophen-2-yI-butyric acid methyl ester<br>
A mixture of thiophen-2-yl-acetic acid methyl ester (3.00 g, 19.2 mmol) in DMF (85 mL)<br>
at 0 C is treated with NaH (60% dispersion in mineral oil, 1.71 g, 42.8 mmol). After 5.<br>
min, iodoethane (3.5 mL, 43.8 mmol) is added. The reaction mixture is warmed to rt and<br>
stirred overnight. The mixture is cooled in a cold water bath and quenched with H2O<br>
(150 mL). The mixture is extracted with EtOAc (3 x 100 mL). Combined extracts are<br>
washed with H2O, brine, dried over MgS04, filtered, and concentrated. The residue is<br>
loaded onto silica gel and eluted with hexanes using a gradient of 0% to 50% EtOAc to<br>
provide 2-ethyl-2-thiophen-2-yl-butyric acid methyl ester 3.67 g, 909%) as a light yellow<br>
oil.<br>
Step B<br>
2-Ethyl-2-thiophen-2-yl-butan-l-ol<br>
A solution of 2-methyl-2-thiophen-2-yl-propionic acid methyl ester (3.66 g, 17.2 mmol)<br>
in CH2C12 (85 mL) at 0 C is treated with diisobutylaluminum hydrde (Dibal-H, 1.0 M<br>
PhMe, 38.0 mL, 384.0 mmol) and warmed to rt overnight. The reaction mixture is<br>
carefully poured into IN tartaric acid (100 mL) and stirred for 3 d. The layers are<br>
separated and the aqueous layer is extracted with CH2CI2 (100 mL). The combined<br>
extracts are dried over MgS04, filtered, and concentrated. The residue is loaded onto<br>
silica gel and eluted with hexanes using a gradient of 0% to 75% EtOAc to give 2-ethyl-<br>
2-thiophen-2-yl-butan-l-ol (2.87 g, 90%) as a pink oil.<br>
Step C<br>
5-(l-Ethyl-l-hydroxymethyl-propyl)-thiophcne-2-carboxylic acid<br>
A solution of 2-ethyl-2-thiophen-2-yI-butan-l-ol (2.87 g, 15.6 mmol) in THF (100 mL) is<br>
cooled to -78 C and treated with f-BuLi (1.7M in pentane, 19.3 mL, 32.8 mmol)<br>
dropwise over 10 min. After stirring for 20 min, CO2 (g) is bubbled through the solution<br>
for 3 min. The solution is then warmed to rt and stirred overnight. The reaction is<br>
acidified with IN HCl (35 mL). The mixture is extracted with EtOAc (3 x 100 mL). The<br>
combined extracts are dried over MgS04, filtered, and concentrated. The residue is<br>
loaded onto Cis resin and eluted witii H2O using a gradient of 15% to 100% MeCN to<br>
give 5-(l-emyl-l-hydroxymethyl-propyl)-uiiophene-2-carboxylic acid (0.7471 g, 21%) as<br>
a white solid. MS (ES): 227.1 [M-H]StepD<br>
5-(l-EthyI-l-hydroxvmethyI-propyl)-thiophene-2-carboxylic acid methyl ester<br>
A solution of 5-(l-ethyl-l-hydroxymethyl-propyl)-thiophene-2-carboxylic acid (0.750 g,<br>
3.28 mmol) in DMF (16.0 mL) is treated with K2CO3 (0.684 g, 6.00 mmol), iodomethane<br>
(0.27 mL, 4.34 mmol), and stirred at rt overnight. The mixture is poured into HjO (30<br>
mL) and extracted with EtOAc (3 x 30 mL). The combined extracts are washed with<br>
H2O, brine, dried over MgS04, filtered, and concentrated. The residue is loaded onto<br>
silica gel and eluted with hexanes using a gradient of 0% to 75% EtOAc to give 5-(l-<br>
ethyl-l-hydroxymethyl-propyl)-thiophene-2-carboxylic acid methyl ester (0.571 g, 72%)<br>
as a clear syrup. MS (ES): 243.2 [M+Hf.<br>
The following compound is made in a substantially similar manner:<br>
Preparation 24<br>
. (R,S)-5-(l-Hydroxymethyl-propyl)-thiophene-2-carboxylic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Example 23 using 1 eq<br>
of sodium hydride and iodoethane as the starting materials in step A. MS (ES): 215.1<br>
[M+Hf.<br>
Preparation 25<br>
(R)-5^1-Hydroxy-4,4-dimethyl-pentyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
Step A<br>
5-Formyl-thiophene-2-carboxylic acid ethyl ester<br>
A solution of diisopropylamine (0.588 mL, 60 mmol) in THF (20 mL) under N2 is cooled<br>
to -78 C and treated with n-butyllithium (2.5 M in hexanes, 1.66 mL). The mixture is<br>
then wanned to 0 C for 10 min, cooled back to -78 C, treated dropwise with a solution<br>
of thiophene-2-carboxylic acid ethyl ester (0.5 g, 3.2 mmol) in THF (12 mL), and stirred<br>
5ijkin. N,N-Dimethylformamide (0.324 mL, 4.16 mmol) is then added, and the reaction<br>
is allowed to warm to rt, while stirring overnight. Aqueous buffer (pH = 7) is added, and<br>
the product is extracted into ethyl acetate (3x). Combined organic layers are dried,<br>
filtered, and concentrated. The resulting residue is applied to silica gel and eluted using<br>
hexanes with an ediyl acetate gradient from 0% to 40% to give 5-formyl-thiophene-2-<br>
carboxylic acid ethyl ester (325 mg).<br>
Step B<br>
3,3-Dimethylbutylmagnesium bromide<br>
In an oven-dried flask, a suspension of magnesium turnings (1.82 g, 75 mmol) in THF (40<br>
mL) is treated with molecular iodine (254 mg, 1 mmol). To this mixture is added twenty<br>
drops of a solution of 3,3-dimethylbutyl bromide (7.14 mL, 50 mmol) in THF (10 mL)<br>
via a fitted separatory funnel. The resulting mixture is heated to reflux, followed by<br>
addition of the remaining 3,3-dimethylbutyl bromide solution. The reaction mixture is<br>
allowed to reflux for lh, cooled to rt, and used as is (1.0 M solution of 3,3-<br>
dimethylbutylmagnesium bromide in THF, 50 mmol).<br>
StepC<br>
(R)-5-(l-Hydroxy-4,4-dimethyl-pentyl)-thiophene-2-carboxyIic acid ethyl ester<br>
A solution of 5-formyl-thiophene-2-carboxylic acid ethyl ester (3.12 g, 16.9 mmol) in<br>
THF (169 mL) under N2 is cooled to 0 C, treated with 3,3-dimediylbutylmagnesium<br>
bromide (1.0 M in THF, 16.9 mL, 16.9 mmol), allowed to warm to rt, and stirred<br>
overnight. The reaction is men acidified, extracted into ethyl acetate (2x), dried, filtered,<br>
and concentrated. The resulting residue is applied to silica gel and eluted using hexanes<br>
with an ethyl acetate gradient from 0% to 60% to give the title compound (730 mg).<br>
Preparation 26<br>
2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-ol<br><br>
To a solution of 4-iodo-3,5-dimethyl-phenol (3.35 g, 13.5 mmol) in THF (81 ml)<br>
is added (4-trifluoromethyl)phenylboronic acid (3.35 g, 16.2 mmol), potassium fluoride<br>
(1.94 mg, 40.6 mmol), palladium(n) acetate (152 mg, 0.67 mmol), and (oxydi-2,1-<br>
phenylene)bis-(diphenylphosphine) (730 mg, 1.35 mmol). The reaction mixture is heated<br>
to reflux overnight After cooling to rt, the reaction mixture is partitioned between ethyl<br>
acetate and water. The aqueous layer is back-extracted with ethyl acetate, the combined<br>
organic layers are dried and concentrated. The resulting residue is applied to silica gel and<br>
eluted using hexanes with an ethyl acetate gradient from 0% to 70% to give the title<br>
compound (3.3 g).<br>
Preparation 27<br>
4'-tert-Butyl-2,6-dimethyl-biphenyl-4-ol<br><br>
This compound is made in a substantially similar manner as exemplified in Preparation<br>
26 staring from 4-tert-butyl-phenyl boronic acid and 4-bromo-3,5-dimethyl phenol.<br>
Preparation 27<br>
4'-tert-ButyI-2-methyl-biphenyl-4-ol<br><br>
This compound is made by the general method as exemplified in Preparation 26<br>
using 4-bromo-3-methyl-phenol and 4-tert-butyl-phenyl boronic acid as reagents.<br>
Preparation 28<br>
6-(4-tert-Butyl-phenyl)-pyridin-3-ol<br><br>
To a solution of 6-Chloro-pyridin-3-ol (3.10 g, 23.9 mmol) in toluene (30 ml) is added 4-<br>
terf-butyl-phenylboronic acid (5.46 g, 30.6 mmol), potassium fluoride (2.82 g, 47.9<br>
mmol), and palladium tetrakis triphenylphosphine (1.20 g, 1.20 mmol). Water (15 mL) is<br>
added and the reaction mixture is heated to reflux overnight. After cooling to it, the<br>
reaction mixture is partitioned between ethyl acetate and water. The aqueous layer is<br>
back-extracted with ethyl acetate, the combined organic layers are dried and concentrated.<br>
Tljie resulting residue is applied to silica gel and eluted using hexanes with an ethyl<br>
acetate gradient to give the title compound (2.06 g).<br>
Preparation 29<br>
6-(4-Trifluoromethyl-phenyl)-pyridin-3-oI<br><br>
The titled compound is made in a manner substantially similar to Preparation 28 starting<br>
from the 6-chloro-pyridin-3-ol and 4-trifluoromethylphenyl boronic acid.<br>
Preparation 30<br>
4'-tert-Butyl-2,6-dimethyl-biphenyl-4-thiol<br>
Step A <br>
Dimethyl-thiocarbamic acid 0-(4'-tert-butyI-2,6-dimethyI-biphenyl-4-yl) ester<br>
To a solution of 4'-tert-butyl-2,6-dirnethyl-biphenyl-4-ol (10 g, 37.3 mmol) in dioxane<br>
(157 ml) is added 4-dimethylaminopyridine (476 mg, 3.9 mmol), triethylamine (10 mL,<br>
78.6 mmol), and dimethyldiiocarbamoyl chloride (6.1 g, 49.1 mmol). The reaction<br>
mixture is heated to reflux overnight. After cooling to rt, the reaction mixture is<br>
partitioned between ethyl acetate and water. The aqueous layer is back-extracted with<br>
ethyl acetate, and the combined organic layers are dried and concentrated. The resulting<br>
residue is applied to silica gel and eluted using 20% ethyl acetate in hexanes to give<br>
dimethyl-thiocarbamic acid 0-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yl) ester (12.2 g).<br>
StepB<br>
Dimethyl-thiocarbamic acid S-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yI) ester<br>
A suspension of dimethyl-thiocarbamic acid 0-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yl)<br>
ester (12.1 g, 35.4 mmol) in tetradecane (80 mL) was heated at 245 C for 16 h. After<br>
cooling to rt, a solid precipitate is filtered, washed with heptane, and dried under vacuum<br>
at 40 C. The resulting residue is applied to silica gel and eluted using hexanes with an<br>
ethyl acetate gradient from 0% to 60% to give dimethyl-thiocarbamic acid S-(4'-tert-<br>
butyl-2,6-dimethyl-biphenyI-4-yl) ester (8.86 g).<br>
StepC<br>
4'-tert-Butyl-2,6-dimethyl-biphenyl-4-thioI<br>
To a solution of dimethyl-thiocarbamic acid S-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yl)<br>
ester (8.8 g, 25.8 mmol) in methanol (65 mL) is added sodium methoxide (1.39 g, 25.8<br>
mmol). The reaction mixture is heated to reflux overnight After cooling to rt, the<br>
reaction mixture is neutralized with 5N HC1, concentrated to 1/3 volume, treated with<br>
brine, and extracted into dichloromethane. The aqueous layer is back-extracted with<br>
dichloromethane, and the combined organic layers are dried and concentrated. The<br>
resulting residue is applied to silica gel and eluted using hexanes with an ethyl acetate<br>
gradient from 0% to 50% to give the title compound (5.84 g).<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 31<br>
2,6-Dimethyl-4'-trifluoromethyI-biphenyl-4-thiol<br>
MS (ES): 281.1 [M-H]\ <br>
Preparation 32<br>
4'-Isopropyl-2,6-dimethyl-biphenyl-4-thioI<br><br>
Preparation 33<br>
(R^S)-3.({5-tl-(2,6-DimethyI-4,-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-<br>
2-carbonyl}-amino)-propionic acid<br><br>
Step A<br>
(R,S)-5-[l-(2,6-Dimethyl-4'.trifluoromethyI-biphenyI-4-yIoxy)-ethyI]-thiophene-2-<br>
carboxylic acid ethyl ester<br>
A mixture of ()-5-(l-hydroxy-ethyl)-thiophene-2-carboxylic acid ethyl ester (0.402 g,<br>
2.01 mmol), 2,6-dimcthyl-4'-trifluoromethyl-biphenyl-4-ol (0.593 g, 2.23 mmol), and<br>
PPh3 (0.798 g, 3.04 mmol) is dissolved in toluene (20 mL) and treated with 1,1'-<br>
(azodicarbonyl)dipiperidine (ADDP, 0.763 g, 3.02 mmol) and stirred overnight at rt. The<br>
mixture is diluted with MeOH until homogeneous and concentrated. The residue is<br>
loaded onto silica gel and eluted using hexanes with an ethyl acetate gradient from 0% to<br>
40% giving ()-5-[ 1 -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-<br>
thiophene-2-carboxylic acid ethyl ester (0.638 g, 71%) as a clear syrup. MS (ES): 447.3<br>
[M-H]StepB<br>
(R,S)-5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-<br>
carboxylic acid<br>
To a mixture of ()-5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-<br>
thiophene-2-carboxylic acid ethyl ester (0.636 g, 1.42 mmol) in THF (14 mL) is added<br>
lithium hydroxide (IN aqueous, 14 mL). The mixture is warmed to 70 C and stirred<br>
overnight. The reaction mixture is acidified with IN HC1 (15 mL), extracted into ethyl<br>
acetate (3 x 25 mL), dried over MgS04, and concentrated, to provide ()-5-[l-(2,6-<br>
dimethyW'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carboxylic acid (0.552<br>
g, 92%) as a white foam. MS (ES): 419.2 [M-H]".<br>
Step C<br>
(RJS)-3-({5.[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-<br>
2-carbonyl}-amino)-propionic acid methyl ester<br>
To a mixture of (&gt;5-[l-(2,6-dimethyl-4'-trifIuoromethyl-biphenyl-4-yloxy)-ethyl]-<br>
thiophene-2-carboxylic acid (0.545 g, 1.30 mmol), 3-amino-propionic acid methyl ester<br>
hydrochloride (0.199 g, 1.43 mmol), and 1-hydroxybenzotriazole hydrate (HOBt, 0.217 g,<br>
1.60 mmol) in DMF (13.0 mL) is added N, N-diisopropylemylarnine (0.67 niL, 3.84<br>
mmol), then N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDCI,<br>
0.330 g, 1.72 mmol) and stirred overnight. The reaction mixture is poured into H2O (25<br>
mL) and extracted with EtOAc (3 x 25 mL). Combined organic extracts are washed with<br>
H2O, brine, dried over MgS04, filtered, and concentrated. The residue is loaded onto<br>
silica gel and etuted using hexanes with an ethyl acetate gradient from 0% to 75% to<br>
provide ()-3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.490 g, 75%) as a white<br>
foam. MS (ES): 504.3 [M-H]The following compounds are made in a substantially similar manner.<br>
Preparation 34<br>
(R^S)-3-({5-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyI]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES): 504.2 [M-H]\ The<br>
racemic material (183 mg) is separated by chiral HPLC (column: Chiralpak AD 4.6 x 150<br>
mm; eluent: 50% heptane:50% isopropanol; flow rate: 0.6 mL/min; UV absorbance<br>
wavelength: 270 nm) to provide chiral Isomer 1 (71 mg, 98.4% ee) and chiral Isomer 2<br>
(74 mg, 99.8% ee).<br>
Preparation 35<br>
(R3)-3-({5-[3-Methyl-l-(4,-trifluoromethyl-biphenyl-4-yIoxy)-butyl]-<br>
thiophene-2-carbonyI}-amino)-propionic acid methyl ester<br><br>
JJjiiS compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES): 518.3 [M-H]'.<br>
Preparation 36<br>
(RyS)-3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-octyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES): 560.2 [M-H]'. The<br>
racemic material (287 mg) is separated by chiral HPLC (column: Chiralpak AD 4.6 x 150<br>
mm; eluent: 100% 3A ethanol; flow rate: 0.6 mL/min; UV absorbance wavelength: 270<br>
nm) to provide chiral Isomer 1 (131 mg, 98.1% ee) and chiral Isomer 2 (125 mg, 98.3%<br>
ee).<br>
Preparation 37<br>
(R,S)-3-({5-[l-(4,-tert-ButyI-2,6-dimethyl-biphenyI-4-yloxy)-ethyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
tert-butyl-2,6-dimethyl-biphenyl-4-ol as the starting material. MS (ES): 492.1 [M-H]".<br>
Preparation 38<br>
(R,S)-3.({3-Chloro-5-[l.(2,6-dimethyl-4'-trifluoromethyl.biphenyI-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using<br>
2,6-dimethyl-4'-trifluoromeihyl-biphenyl-4-ol as the starting material. MS (ES): 552.2<br>
[M-H]\ '<br>
Preparation 39<br>
0*,S)-3
----------thiophene-2-carbonyl}-amino)-propionic acid methyl ester--------<br><br>
This compound is made by. the general method as exemplified in Preparation 33 using 2-<br>
methyl-4'-trifluoromethyl-biphe!nyl-4-ol as the starting material. MS (ES): 538.2 [M-H]Preparation 40<br>
(R3)-3-({5-[l-(2,6-Dimethyl-4,-trifluoromethyI-bipbenyl-4-yloxy)-2-methyI-propyl].<br>
thiophene.2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using<br>
2,6-dimettiyl-4'-trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES): 532.2<br>
[M-HJPreparation 41<br>
(R,S)-3-({5-[2-MethyI.l-(2-methyl-4,-trinuoromethyl-biphenyl-4-yloxy)-propyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 2-<br>
methyl-4'-trifluoromethyl-bipbenyl-4-ol as the starting material. MS (ES): 518.1 [M-H]Preparation 42<br>
(R,S)-3-({5-ll-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
tert-butyI-2,6-dirnethyl-bipbenyl-4-ol as the starting material. MS (ES): 522.3 [M+H]+.<br>
The racemic material (261 nig) is separated by chiral HPLC (column: Chiralpak OJ-H 4.6<br>
x 150 mm; eluent: 100% MeOH; flow rate: 0.6 mL/min; UV absorbance wavelength: 270<br>
nm) to provide chiral Isomer 1 (120 mg, 99.5% ee) and chiral Isomer 2(119 mg, 100%<br>
ee).<br>
Preparation 43<br>
(R^S)-3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
tert-butyl-2-methyl-biphenyl-4-ol as the starting material. MS (ES): 506.2 [M-H]\ The<br>
racemic material (235 mg) is separated by chiral HPLC (column: Chiralpak AD-H 4.6 x<br>
150 mm; eluent: 90% heptane:10% isopropanol; flow rate: 0.6 mL/min; UV absorbance<br>
wavelength: 250 nm) to provide chiral Isomer 1 (105 mg, 99.8% ee) and chiral Isomer 2<br>
(109 mg, 97.3% ee).<br>
Preparation 44<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-butyI]-thiophene-<br>
2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using<br>
2,6-dimemyl-4'-trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES):<br>
532.1[M-H]Preparation 45<br>
(R,S)-3-({5-[l-(2-MethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 2-<br>
methyW-trifluoromethyl-biphenyl^-ol as the starting material. MS (ES): 518.2 [M-H]".<br>
Preparation 46<br>
(R,S)-3.({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
. This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
tert-butyl-2,6-dimemyl-biphenyl-4-ol as the starting material. MS (ES): 522.5 [M+Hf.<br>
Preparation 47<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyM-yloxy)-butyl]-thlophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
tert-butyl-2-methyl-biphenyl-4-ol as the starting material. MS (ES): 508.5 [M+H]+.<br>
Preparation 48<br>
(R,S)-3.({5.[l-(2,6.Dimethyl-4*-trinuoromethyl-biphenyl-4-yloxy)-3^-dimethyl-<br>
butyl]-thiophene-3-carbonyI)-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using<br>
2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES): 560.3<br>
[M-H]'. The racemic material (186 mg) is separated by chiral HPLC (column: Chiralpak<br>
AD-H 4.6 x 150 mm; eluent: 2.5% 3A ethanol: 2.5% MeOH: 95% Heptane; flow rate: 0.6<br>
mL/min; UV absorbance wavelength: 250 nm) to provide chiral Isomer 1 (92 mg, 95.4%<br>
ee) and chiral Isomer 2 (83 mg, 100% ee).<br>
Preparation 49<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-lrifluoromethyl-biphenyl-4-yloxy)-pentyl]-thiophcne-<br>
2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using<br>
2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES): 546.3<br>
[M-H]".<br>
Preparation 50<br>
(R,S)-3-({5[l-(2-Methyl-4'-trifluoromethyl.biphenyl-4-y]oxy).pentyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 2-<br>
methyl-4'-trifluoromethyl-biphenyl-4-ol as the starting material. MS (ES): 532.3 [M-H]'.<br>
Preparation 51<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyI-biphenyl-4-y1oxy).pentyl]-ihiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
tert-butyl-2,6-dimethyl-biphenyl-4-ol as the starting material. MS (ES): 534.2 [M-H]".<br>
Preparation 52<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2-methyI-biphenyl-4-yloxy)-pentyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4'-<br>
tert-butyl-2-methyl-biphenyl-4-ol as the starting material. MS (ES): 520.3 [M-H]".<br>
Preparation 53<br>
(R3)-3-({5-[l-(4-Iodo-3^-dimethyl-phenoxy)-propyl]-thiophene-2-carbonyl&gt;-<br>
amino)-propionic acid methyl ester<br><br>
%is compound is made by the general method as exemplified in Preparation 33 using 4-<br>
iodo-3,5-dimethyl-phenol as the starting material. MS (ES): 500.1 [M-H]\ The racemic<br>
material (2.122 g) is separated by chiral HPLC (column: Chiralpak OJ-H 4.6 x 150 mm;<br>
eluent: 100% MeOH; flow rate: 0.6 mL/min; UV absorbance wavelength: 280 nm) to<br>
provide chiral Isomer 1 (1.06 g, 99.7% ee) and chiral Isomer 2 (1.07 g, 99.4% ee).<br>
Preparation 54<br>
(R3)-3-({5-[l-(4-Iodo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4-<br>
iodo-3,5-dimethyl-phenol as the starting material. MS (ES): 514.0 [M-H]". The racemic<br>
material (1.793 g) is separated by chiral HPLC (column: Chiralpak OJ-H 4.6 x 150 mm;<br>
eluent: 100% MeOH; flow rate: 0.6 mL/min; UV absorbance wavelength: 270 nm) to<br>
provide chiral Isomer 1 (0.831 g, 99.7% ee) and chiral Isomer 2 (0.885 g, 98.6% ee).<br>
Preparation 55<br>
(R^S)-3-({5-[l-(4-Iodo-3,5-dimethyl-phenoxy)-butyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 33 using 4-<br>
iodo-3,5-dimethyl-phenol as the starting material. MS (ES): 516.3 [M+H]\ The racemic<br>
material (1.697 g) is separated by chiral HPLC (column: Chiralpak AD-H 4.6 x 150 mm;<br>
eluent: 100% MeOH; flow rate: 0.6 mL/min; UV absorbance wavelength: 280 nm) to<br>
provide chiral Isomer 1 (0.733 g, 99.2% ee) and chiral Isomer 2 (0.820 g, 99.8% ee).<br>
Preparation 56<br>
5-t2-(2,6-Dimethyl-4'-trifluoromethyI-biphenyI-4-yloxy)-l,l-dimethyl-ethyl]-<br>
thiophene-2-carboxylic acid methyl ester<br>
Step A<br>
2-Methyl-2-thiophen-2-yl-propionic acid methyl ester<br>
A mixture of thiophen-2-yl-acetic acid methyl ester (2.001 g, 12.81 mmol) in DMF (40<br>
mL) at 0 C is treated with NaH (60% dispersion in mineral oil, 1.144 g, 28.60 mmol).<br>
After 2 min., iodorhethane (1.93 mL, 31.00 mmol) is added. The reaction mixture is<br>
warmed to rt and stirred overnight. The mixture is cooled in a cold water bath and<br>
quenched with H2O (40 mL). The mixture is diluted with additional H2O (40 mL) arid<br>
extracted with EtOAc (3 x 50 mL). Combined extracts washed with H20, brine, dried<br>
over MgS04, filtered, and concentrated. The residue is loaded onto silica gel and eluted<br>
with hexanes using a gradient of 0% to 40% EtOAc to provide 2-methyl-2-thiophen-2-yl-<br>
propionic acid methyl ester (2.107 g, 89%) as a clear oil.<br>
StepB<br>
2-Methyl-2-thiophen-2-yl-propan-l-ol<br>
A solution of 2-methyl-2-thiophen-2-yl-propionic acid methyl ester (2.085 g, 11.32<br>
mmol) in CH2CI2 (55 mL) at 0 C is treated with diisobutylaluminum hydrde (Dibal-H,<br>
1.0 M PhMe, 24.0 mL, 24.0 mmol) and warmed to rt after 4 min. After 1.5 h the reaction<br>
mixture is cooled to 0 CC and quenched with IN tartaric acid (50 mL) and stirred for 2 d.<br>
The layers are separated and the aqueous layer is extracted with CH2CI2 (1x50 mL). The<br>
combined extracts are dried over MgS04, filtered, and concentrated. The residue is<br>
loaded onto silica gel and eluted with hexanes using a gradient of 0% to 75% EtOAc to<br>
give 2-methyl-2-thiophen-2-yl-propan-l-ol (1.494 g, 84%) as a clear oil.<br>
StepC<br>
5-(2-Hydroxy-l,l-dimethyl-ethyl)-thiophene-2-carboxylicacid<br>
A solution of 2-methyl-2-thiophen-2-yl-propan-l-ol (1.481 g, 9.476 mmol) in THF (70<br>
mL) is cooled to -78 C and treated with f-BuLi (1.7M in pentane, 11.7 mL, 19.9 mmol)<br>
dropwise over 14 min. After stirring for 15 min, CO2 (g) is bubbled through the solution<br>
5 min. The solution is then wanned to rt and stirred overnight. The reaction is diluted<br>
with H2O and poured into IN HC1 (20 mL). The mixture is extracted with EtOAc (50<br>
mL, 2 x 25 mL). The combined extracts are dried over MgSCXj, filtered, and cone. The<br>
residue is loaded onto C^ and eluted with H20 using a gradient of 15% to 100% MeCN<br>
to give 5-(2-hydroxy-l,l-dimethyl-ethyl)-thiophene-2-carboxylic acid (0.511 g, 27%) as a<br>
white solid. MS (ES): 199.0 [M-H}StepD<br>
5-(2-Hydroxy-l,l-dimethyi-ethy])-thiophene-2-carboxylic acid methyl ester<br>
A solution of 5-(2-hydroxy-l,l-dimethyl-ethyl)-thiophene-2-carboxylic acid (0.495 g,<br>
2.47 mmol) in DMF (12.0 mL) is treated with K2C03 (0.515 g, 3.73 mmol), iodomethane<br>
(0.23 mL, 3.69 mmol), and stirred at rt overnight. The mixture is poured into H2O (25<br>
mL) and extracted with EtOAc (3 x 25 mL). The combined extracts are washed with<br>
H2O, brine, dried over MgS04, filtered, and concentrated. The residue is loaded onto<br>
silica gel and eluted with hexanes using a gradient of 0% to 75% EtOAc to give 5-(2-<br>
hydroxy-l,l-dimethyl-ethyl)-thiophene-2-carboxylic acid methyl ester (0.439 g, 83%).<br>
MS (ES): 215.1 [M+H]+.<br>
StepE<br>
5-[2-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-l,l-dimethyl-ethyl]-<br>
thiophene-2-carboxyIic acid methyl ester<br>
A mixture of 5-(2-hydroxy-l,l-dimethyl-ethyl)-thiophene-2-carboxylic acid methyl ester<br>
(0.436 g, 2.04 mmol), 2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol (0.596 g, 2.24<br>
mmol), and PPh3 (0.793 g, 3.02 mmol) is dissolved in toluene (20 mL), treated with 1,1'-<br>
(azodicarbonyl)dipiperidine (ADDP, 0.763 g, 3.02 mmol), and stirred overnight at 80 C.<br>
The mixture is then cooled to rt, diluted with MeOH until homogeneous, and<br>
concentrated. The residue is loaded onto silica gel and eluted using hexanes with an ethyl<br>
acetate gradient from 0% to 40% to afford 5-[2-(2,6-dimethyl-4'-trifluoromethyl-<br>
biphenyl-4-yloxy)-l,l-dimethyl-ethyl]-thiophene-2-carboxylic acid methyl ester (0.394 g,<br>
42%). MS (ES): 463.3 [M+H]+.<br>
The following compounds are made in a substantially similar manner;<br>
Preparation 57<br>
S-UK^WmetliyM'-trlflaoroinethyl-blphenyl^-yloxyinethylVl-ethyl-propyl]-<br>
thiopbene-2-carboxyItc add methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 56 using<br>
iodoethane as me starting material. MS (ES):_4S1_.3 (M+HJ*j _______.<br>
Preparation 58<br>
5-[l-AJryl-lK2,6HlimethyM^Uinuon)methyl-biphenyl^yloxym*thyl)-bnt-3-enyl]-<br>
thiophene-2-carboxytk add methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 56 using<br>
allyl bromide as the starting material. MS (ES): 515.3 [M+H]Preparation 59<br>
3-
enyl]-thiophne-2-carbonyl}-ainino&gt;propioiik add methyl ester<br><br>
5-[l-allyl-l-(2,6-diraethyI-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-but-3-enyl3-<br>
thiophene-2-carboxylic acid<br>
A solution of 5-[l-allyl-l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-but-<br>
3-enyl]-thiophene-2-carboxylic acid methyl ester (0.186 g, 0.361 mmol) in THF (4.0 mL)<br>
is treated with LiOH (IN aqueous, 4.0 mL, 4.0 mmol), warmed to 70 C, and stirred<br>
overnight. The reaction mixture is cooled to rt., acidified with HC1 (IN aqueous, 4.2<br>
mL), and extracted with EtOAc (3 x 10 mL). The combined extracts are dried over<br>
MgS04, filtered, and cone, to provide 5-[l-allyl-l-(2,6-dimethyl-4'-trifluoromethyl-<br>
biphenyl-4-yIoxymethyl)-but-3-enyl]-thiophene-2-carboxylic acid (0.171 g, 94%) as a<br>
white foam. MS (ES): 501.4 [M+H]Step B<br>
3-({5-[l-AHyl-l-(2,6-dimethyI-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-but-3-<br>
eny!]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br>
To a mixture of 5-[l-allyl-l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-<br>
but-3-enyl]-thiophene-2-carboxylic acid (0.1695 g, 0.338 mmol), 3-amino-propionic acid<br>
methyl ester hydrochloride (0.0533 g, 0.382 mmol), and 1-hydroxybenzotriazole hydrate<br>
(HOBt, 0.0561 g, 0.415 mmol) in DMF (3.5 mL) is added N, W-diisopropylethylamine<br>
(0.175 mL, 1.00 mmol), thenN-(3-dimethylaminopropyl)-N'-ethylcarbodiimide<br>
hydrochloride (EDCI, 0.0836 g, 0.436 mmol) and stirred overnight. The reaction mixture<br>
is poured into H2O (10 mL) and extracted with EtOAc (3 x 10 mL). Combined organic<br>
extracts are washed with HjO, brine, dried over MgSCU, filtered, and concentrated. The<br>
residue is loaded onto silica gel and eluted using hexanes with an ethyl acetate gradient<br>
from 0% to 75% to provide 3-({5-[l-allyl-l-(2,6-dimemyl-4Mrifluoromethyl-biphenyl-4-<br>
yloxymethyl)-but-3-enyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br>
(0.138 g, 70%) as a white foam. MS (ES): 584.3 [M-H]The following compounds are made in a substantially similar manner:<br>
Preparation 60<br>
3-({5-[2-(2,6-Dimethyl-4,-trifluoromethyI-biphenyl-4-yloxy)-l,l-dimethyl-ethyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 59 using 5-<br>
[2-(2,6-dimethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-1,1 -dimethyl-ethyl]-thiophene-2-<br>
carboxylic acid methyl ester as the starting material. MS (ES): 534.4 [M+HJPreparation 61<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyI-biphenyl-4-yloxymethyl)-l-ethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 59 using 5-<br>
[l-(2,6-dimethyl-4'-trifluoromemyl-biphenyl^-yloxymethyl)-l-ethyl-propyl]-thiophene-<br>
2-carboxylic acid methyl ester as the starting material. MS (ES): 562.5 [M+H]+.<br>
Preparation 62<br>
3-({5-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-cyclopent-3-<br>
enyI]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
Step A<br>
^je-dimethyl^'-trifluoromethyl-biphenyl^-yloxymethyO-cycIopent-S-enyl]-<br>
thiophene-2-carboxyIic acid methyl ester<br>
A solution of 5-[l-allyl-l-(2,6-dimethyl-4'-trifluoromethyI-biphenyl-4-yloxyniethyl)-but-<br>
3-enyl]-thiophene-2-carboxylic acid methyl ester (0.292 g, 0.567 mmol) in CH2C12 (270<br>
mL) is treated with [l,3-bis-(2,4,6-trimethylphenyl)-2-<br>
imidazolidinylidene)dichloro(phenylmethylene)-(tricyclohexylphosphine)ruthenium]<br>
(0.0528 g, 0.0622 mmol) for 4 h and concentrated. The residue is loaded onto silica gel<br>
and eluted using hexanes with an ethyl acetate gradient from 0% to 40% to afford 5-[l-<br>
(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-cyclopent-3-enyl]-thiophene-<br>
2-carboxylic acid methyl ester (0.240 g, 87%) as a colorless syrup. MS (ES): 487.4<br>
[M+H]+.<br>
StepB<br>
5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yIoxymethyl)-cycIopent-3-enyl]-<br>
thiophene-2-carboxylic acid<br>
A solution of 5-[l-(2,6-dimethyl-4'-ttifluoromethyl-biphenyl-4-yloxymethyl)-cyclopent-<br>
3-enyl]-thiophene-2-carboxylic acid methyl ester (0.239 g, 0.492 mmol) in THF (5.0 mL)<br>
is treated witii LiOH (IN aqueous, 5.0 mL, 5.0 mmol), warmed to 70 C, and stirred<br>
overnight. The reaction mixture is cooled to rt, acidified with HC1 (IN aqueous, 5.2 mL),<br>
and extracted with EtOAc (3x10 mL). The combined extracts are dried over MgS04,<br>
filtered, and concentrated to provide 5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-<br>
yloxymethyl)-cyclopent-3-enyl]-thiophene-2-carboxylic acid (0.210 g, 90%) as a yellow<br>
foam. MS (ES): 471.2 [M-H]'.<br>
Step C<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-cyclopent-3-<br>
enyl]-thiophene-2-carbony!}-amino)-propionic acid methyl ester<br>
To a mixture of 5-(l-(2,6-dimethyl-4,-trifluoromeuTiyl-biphenyl-4-yloxymethyl)-<br>
cyclopent-3-enyl]-thiophene-2-carboxylic acid (0.204 g, 0.433 mmol), 3-amino-propionic<br>
acid methyl ester hydrochloride (0.0665 g, 0.476 mmol), and 1-hydroxybenzotriazole<br>
hydrate (HOBt, 0.0716 g, 0.530 mmol) in DMF (4.0 mL) is added N, N-<br>
diisopropylethylamine (0.240 mL, 1.37 mmol), then N-(3-dimethylaminopropyl)-N'-<br>
ethylcarbodiimide hydrochloride (EDCI, 0.106 g, 0.553 mmol) and stirred overnight. The<br>
reaction mixture is poured into H2O (10 mL) and extracted with EtOAc (3 x 10 mL).<br>
""" Combined organic extracts are washed with H2O, brine, dried over MgS04, filtered, and<br>
concentrated. The residue is loaded onto silica gel and eluted using hexanes with an ethyl<br>
acetate gradient from 0% to 75% to provide 3-({5-tl-(2,6-dimethyl-4'-trifluoromethyl-<br>
biphenyl-4-yloxymethyl)^clopent-3-enyl]-thiophene-2-carbonyl}-amino)-propionic<br>
acid methyl ester (0.158 g, 65%) as a white foam. MS (ES): 556.3 [M-H]Preparation 63<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyI)-cyclopentyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
A solution of 3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-<br>
cydopent-3-enyl]-thiophene-2-carbonyl}-anu^o)-propionic acid methyl ester (0.0828 g,<br>
0.148 mmol) in EtOH (2.0 mL) is treated with 10% palladium on carbon (16 mg), flushed<br>
with H2, and stirred under 1 atm pressure for 50 min. The mixture is then filtered through<br>
Celite and concentrated, to provide 3-({5-tl-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-<br>
4-yloxvmemyl)-cyclopentyl]-miophene-2-caitonyl}-arnino)-propionic acid methyl ester<br>
(0.0770 g, 93%) as a white foam. MS (ES): 558.3 [M-H]~.<br>
Preparation 64<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-l-propyl-butyl]-<br>
thiophene-2'Carbonyl}-amino)-propionic acid methyl ester<br><br>
solution of 3-({ 5-[l-allyl-l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-<br>
but-3-enyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.0679 g, 0.116<br>
mmol) in EtOH (2.0 niL) is treated with 10% palladium on carbon (12 mg), flushed with<br>
H2, and stirred under 1 atm pressure for 2 h. The mixture is then filtered through Celite<br>
and cone, to provide 3-({5-[l-(2,6-Dimediyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-<br>
l-propyl-butyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.0591 g,<br>
86%) as a white foam. MS (ES): 588.4 [M-H]Preparation 65<br>
(R,S)-5-(4,4,4-Trifluoro-l-hydroxy-butyl)-thiophene-2-carboxylic acid ethyl ester<br><br>
A solution of lithium diisopropyl amide (37.35 mL, 67.22 mmol) in tetrahydrofuran is<br>
cooled to -78 C, treated dropwise with a solution of thiophene-2-carboxylic acid ethyl<br>
ester (7.0 g, 44.81 mmol) in THF (100 mL), and stirred 5 min. 3-trifluoromethyl-<br>
butyraldehyde (9.81 g, 67.22 mmol) is then added, and the reaction is allowed to warm to<br>
rt while stirring overnight. Aqueous buffer (pH = 7) is added, and the product is extracted<br>
into ethyl acetate (3 x). Combined organic layers are dried, filtered, and concentrated.<br>
The resulting residue is applied to silica gel and eluted using hexanes with an ethyl<br>
acetate gradient from 0% to 60% to give the title compound (4.54 g).<br>
Preparation 66<br>
4-Bromo-3,5-dimethyl-benzenethiol<br>
Step A <br>
Dimethyl-thiocarbamic acid 0-(4-bromo-3,5-dimethyl-phenyl) ester<br>
4-Bromc-3,5-dimethyl-phenol (10.0 g, 50.01 mmol) was dissolved into dry dioxane (200<br>
mL) and combined with 4-dimethylamino pyridine (1.0 g, 5.2 mmol), triethylamine<br>
(12.77 mL, 100.1 mmol), and dimethylamino-thiocarbomoyl chloride (7.69 g, 62.51<br>
mmol). The reaction was heated to reflux under nitrogen. The reaction was monitored by<br>
TLC until all of the phenol was consumed, 20 h. After cooling to room temperature, me<br>
reaction was diluted with ethyl acetate (200 mL). Water (75 mL) was added and the two<br>
layers were separated. The organic layer was washed with brine (75 mL) then dried over<br>
anhydrous sodium sulfate. The solvent was removed and the residue was purified by<br>
column chromatography, (6.4 g or 55% yield).<br>
StepB<br>
Dimethyl-thiocarbamic acid S-(4-bromo-3,5-dimethyl-phenyl) ester<br>
Dimethyl-thiocarbamic acid 0-(4-bromo-3,5-dimeuiyl-phenyl) ester (6.4 g, 22.3 mmol)<br>
was diluted with 50 mL of tetradecane and heated to reflux under nitrogen. The reaction<br>
was monitored by TLC until all the conversion was complete, 20 h. The reaction was<br>
allowed to cool to room temperature and then loaded onto silica gel column and purified<br>
using flash column chromatography, yielding 5.78 g, or 90% of the target product.<br>
StepC<br>
4-Bromo-3,5-dimethyl-benzenethiol<br>
Dimethyl-thiocarbamic acid S-(4-bromo-3,5-dimethyl-phenyl) ester (5.78 g, 20.14 mmol)<br>
was diluted with methanol (50 mL) and to this was added sodium methoxide (4.75 mL of<br>
4.25M in methanol, 20.14 mmol). The reaction was heated to reflux under nitrogen and<br>
monitored by TLC. After complete conversion, 20h., the reaction was allowed to cool to<br>
. room temperature. The reaction was neutralized with IN HC1 (7.5 mL) and diluted with<br>
ethyl acetate (150 mL). The two phases were separated and the organic layer was washed<br>
with water (75 mL), then brine (75 mL). The organic layer was men dried over<br>
anhydrous sodium sulfate, then concentrated and loaded onto silica gel column. The title<br>
compound was purified using flash column chromatography, yielding 4.0 g, or 92%.<br>
Preparation 67<br>
(R,S)-5-[l-(4-Bromo-3&gt;5-dimethyl-phenoxy)-4,4,4-trifluoro-butyI]-thiophene-2-<br>
carboxylic acid ethyl ester<br><br>
^olution of 4-bromo-3,5-dimethyl-phenol (3.29 g, 16.44 mmol) and (R,S)-5-(l-<br>
Hydroxy-3-methyl-butyl)-thiophene-2-carboxylic acid ethyl ester (3.0 g, 13.15 mmol) in<br>
toluene is degassed and filled with nitrogen for 3 times. Tributylphosphine (4.87 mL,<br>
19.73 mmol) is added to the reaction mixture under nitrogen at 0 C, followed by addition<br>
of l,l'-(azodicarbonyl)-dipiperidine (4.98 g, 19.73 mmol). The reaction mixture is .<br>
allowed to warm to room temperature and stirred overnight, the mixture is loaded on<br>
silica gel column and purified by flash column chromatography, 4.1 g or 60% yield.<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 68<br>
(R,S)-5-[l-(4-Iodo-3^-dimethyl-phenoxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 67 starting<br>
from the 4-iodo-3,5-dimethyl-phenoI and 5-(4,4,4-Trifluoro-l-hydroxy-butyl)-thiophene-<br>
2-carboxylic acid ethyl ester.<br>
Preparation 69<br>
(R,S)-5-[l-(4-Bromo-3&gt;5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-thiophene-<br>
2-carboxylic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 67 starting<br>
from 4-bromo-3,5-dimethyl-benzenethiol and 5-(4,4,4-trifluoro-l-hydroxy-butyl)-<br>
thiophene-2-carboxylic acid ethyl ester.<br>
Preparation 70<br>
(R,S)-5-[l-(4-Bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-thiophene-2-carboxyIic<br>
acid<br><br>
To a mixture of 5-[l-(4-bromo-3,5-dimethyl-phenoxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carboxylic acid ethyl ester (4.1 g, 9.67 mmol) in tetrahydrofuran (20 mL) is added sodium<br>
hydroxide (5N aqueous, 10 mL) at room temperature, brought to reflux under nitrogen,<br>
and stirred overnight. The reaction mixture is acidified by 5 N HC1 (10 mL), extracted<br>
into ethyl acetate, dried and concentrated, then dried under vacuum, giving the title<br>
compound 3.7 g or 96.6% yield.<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 71<br>
(R,S)-5-[4,4,4-Trifluoro-l-(4-iodo-3,5-dimethyl-phenoxy)-butyl]-thiophene-2-<br>
carboxylic acid<br><br>
This compound is made by the general method as exemplified in Preparation 70 starting<br>
from5-[l-(4-iodo-3,5-dimethyl-phenoxy)-4,4,4-trifluoro-butyl]-thiophene-2-carboxylic<br>
acid ethyl ester.<br>
Preparation 72<br>
(R,S)-5-[l-(4-Bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-thiophene-<br>
2-carboxylic add<br><br>
Tiis compound is made by the general method as exemplified in Preparation 70 starting<br>
l"l!rom5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carboxylic acid ethyl ester.<br>
Preparation 73<br>
(R,S)-3-({5-[l-(4-Bromo-3^-dimethyl-phenoxy)-3-methyl-butyl]-thiophene-2-<br>
carbonyl)-amino)-propionic acid methyl ester<br><br>
To a mixture of 5-[l-(4-bromo-3,5-dimediyl-phenoxy)-3-methyl-butyl]-thiophene-2-<br>
carboxylic acid (3.7 g, 9.34 mmol) in dichloromethane (40 mL) is added chloro-<br>
dimethoxy-triazine (1.69 g, 9.62 mmol) and 4-methylmorpholine (1.08 mL, 9.81 mmol)<br>
under nitrogen. The reaction is allowed to stir under nitrogen at room temperature<br>
overnight. The beta-alanine methyl ester hydrochloride salt (1.85 g, 10.28 mmol) is then<br>
added to the reaction mixture, followed by addition of 4-methylmorpholine (2.16 mL,<br>
19.62 mmol) and allowed to stir at room temperature. Some water (
added to help solubility. The reaction is monitored by HPLC, and upon complete<br>
consumption of the acid, the reaction is diluted with dichloromethane. The reaction is<br>
diluted with water and rinsed with IN HC1. Upon acidification, the two layers are<br>
separated. The organic layer is washed with brine, dried over anhydrous sodium sulfate,<br>
and concentrated. Flash column chromatography gave the pure compound, 4.2 g or<br>
93.4% yield.<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 74<br>
(R^S)-3-({5-[4,4,4-Trifluoro-l-(4-iodo-3,S-dimethyl-phenoxy)-butyl]-thiophene-2-<br>
carbonyI}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 73 starting<br>
rrom5-[4,4,4-trifluoro-l-(4-iodo-3,5-dimethyl-phenoxy)-butyl]-thiophene-2-carboxylic<br>
acid.<br>
Preparation 75<br>
3-({5-[4/l^l-Trifluoro-l-(4-iodo-3,5-dimethyl-phenoxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, Isomer 1<br><br>
Procedure AA, Chiral Separation<br>
The(R,S)-3-({5-[4,4,4-trifluoro-l-(4-iodo-3,5-dimethyl-phenoxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester was resolved on a Chiralpak AD-H column<br>
(0.46 x 15.0 cm) with a flow rate of 0.6 rnL/min. and detection at 270 ran. Eluted with<br>
3A alcohol solvent and concentrated the fractions to provide a pure enantiomer ester<br>
(chiral isomer 1,99% ee).<br>
The following enantiomeric pure compounds were obtained by a procedure<br>
similar to chiral separation Procedure AA using Chiralcel OD-H column (4.6 x 250 mm),<br>
or Chiralpak AD-H column (4.6 x 150 mm), or using Chiralcel OJ column (4.6 x 250<br>
mm):<br>
Preparation 76<br>
3-({5-[4,4,4-Trifluoro-l-(4-iodo-3,5-dimethyl.phenoxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, Isomer 2<br><br>
3-({S-[4,4,4-Trifluoro-l-(4,-isopropyI-2,6-dimethy!-biphenyI-4-yloxy)-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester, Isomer 2<br><br>
3-( {5-[4,4,4-Trifluoro-1 -(4-iodo-3,5-dimemyl-phenoxy)-butyl]-thiophene-2-carbonyl J-<br>
amino)-propionic acid methyl ester (300 mg, 0.53 mmol) was dissolved in toluene (1.5<br>
mL), followed by palladium tetrakis triphenylphosphine (30 mg, 0.03 mmol), 4-<br>
isopropyl-phenyl boronic acid (173 mg, 1.05 mmol), and potassium fluoride (61.2 mg,<br>
1.05 mmol). The reaction was purged with nitrogen and heated to reflux, then water (1.5<br>
mL) was added. The reaction was monitored by HPLC, and upon completion, allowed to<br>
cool to room temperature. The reaction was diluted witfi EtOAc and then Celite added,<br>
followed by water. This mixture was then filtered through a pad of Celite. The solution<br>
was separated in a separatory funnel and the organic layer was washed with 0.1N sodium<br>
hydroxide, water, and brine. The organic layer was dried over anhydrous sodium sulfate<br>
and concentrated. The product was purified by flash column chromatography (225 mg).<br>
MS(ES): 562.3 [M+H]+.<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 78<br>
3-({5-t4,4,4-Trifluoro-l-(4'-isopropyl-2,6-dimethyI-biphenyl-4-yloxy)-butyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester, Isomer 1<br><br>
MS(ES): 562.3 [M+H]+.<br>
Preparation 79<br>
3-({S-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-4/l,4-trifluoro-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester, Isomer 1<br><br>
This compound is made by the general method as exemplified in Preparation 77 using 3-<br>
({5-[4,4Atrifluoro-l-(4riodo-3,5-dimethyl-phenoxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester - chiral Isomer 1 and 4-trifluoromethoxy-phenyl<br>
boronic acid as the starting materials. MS(ES): 604.3 [M+H]+.<br>
Preparation 80<br>
3-({5-[l-(2,6-Dimethyl-4,-trifluoromethoxy-biphenyI-4-yloxy)-4,4,4-trifluoro-butyI]-<br>
thiophene-2-carbonyI}-amino)-propionic acid methyl ester, Isomer 2<br><br>
MS(ES): 604.3 [M+H1+.<br>
Preparation 81<br>
3-({5-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-proplonic acid methyl ester, Isomer 1<br><br>
This compound is made by the general method as exemplified in Preparation 77 using 3-<br>
({5-[4,4,4-trrfluoro-l-(4-iodo-3,5-dimethyl-phenoxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester - chiral Isomer 1 and 4-ethyl-phenyl boronic acid as<br>
the starting materials. MS(ES): 548.3 [M+H]+.<br>
Preparation 82<br>
3-({5-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4.yJoxy)-4,4,4-trifluoro-butylJ-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, Isomer 2<br><br>
MS(ES): 548.3 [M+H]+.<br>
Preparation 83<br>
(R,S)-3-({5-[l-(4-Bromo-3,S-dimethyl-phenylsuIfanyI)-4,4,4-trilluoro-butyl].<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 73 starting<br>
fromthe5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carboxylic acid.<br>
Preparation 84<br>
3-({5-[l-(4-Bromo-3^-dimethyl-phenyIsulfanyl)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, Isomer 1<br><br>
The racemic material was resolved using a procedure similar the chiral separation of<br>
Procedure AA, to obtain the pure enantiomer esters of Isomer 1 and Isomer 2 (Preparation<br>
85).<br>
Preparation 85<br>
3-({5-H-(4-Bromo-3J5-dimethyI-phenylsulfanyl)-4,4,4-trinuoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, Isomer 2<br><br>
Preparation 86<br>
3-((5-[H4'-tert-Butyl-2,6^imethyl-biphenyM-yisuiraDyI)-4,4/t-trtf1uoro-lHityll-<br>
thiophene-2-carbonyl}-amlno)-propkmlc add methyl ester, Isomer 2<br><br>
This compound is made by tbe general method as exemplified in Preparation 77 using 3-<br>
({5-[H4-bTonxv3,5^1iinethyl-phenylsulfanyl)^,4,4-trifluoro-b\rtyl]-thiophece-2-<br>
carbonyl}-amino)-propionJc acid methyl ester chiral Isomer 2 and 4-t-butyl-phenyl<br>
boronic acid as the starting materials. MS(ES): 592.2 [M+H]+.<br>
Preparation 87<br>
3-{(5-[l-{4*-Urt-ButyI-2(6^imethyl-biphenyl-4-ylsulfaByl&gt;-4^^-trifluoro-butyl]-<br>
thlophene&gt;2-carbonyl}&gt;amino)-propioaic add methyl ester, Isomer 1<br><br>
This compound is made by the general method as exemplified in Preparation 77 using 3-<br>
({5-[l-(4-bron-3,5^imemyl-phenylsulfanylH.4,4-trifluoro^ur&gt;l]-thiophene-2-<br>
carbcmyl }-amino)-propionic add methyl ester chiral Isomer 1 and 4-t-butyl-pbenyl<br>
boronic add as tbe starting materials. MS(ES): 592.2 [M+HJ+.<br>
Preparation 88<br>
(R3)-MH4'-tert-Butyl-2,6^imethyl-biphenyl-4-yloxyHt4/l-trinuon&gt;-butyl&gt;<br>
thiophene-2-carboxylic add ethyl ester<br><br>
A solution of 4'-tert-butyl-2,6-dirnethyl-biphenyl-4-ol (563 mg, 2.22 mmol) and (R,S)5-<br>
(4,4,4-trifluoro-l-hydroxy-butyl)-thiophene-2-carboxylic acid ethyl ester (500 mg, 1.77<br>
mmol) in toluene is degassed and filled with nitrogen for 3 times. Tributylphosphine<br>
(0.66 mL, 2.66 mmol) is added to the reaction mixture under nitrogen at 0 C, followed<br>
by addition of l,r-(azodicarbonyl)-dipiperidine (671 mg, 2.66 mmol). The reaction<br>
mixture is allowed to warm to room temperature and stirred overnight, the mixture is<br>
loaded on silica gel column and purified by flash column chromatography, 862 mg or<br>
94% yield.<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 89<br>
(R,S).5-[l.(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trinuoro-butyl]-<br>
thiophene-2-carboxylic acid ethyl ester<br><br>
Starting from the 2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol and (R,S)5-(4,4,4-<br>
trifluoro-l-hydroxy-butyl)-thiophene-2-carboxylic acid ethyl ester.<br>
Preparation 90<br>
(R^S)-5-[l-(4,-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carboxylic acid<br><br>
To a mixture of 5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carboxylic acid ethyl ester (800 mg, 1.54 mmol) in tetrahydrofuran (10 mL)<br>
is added sodium hydroxide (5N aqueous, 5 mL) at room temperature, brought to reflux<br>
under nitrogen, and stirred overnight. The reaction mixture is acidified by 5 N HC1 (5<br>
mL), extracted into ethyl acetate, dried and concentrated, then dried under vacuum, giving<br>
the title compound 747 mg or 98.7% yield.<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 91<br>
(R3)-5-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyI-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carboxylic acid<br><br>
This compound is made by the general method as exemplified in Preparation 90 starting<br>
fromS-tl^Z.S-dimethyl^'-trifluoromethyl-biphenyM-yloxyM^^-trifluoro-butyl]-<br>
thiophene-2-carboxylic acid ethyl ester.<br>
Preparation 92<br>
(R,S)-3.({5-[l-(4'-tert-ButyI.2,6-dimethyl-biphenyl-4-yloxy)-4^,4-trifIuoro-butyl].<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
To a mixture of 5-[ 1 -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4.4,4-trifluoro-butyl]-<br>
thiophene-2-carboxylic acid (747 mg, 1.52 mmol) in dichloromethane (10 mL) is added<br>
chloro-dimethoxy-triazine (276 mg, 1.57 mmol) and 4-methylmorpholine (0.180 mL, 1.6<br>
mmol) under nitrogen. The reaction is allowed to stir under nitrogen at room temperature<br>
overnight. The beta-alanine methyl ester hydrochloride salt (302 mg, 1.57 mmol) is then<br>
added to the reaction mixture, followed by addition of 4-rriethylmorpholine (0.360 mL,<br>
fO mmol) and allowed to stir at room temperature. Some water (
added to help solubility. The reaction is monitored by HPLC, and upon complete<br>
consumption of the acid, the reaction is diluted with dichloromethane. The reaction is<br>
diluted with water and rinsed with IN HC1. Upon acidification, the two layers are<br>
separated. The organic layer is washed with brine, dried over anhydrous sodium sulfate,<br>
and concentrated. Flash column chromatography gave the pure compound, 252 mg or<br>
28.8% yield.<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 93<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyI-biphenyl-4-yloxy)-4,4,4-trifluoro-<br>
butyl]-thiophene-2-carbonyI}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 92 from 5-<br>
[l-(2,6-dimemyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carboxylic acid.<br>
Preparation 94<br>
(R3)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester<br>
Step A <br>
(R,S)-S-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yIoxy)-ethyl]-thiophene-2-<br>
carboxylic acid ethyl ester<br>
A mixture of ()-5-(l-hydroxy-ethyl)-thiophene-2-carboxylic acid ethyl ester (6.416 g,<br>
2.08 mmol), 4'-tert-butyI-2,6-dimethyl-biphenyl-4-ol (0.561 g, 2.20 mmol), and PPh3<br>
(0.787 g, 3.00 mmol) is dissolved in toluene (19 mL) and treated with 1,1'-<br>
(azodicarbonyl)dipiperidine (ADDP, 0.760 g, 3.01 mmol) and stirred overnight at rt. The<br>
mixture is diluted with MeOH until homogeneous and cone. The residue is loaded onto<br>
silica gel and eluted using hexanes with an ethyl acetate gradient from 0% to 40% giving<br>
()-5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carboxylicacid<br>
ethyl ester (0.604 g, 671%) as a clear syrup.<br>
StepB<br>
(R,S)-5-[l-(4,-tert.ButyI-2,d-dimethyI-biphenyl-4-yloxy)-ethyll-thiophene-2-<br>
carboxylic acid<br>
To a mixture of (&gt;5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene-<br>
2-carboxylic acid ethyl ester (0.603 g, 1.38 mmol) in THF (14 mL) is added lithium<br>
hydroxide (IN aqueous, 14 mL). The mixture is warmed to 70 C and stirred overnight.<br>
The reaction mixture is acidified with IN HC1 (15 mL), extracted into ethyl acetate (3x25<br>
mL), dried over MgS04, and concentrated, to provide ()-5-[l-(4'-tert-butyl-2,6-dimethyl-<br>
biphenyI-4-yloxy)-ethyl]-thiophene-2-carboxyIic acid (0.554 g, 98%) as a white foam.<br>
MS CBS): 407.3 [M-H]".<br>
Step C<br>
(R,S)-3.({5-[l.(4'-tert-ButyI-2,6-diinethyl-biphenyl-4.yloxy)-ethyl].thiophene.2-<br>
carbonyl}-amino)-propionic acid methyl ester<br>
To a mixture of ()-5-[ 1 -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene~<br>
2-carboxylic acid (0.546 g, 1.34 mmol), 3-amino-propionic acid methyl ester<br>
hydrochloride (0.204 g, 1.46 mmol), and 1-hydroxybenzotriazole hydrate (HOBt, 0.217 g,<br>
1.60 mmol) in DMF (12.3 mL) is added N, iV-diisopropylethylamine (0.70 mL, 4.01<br>
mmol), then N-(3-dimethylaminopropyl)-N'-ethyIcarbodiimide hydrochloride (EDCI,<br>
0.333 g, 1.74 mmol) and stirred overnight. The reaction mixture is poured into H2O (25<br>
mL) and extracted with EtOAc (3 x 25 mL). Combined organic extracts are washed with<br>
H2O, brine, dried over MgSC&gt;4, filtered, and concentrated. The residue is loaded onto<br>
silica gel and eluted using hexanes with an ethyl acetate gradient from 0% to 75% to<br>
provide ()-3-({ 5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-<br>
carbonyI}-amino)-propionic acid methyl ester (0.472 g, 71%) as a white solid. MS (ES):<br>
492.1 [M-H]". The racemic material is separated by chiral HPLC (column: Chiralpak<br>
OD-H 4.6 x 150 mm; eluent: 10:90 3A alcohol/Heptane; flow rate: 0.6 mL/min; UV<br>
gr ^sorbance wavelength: 270 nm) to provide Isomer 1 (0.180 g, 98.3% ee) and Isomer 2<br>
iai90 g, 96.7% ee).<br>
The following compounds are made in a substantially similar manner:<br>
Preparation 95<br>
(R,S)-3-({5-[l-(4-Iodo-3^-dimethyI-phenoxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyI}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94, Step A<br>
using 4-iodo-3,5-dirnethyl-phenol and 5-(l-hydroxy-2-memyl-propyl)-thiophene-2-<br>
carboxylic acid ethyl ester as the starting materials to provide ()-3-({5-[l-(4-iodo-3,5-<br>
dimethyl-phenoxy)-2-methyl-propyl] -thiophene-2-carbonyl} - amino)-propionic acid<br>
methyl ester (1.796 g) as a white solid. MS (ES): 514.0 [M-H]". The racemic material is<br>
separated by chiral HPLC (column: Chiralpak OJ-H 4.6 x 150 mm; eluent: 100% MeOH;<br>
flow rate: 0.6 mL/min; UV absorbance wavelength: 270 nm) to provide Isomer 1 (0.885<br>
g, 98.67% ee) and Isomer 2 (0.831 g, 99.7% ee).<br>
Preparation 96<br>
(R,S)-3-({5-{l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-2R-hydroxy-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using<br>
2,6-dimethyl-4*-trifluoromethyl-biphenyl-4-ol as the starting material in Step A and 2R-<br>
hydroxy-propionic acid methyl ester in Step C to provide ()-3-({5-[l-(2,6-Dimethyl-4'-<br>
trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-tbiophene-2-carbonyl}-amino)-2/?-<br>
hydroxy-propionic acid methyl ester hydrochloride salt (0.29 lg) as a white foam. MS<br>
(ES): 548.2 [M-H]". The diastereomeric material is separated by chiral HPLC (column:<br>
Chiralpak OJ-H 4.6 x 150 mm; eluent: 100% MeOH; flow rate: 0.6 mL/min; UV<br>
absorbance wavelength: 280 nm) to provide Isomer 1 (0.113 g, 99% de) and Isomer 2<br>
(0.107 g, 99% de).<br>
Preparation 97<br>
(R,S)-3-({5-[l-(4'.tert-Butyl-2,6-dimethy]-biphenyl-4-yIoxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-2R-hydroxy-propionic add methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using 4'-<br>
tert-butyl-2,6-dimethyl-biphenyl-4-ol as the starting material in Step A and 2R-hydroxy-<br>
propionic acid methyl ester hydrochloride salt in Step C to provide ()-3-({5-[l-(4'-tert-<br>
Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propy]]-thiophene-2-carbonyl}-amino)-<br>
2-hydroxy-propionic acid methyl ester (0.327g) as a white/tan solid. MS (ES): 536.3 [M-<br>
HV. The diastereomeric material is separated by chiral HPLC (column: Chiralpak OJ-H<br>
4.6 x 150mm; eluent: 100% MeOH; flow rate: 0.6 mL/min; UV absorbance wavelength:<br>
280 nm) to provide Isomer 1 (0.132 g, &gt;99% de) and Isomer 2 (0.127 g, &gt;99% de).<br>
Preparation 98<br>
(R3).3-({S-[l-(2,6-Dimethyl-4'-trifluoromethyI-biphenyl-4-yloxy)-2-inethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-2S-hydroxy-propionic acid ethyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using<br>
2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol as the starting material in Step A and 25-<br>
bydroxy-piopionic acid ethyl ester hydrochloride salt in Step C to provide ()-3-({5-[l-<br>
(2,6-dimethyI-4,-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl} -amino)-25'-hydroxy-propionic acid methyl ester (0.387g) as a white foam. MS<br>
(ES): 562.2 [M-H] The diastereomeric material is separated by chiral HPLC (column:<br>
Chiralpak OJ-H 4.6 x 150mm; eluent: 100% MeOH; flow rate: 0.6 mL/min; UV<br>
ance wavelength: 280 nm) to provide Isomer 1 (0.1573 g, &gt;99% de) and Isomer 2<br>
(0.149 g, 98.9% de).<br>
Preparation 99<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethy!-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-2S-hydroxy-propionic acid ethyl ester .<br><br>
This compound is made by the general method as exemplified in Preparation 94 using 4'-<br>
tert-butyl-2,6-dimethyl-biphenyl-4-ol as the starting material in Step A and 25-hydroxy-<br>
propionic acid ethyl ester hydrochloride salt in Step C to provide ()-3-({5-[l-(4'-tert-<br>
butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-carbonyl}-amino)-2-<br>
hydroxy-propionic acid ethyl ester (0.326g) as a white foam. MS (ES): 550.3 [M-H]'.<br>
The diastereomeric material is separated by chiral HPLC (column: Chiralpak OJ-H 4.6 x<br>
150 mm; eluent: 100% MeOH; flow rate: 0.6 mlVmin; UV absorbance wavelength: 280<br>
nm) to provide Isomer 1 (0.127 g, 99% de) and Isomer 2 (0.116 g, &gt;99% de).<br>
Preparation 100<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-y]oxy)-butyl]-thiophene-2-<br>
carbony]}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using 4'-<br>
tert-butyl-2-methyl-biphenyl-4-ol in Step A and 3-amino-propionic acid methyl ester<br>
hydrochloride salt in Step C as the starting materials to provide ()-3-({5-[l-(4'-tert-<br>
Butyl-2-dimethyl-biphenyl-4-yloxy)-butyl}-thiophene-2-carbonyl} -amino)-propionic acid<br>
methyl ester (0.398 g) as a white solid. MS (ES): 508.5 [M+H]+. The racemic material is<br>
separated by chiral HPLC (column: Chiralpak AD-H 4.6 x 150 mm; eluent: 85:15<br>
Heptane/IPA; flow rate: 0.6 mL/min; UV absorbance wavelength: 260 nm) to provide<br>
Isomer 1 (0.170 g, 99% ee) and Isomer 2 (0.147 g, 96.2% ee).<br>
Preparation 101<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethy]-biphenyI-4-yloxy)-butyI]-thiophene-2-<br>
carbonyI}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using 4'-<br>
tert-butyl-2,6-dimethyl-biphenyl-4-ol in Step A and 3-amino-propionic acid metiiyl ester<br>
hydrochloride salt in Step C as the starting materials to provide ()-3-({5-[l-(4'-tert-<br>
Butyl-2,6-dimemyI-biphenyl-4-yloxy)-butyl]-miophene-2-carbonyl}-arnino)-propionic<br>
acid methyl ester (0.434 g) as a white solid. MS (ES): 522.5 [M+H]+. The racemic<br>
material is separated by chiral HPLC (column: Chiralpak OD-H 4.6 x 150 mm; eluent:<br>
5:95 3A alcohol/Heptane; flow rate: 0.6 rnL/min; UV absorbance wavelength: 270 nm) to<br>
provide Isomer 1 (0.187 g, 97.0% ee) and Isomer 2 (0.167 g, 92.8% ee).<br>
Preparation 102<br>
(R,S)-3-({5-[l(2,6-Dimethy-4'-trifluoromethyl-biphenyl-4-yloxy)-pentyll-thiophene-<br>
2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using<br>
2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol in Step A and 3-amino-propionic acid<br>
methyl ester hydrochloride salt in Step C as the starting materials to provide ()-3-({ 5-[l-<br>
(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-carbonyl} -<br>
amino)-propionic acid methyl ester (0.391 g) as a clear syrup. MS (ES): 546.3 [M-H]".<br>
The racemic material is separated by chiral HPLC (column: Chiralpak OD-H 4.6 x 150<br>
mm; eluent: 10:90 IP A/Heptane; flow rate: 0.6 rnL/min; UV absorbance wavelength: 270<br>
nm) to provide Isomer 1 (0.155 g, 99.0% ee) and Isomer 2 (0.117g, 98.5% ee).<br>
Preparation 103<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-l-ethyl-propyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using 4'-<br>
tert-butyl-2,6-dimethyl-biphenyl-4-ol and5-(l-ethyl-l-hydroxymethyl-propyl)-thiophene-<br>
2-carboxylic acid methyl ester in Step A and 3-amino-propionic acid methyl ester<br>
hydrochloride salt in Step C as the starting materials to provide 3-({5-[l-(4'-tert-butyl-<br>
2,6-dimemyl-biphenyl-4-yloxymethyl)-l-ethyl-propyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester (0.189 g) as a white solid.<br>
Preparation 104<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yIoxymethyl)-propyI]-<br>
thiophene-2-carbonyl]-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using 4'-<br>
tert-butyl-2,6-dimethyl-biphenyl-4-ol and5-(l-hydroxymethyl-propyl)-thiophene-2-<br>
carboxylic acid methyl ester in Step A and 3-amino-propionic acid methyl ester<br>
hydrochloride salt in Step C as the starting materials to provide ()-3-({5-[l-(4'-tert-butyl-<br>
2,6-dimethyl-biphenyl-4-yloxymemyl)-propyl]-thiophene-2-carbonyl)-amino)-propionic<br>
acid methyl ester (0.213 g) as a white solid. MS (ES): 520.3 [M-H]\ The racemic<br>
material is separated by chiral HPLC (column: Chiralpak AD-H 4.6 x 150mm; eluent:<br>
20:80 IP A/supercritical C02; flow rate: 5 mlVmin; UV absorbance wavelength: 270 nm)<br>
to provide Isomer 1 (0.074 g, &gt;99% ee) and Isomer 2 (0.078g, &gt;99% ee).<br>
Preparation 105<br>
(R,S)-3-({S-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yIoxymethyl)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using<br>
2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol and 5-(l-hydroxymethyl-propyl)-<br>
thiophene-2-carboxylic acid methyl ester in Step A and 3-amino-propionic acid methyl<br>
ester hydrochloride salt in Step C as the starting materials to provide ()-3-({ 5-[l-(2,6-<br>
dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (0.225 g) as a white solid. MS (ES): 532.3 [M-H]<br>
The racemic material is separated by chiral HPLC (column: Chiralpak AD-H 4.6 x 150<br>
mm; eluent: 20:80 EPA/supercritical CO2; flow rate: 5 mL/min; UV absorbance<br>
wavelength: 270 run) to provide Isomer 1 (0.049 g, &gt;99% ee) and Isomer 2 (0.049g,<br>
96.8% ee).<br>
Preparation 106<br>
(R,S)-3-({4-ailoro-S-[l-(2,6-dimethyl-4,-trifluoromethyl-biphenyI-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 94 using<br>
2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ol and 4-chloro-5-( 1-hydroxy-propyl)-<br>
thiophene-2-carboxylic acid methyl ester in Step A and 3-amino-propionic acid methyl<br>
ester hydrochloride salt in Step C as the starting materials to provide ()-3-({4-chloro-5-<br>
6-dimethyl-4'-trifluororaethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (0.094 g) as a white foam. MS (ES): 552.2 [M-H]".<br>
Preparation 107<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-trinuoromethyl-biphenyl-4-yIsuIfanyl)-2-methyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
Step A<br>
(R,S)-5-[l-(2,6-Dimethyl-4,-trifiuoromethyl-biphenyl-4-ylsulfanyI)-2-methyl-propyl]-<br>
thiophene-2-carboxyIic acid ethyl ester<br>
A solution of ()-5-(l-hydroxy-2-methyl-propyl)-thiophene-2-carboxylic acid ethyl ester<br>
(0.321 g, 1.41 mmol) and 4'-tert-butyl-2,6-diraethyl-biphenyl-4-thiol (0.427 g, 1.51<br>
mmol) in 1,2-dichloroethane (13 mL) is treated with zinc iodide (0.474 g, 1.48 mmol) and<br>
stirred overnight at rt. The reaction mixture is then partitioned between water and<br>
dichloromethane. The reaction mixture is filtered and concentrated. The resulting<br>
residue is applied to silica gel and eluted using hexanes with an ethyl acetate gradient<br>
from 0% to 40% to give ()-5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-<br>
2-methyl-propyl]-thiophene-2-carboxylic acid ethyl ester (0.469,70% g) as a clear syrup.<br>
MS (ES): 481.1 [M+H]+.<br>
Step B<br>
(R,S)-5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsuIfanyl)-2-methyl-propyl]-<br>
thiophene-2-carboxyIic acid<br>
To a mixture of ()-5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-2-<br>
methyl-propyl]-thiophene-2-carboxylic acid ethyl ester (0.458 g, 0.961 mmol) in THF<br>
(9.0 mL) is added lithium hydroxide (1N aqueous, 9.0 mL). The mixture is wanned to 70<br>
C and stirred overnight. The reaction mixture is cooled to rt, acidified with IN HC1 (9.5<br>
mL), extracted into ethyl acetate (3 x 25 mL), dried over MgSCU, and concentrated to<br>
provide ()-5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-2-methyl-<br>
propyl]-thiophene-2-carboxylic acid (0.431 g, 96%) as a white foam. MS (ES): 463.2<br>
[M-H]".<br>
StepC<br>
(R^-S-ClS-El^^-Dimethyl^'-trifluoromethyl-biphenyM.ylsuIfanyO-Z-methyl-<br>
propyl]-thiqphene-2-carbonyl}-amino)-propionic acid methyl ester<br>
To a mixture of ()-5-[l-(2,6-dimethyl-4'-trifluorometfayl-biphenyl-4-ylsulfanyl)-2-<br>
methyl-propyl]-thiophene-2-carboxylic acid (0.420 g, 0.905 mmol), 3-amino-propionic<br>
acid methyl ester hydrochloride (0.148 g, 1.06 mmol), and 1-hydroxybenzotriazole<br>
hydrate (HOBt, 0.151 g, 1.12 mmol) in DMF (9.0 mL) is added N, N-<br>
. diisopropylethylamine (0.49 mL, 2.81 mmol), then N-(3-dimethylaminopropyl)-N'-<br>
ethylcarbodiimide hydrochloride (EDCI, 0.0.228 g, 1.19 mmol) and stirred overnight.<br>
The reaction mixture is poured into H2O (25 mL) and extracted with EtOAc (3 x 25 mL).<br>
Combined organic extracts are washed with H20, brine, dried over MgS04, filtered, and<br>
concentrated. The residue is loaded onto silica gel and eluted using hexanes with an ethyl<br>
acetate.gradient from 0% to 75% to provide ()-3-({5-[l-(2,6-dimethyl-4'-<br>
trifluoromethyl-biphenyl-4-ylsulfanyl)-2-methyl-propyl]-thiophene-2-carbonyl }-amino)-<br>
propionic acid methyl ester (0.347 g, 70%) as a white foam. MS (ES): 548.1 [M-H]'.<br>
The racemic material is separated by chiral HPLC (column: Chiralpak AD-H 4.6 x 150<br>
mm; eluent: 10:90 3A alcohol/Heptane; flow rate: 0.6 mL/min; UV absorbance<br>
wavelength: 280 nm) to provide Isomer 1 (0.126 g, &gt;99% ee) and Isomer 2 (0.119g,<br>
94.5% ee).<br>
The following compounds are made in a substantially similar manner.<br>
Preparation 108<br>
^^^-({S-El^'-tert-Butyl^je-dimethyl-biphenyl^-ylsulfanyO-ethyll-thiophene-Z-<br>
carborjyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 107 using<br>
4'-tert-butyI-2,6-dtaethyl-biphenyl-4-thiol and ()-5-(l-hydroxy-ethyl)-thiophene-2-<br>
carboxylic acid ethyl ester in Step A and 3-amino-propionic acid methyl ester<br>
hydrochloride salt in Step C as the starting materials to provide ()-3-({5-[l-(4'-tert-butyl-<br>
2,6^Jimethyl-biphenyl-4-ylsulfanyl)-ethyl)-thiophene-2-carbonyl} -amino)-propionic acid<br>
methyl ester (0.279 g) as a white foam. MS (ES): 508.3 [M-H]".<br>
Preparation 109<br>
(R,S)-3-({5-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-2,2-dimethyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 107 using<br>
()-5-(l-hydroxy-2,2-dimethyl-propyl)-thiophene-2-carboxylic acid ethyl ester in Step A<br>
and 3-amino-propionic acid methyl ester hydrochloride salt in Step C as the starting<br>
materials to provide ()-3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-<br>
2,2-dimethyl-propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.168<br>
g) as a white foam. MS (ES): 562.1 [M-H]". The racemic material is separated by chiral<br>
HPLC (column: Chiralpak AD-H 4.6 x 150mm; eluent: 5:95:0.2 EtOH/Heptane/DMEA<br>
(dimethylethyl amine); flow rate: 0.6 mL/min; UV absorbance wavelength: 270 nm) to<br>
provide Isomer 1 (0.059 g, &gt;99% ee) and Isomer 2 (0.053g, 95% ee).<br>
Preparation 110<br>
(R^D-S^iS-U^^-Dimethyl^'-trifluoromethyl-biphenyM-ylsuIfanyO-S-methyl-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 107 using<br>
()-5-(l-hydroxy-3-methyl-butyl)-thiophene-2-carboxylic acid ethyl ester in Step A and<br>
3-amino-propionic acid methyl ester hydrochloride salt in Step C as the starting materials<br>
to provide ()-3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3-methyl-<br>
butyl]-tbiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.191 g) as a white<br>
foam. MS (ES): 562.1 [M-H]Preparation 111<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4,-trifluoromcthyl-biphenyI-4-yIsulfanyl).3,3-dimethyl-<br>
butyl]-thiophene-2-carbonyI}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Example 107 using ()-<br>
5-(l-hydroxy-3,3-dimethyl-butyl)-thiophene-2-carboxylic acid ethyl ester in Step A and<br>
3-Amino-propionic acid methyl ester hydrochloride salt in Step C as the starting materials<br>
to provide ()-3-({5-[l-(2,6-dimethyl-4,-trifluoromethyl-biphenyl-4-ylsulfanyl)-3,3-<br>
dimediyl-butyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.362 g) as a<br>
white foam. MS (ES): 576.2 [M-H]Preparation 112<br>
(R5)-3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-pentyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
This compound is made by the general method as exemplified in Preparation 107 using<br>
()-5-(l-hydroxy-pentyl)-thiophene-2-carboxylic acid ethyl ester in Step A and 3-amino-<br>
propionic acid methyl ester hydrochloride salt in Step C as the starting materials to<br>
provide ()-3-({5-[l-(2,6-dimemyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-pentyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.314 g) as a white foam.<br>
MS (ES): 562.3 [M-H]".<br>
Preparation 113<br>
(R3)-3.({5-[l-(2,6-Dimethyl-4*-trifluoromethyl-biphenyl-4-ylsulfanyI)-butyl3-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br><br>
Thjj^ompound is made by the general method as exemplified in Preparation 107 using<br>
()-5-(l-hydroxy-butyl)-thiophene-2-carboxylic acid ethyl ester in Step A and 3-amino-<br>
propionic acid methyl ester hydrochloride salt in Step C as the starting materials to<br>
provide ()-3-( {5-[ 1 -(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyI)-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.163 g) as a white foam.<br>
MS (ES): 548.0 [M-H]". The racemic material is separated by chiral HPLC (column:<br>
Chiralpak AD-H 4.6 x 150 mm; eluent: 15:85:0.2 EtOH/Heptane/DMEA (dimethylethyl<br>
amine); flow rate: 0.6 mL/min; UV absorbance wavelength: 270 nm) to provide Isomer 1<br>
(0.0769 g, 98.3% ee) and Isomer 2 (O.lOOg, 96.6% ee).<br>
Preparation 114<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester, isomer 2<br><br>
To a mixture of 3-({5-[l-(4-iodo-3,5-dimethyl-phenoxy)-2-methyl-propylJ-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (Isomer 2) (0.304 g, 0.5902 mmol), (4-<br>
trifluoromethoxy)phenylboronic acid (0.153 g, 0.743 mmol), and potassium fluoride<br>
(0.0869 g, 1.807 mmol) in THF (6.0 ml) is added paUadium(II) acetate (30.2 mg, 0.134<br>
mmol), and (oxydi-2,l-phenylene)bis<diphenylphosphine mg mmol the></diphenylphosphine>
leaction mixture is heated to reflux overnight. The reaction mixture is cooled to rt and<br>
poured into H2O (10 mL) and diluted with EtOAc (10 mL). The resulting yellow<br>
emulsion is removed by vacuum filtration through a pad of Celite. The layers are<br>
separated and the aqueous layer is extracted with EtOAc (2 x 10 mL). Combined extracts<br>
are washed with brine (lx), dried over MgS04, filtered, and concentrated. The residue is<br>
loaded onto silica gel and eluted using hexanes with an ethyl acetate gradient from 0% to<br>
75% giving a mixture of product and starting material. This material is then loaded onto<br>
Cig and eluted using H20 with an MeCN gradient from 15% to 100% giving 3-({5-[l-<br>
(2,6-dimethyl-4'-trifluoromethoxy-biphenyI-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (Isomer 2) (0.126 g, 39%) as a white foam.<br>
MS (ES): 508.44 [M+H]+.<br>
The following compound is prepared in a substantially similar manner.<br>
Preparation 115<br>
3-({5-[l-(4'-Isopropyl-2,6-<llmethyl-biphenyi-4-yloxy>2-methyl-propyI]-Uiiopheoe-2-<br>
carbonyl}-amino)-propionk add methyl ester, Isomer 2<br><br>
This compound is made by the general method as exemplified in Preparation 114 using 4-<br>
iscpropyi phenylboronic acid as the starting material to provide 3-({5-[l-(4'-isopropyi-<br>
2,6-&amp;memyl-biphenyM-yloxy)-2-mefoyl-propyl]-miophene-2-carbonyl}-arrM)-<br>
propionic acid methyl ester (Isomer 2) (0.091 g) as a white solid. MS (ES): 550.3<br>
[M+HT.<br>
Example 1<br>
(R^&gt;)-3-
amino)-propionic acid<br>
Step A <br>
(R,S)-5-[l-
acid ethyl ester<br>
To a solution of (R,S&gt; 5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid ethyl ester<br>
(74.3 mg, 0.35 mmol) in toluene (3.5 mL) is added 1, r-(azodicarbonyl)dipiperidine<br>
(ADDP, 131 mg, 0.52 mmol) at room temperature, followed by the addition of<br>
trrphcnylphosphinc (137 mg, 0.52 mmol) and 4'-trifluoromethyl-biphenyl-4-ol (83 mg,<br>
0.35 mmol). The reaction mixture is stirred overnight. The mixture is treated with water,<br>
extracted into ethyl acetate, dried and concentrated, then loaded onto silica gel and elutcd<br>
using hexanes with an ethyl acetate gradient from 0% to 65% giving (R,S)-5-[l-(4'-<br>
trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carboxylic acid ethyl ester (87<br>
mg). MS (ES): 433.1 [M-H]'.<br>
StepB<br>
(R,S)-5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyI]-thiophene-2-carboxyIic<br>
acid<br>
To a mixture of (R,S)-5-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carboxylic acid ethyl ester (85 mg, 0.195 mmol) in ethanol (2.0 mL) is added sodium<br>
hydroxide (5N aqueous, 0.196 mL) at room temperature, and stirred overnight. The<br>
reaction mixture is acidified by IN HC1 (0.198 mL), extracted into ethyl acetate, dried<br>
and concentrated, then dried under vacuum, giving (R,S)-5-[l-(4'-trifluoromethyl-<br>
biphenyl-4-yloxy)-propyl]-thiophene-2-carboxylic acid (59 mg). MS (ES): 405.1 [M-H]".<br>
StepC<br>
(R,S)-3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyI}-<br>
amino)-propionic acid methyl ester<br>
To a mixture of (R,S)-5-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carboxylic acid (56 mg, 0.138 mmol) in DMF (1.4 mL) is added 3-amino-propionic acid<br>
methyl ester hydrochloride(19.3 mg, 0.138 mmol), 1-hydroxybenzotriazole hydrate (23<br>
mg, 0.166 mmol), and diisopropylethylamine (0.048 mL, 0.276 mmol) at room<br>
temperature, and stirred 10 min. The mixture is then treated with N-(3-<br>
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (53 mg, 0.276 mmol), and<br>
stirred overnight. The reaction mixture is treated with 0.1N HC1 and extracted into ethyl<br>
acetate twice. The combined organic layers are washed with brine, dried and<br>
concentrated, and dried under vacuum to give (R,S)-3-({5-[l-(4'-trtfluoromethyl-<br>
biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (81<br>
mg). MS (ES): 464.1 [M+H]+.<br>
StepD<br>
(R,S)-3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid<br>
To a mixture of (R,S)-3-({5-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (61.3 mg, 0.125 mmol) in<br>
methanol (0.662 mL) is added sodium hydroxide (5N aqueous, 0.126 mL) at room<br>
temperature, and stirred overnight. The reaction mixture is acidified by 1 N HC1 (0.662<br>
mL), extracted into dichloromethane, dried and concentrated, then dried under vacuum,<br>
giving the title compound (56 mg). MS (ES): 478.1 [M+H]+.<br>
The following compounds are made in a substantially similar manner.<br>
Example 2<br>
(R,S)-3-({5-[l-(4,-Trifluoromethyl-biphenyl-4-yIoxy)-butyI]-thiophene-2-carbonyl}-<br>
amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-butyl)-thiophene-2-carboxylic acid ethyl ester and 4'-trifluoromethyI-<br>
biphenyl-4-ol as the starting materials. MS(ES): 492.1 [M+H]+.<br>
Example 3<br>
(R3)-3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-ethyl)-thiophene-2-carbonyl}-<br>
amino)-propionic acid<br><br>
This compound is made by the genera] method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-ethyl)-thiophene-2-carhoxylic acid ethyl ester and 4'-trifluoromethyl-<br>
biphenyl-4-ol as the starting materials. MS (ES): 464.1 [M+H]+.<br>
Example 4<br>
(R,S)-3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-hexyl]-thiophene-2-carbonyl}'<br>
amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-hexyl)-thiophene-2-carboxylic acid ethyl ester and 4'-trifluoromethyl-<br>
biphenyl-4-ol as the starting materials. MS (ES): 520.2 [M+H]+.<br>
Example 5<br>
(R,S)-3-({S-[Cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yIoxy)-methyl]-thiophene-2-<br>
. carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R.S)-<br>
5-(cyclohexyl-hydroxy-methyl)-thiophene-2-carboxylic acid ethyl ester and 4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 532.3 [M+H]+.<br>
Example 6<br>
(R,S)-3-({5-[2,2-Dimethyl-l-(4*-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-2,2-dimethyl-propyl)-thiophene-2-carboxylic acid ethyl ester and 4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 506.3 [M+H]+.<br>
Example 7<br>
(R,S)-3-({5-[3&gt;3-Dimethyl-l-(4,-triflooromethyl-biphenyl-4-yloxy)-butyl]-thiophene-<br>
2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-3,3-dimethyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 520.3 [M+H]+.<br>
Example 8<br>
(R,S)-3-({S-t4-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This Compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-4-methyl-pentyl)-thiophene-2-carboxylic acid ethyl ester and 4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 542.3 [M+Na]+.<br>
Example 9<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4*-trlfluoromethyl-biphenyL-4-yloxy)-2^-dimethyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-4-mediyl-pentyl)-thiophene-2-carboxylic acid ethyl ester and 2,6-dimethyl-<br>
4'-trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 534.3 fM+H]+.<br>
Example 10<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4.yloxy)-3,3Hdimethyl.<br>
butyl]-thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-3,3-dimethyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 2,6-<br>
dimethyl-4'-trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 548.3<br>
[M+HJ+.<br>
Example 11<br>
(R,S)-3-({5-[3^-Dimethyl-l-(2-methyl-4,-trifluor6methyl-biphenyI-4-yIoxy)-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S&gt;<br>
5-(l-hydroxy-3,3-dimethyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 2-methyl-<br>
4'-trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 534.3 [M+H]+;<br>
Example 12<br>
(R^S)-3-({5-[l-(4'-tert-ButyI-2-methyl-biphenyI-4-yIoxy)-3^-dimethyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-3,3-dimethyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 4'-tert-<br>
butyl-2-methyl-biphenyl-4-ol as the starting materials. MS (ES): 522.3 [M+H]+.<br>
Example 13<br>
(R,S)-3-[(5-{3,3-Dimethyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}-<br>
thiophene-2-carbonyI)-amino]-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-3,3-dimethyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 6-(4-<br>
trifluoromethyl-phenyl)-pyridin-3-ol as the starting materials. MS (ES): 521.3 [M+H]+.<br>
Example 14<br>
(R3)-3-[(S-{146-(4-tert-Butyl-phenyl)-pjridiii.3-yloxy].33-diincthyl-butyl}-<br>
thiophene-2-carbonyl)-amino]-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S&gt;<br>
5-(l-hydroxy-3,3-dimethyl-butyl)-tbiophene-2-carboxylic acid ethyl ester and 6-(4-tert-<br>
butyl-phenyl)-pyridin-3-olas the starting materials. MS (ES): 509.3 [M+H)Example 15<br>
(R,S)-3-({5-[l-(4,-tert-Butyl-2-methyl-biphenyl-4-yloxy)-2^-dimethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S&gt;<br>
5-(l-hydroxy-2,2-dimethyl-propyl)-thiophene-2-carboxylic acid ethyl ester and 4'-tert-<br>
butyl-2-methyl-biphenyl-4-ol as the starting materials. MS (ES): 508.3 [M+H]+.<br>
Example 16<br>
(R3)-3-({S-[2^-Dimethyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R.S)-<br>
5-(l-hydroxy-2,2-dimethyl-propyl&gt;thiophene-2-carboxylic acid ethyl ester and 2-methyl-<br>
4'-trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 520.3 [M+HJ+.<br>
Example 17<br>
(R,S)-3-({S-[l-(4,-tert-Butyl-2-methyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid ediyl ester and 4'-tert-butyl-2-methyl-<br>
biphenyl-4-ol as the starting materials. MS (ES): 480.2 [M+H]+.<br>
Example 18<br>
(R,S)-3-({5-[l-(2-MethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by die general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid ethyl ester and 2-methyl-4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 492.1 [M+H]+.<br>
Example 19<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-trifluoroniethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid ethyl ester and 2,6-dimethyl-4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 506.2 [M+H]+.<br>
Example 20<br>
(R^S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid ethyl ester and 4'-tert-butyl-2,61<br>
dimethyl-biphenyl-4-ol as the starting materials. MS (ES): 494.2 [M+H]+.<br>
Example 21<br>
(R^Va-^S-ll-Clje-DimethyW-trinuoromethyl-biphcnyl^-yloxyVS-methyl-butyl]-<br>
thiophene-2-carbony)}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-3-methyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 2,6-dimethyl-<br>
4'-trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 534.4 [M+H]+.<br>
Example 22<br>
{R^)-3-({S-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2,2-dimethyI-propyl]-<br>
thiopbene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
S-Cl-hydroxy^^-dimethyl-propy^-thiophene^-carboxylic acid ethyl ester and 4'-tert-<br>
butyl-2,6-dimethyl-biphenyl-4-ol as the starting materials. MS (ES): 522.4 [M+H]+.<br>
Example 23<br>
3-{[5-(4,-tert-Butyl-2,6-dlmethyl-biphenyl-4-yloxymethyl)-thiophene-2-carbonyl]-<br>
aminoj-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using 5-<br>
hydroxymethyl-thiophene-2-carboxylic acid ethyl ester and 4'-tert-butyl-2i6-dimethyl-<br>
biphenyl-4-ol as the starting materials. MS (ES): 466.3 [M+H]+.<br>
Example 24<br>
(R,S)-3-({S-[3-Methyl-l-(2-inethyl-4,-trinuoromethyl-bipheny].4-yIoxy)-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-3-methyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 2-methyl-4'-<br>
trifluoromethyl-biphenyl-4-ol as the starting materials. MS (ES): 520.0 [M+H]+.<br>
Example 25<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2-methyl-bipbenyl-4-yloxy)-3-methyl-butyl]-thiophene-<br>
2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 1 using (R,S)-<br>
5-(l-hydroxy-3-methyl-butyl)-thiophene-2-carboxylic acid ethyl ester and 4'-tert-butyl-2-<br>
methyl-biphenyl-4-ol as the starting materials. MS (ES): 508.3 [M+H]Example 26<br>
3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid, Isomer 1<br>
Step A <br>
3-({5-[l-(4'"Trifluoromethyl-biphenyl-4-yloxy)-ethyl]-fliiopheiie-2-carbonyl}-&amp;mino)-<br>
propionic acid methyl ester, Isomer 1<br>
(R,S)-3 -({5-[ l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-ethyl]-lhiophene-2-carbonyl} -<br>
arnino&gt;propionic acid methyl ester (375 mg) is separated by chiral HPLC (column:<br>
Chiralpak AD 4.6 x 150mm; eluent: 100% 3A ethanol; flow rate: 0.6 mL/min; UV<br>
absorbance wavelength: 280nm) to provide 3-({ 5-[l-(4'-trifluoromethyl-biphenyl-4-<br>
yloxy)-ethyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 1)<br>
(51 mg).<br>
StepB<br>
3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid, Isomer 1<br>
A solution of 3-( {5-[ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 1) (170 mg, 0.356 mmol).in<br>
methanol (7.1 mL) is treated with 5N NaOH (0.712 mL) and shaken at rt for 2h. The<br>
reaction is neutralized with IN HC1 (0.748 mL), and extracted into ethyl acetate (2x).<br>
The combined organic layers are dried and concentrated, giving the title compound (142<br>
mg). MS (ES): 464.2 [M+H]+.<br>
The following compounds are made in a substantially similar manner.<br>
Example 27<br>
3-({5-[l-(4,-Trifluoromethyl-biphenyl-4-yloxy)-ethyI]-thiophene-2-carbonyl}-amino)-<br>
propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
Il-(4'-trifluoromethyl-biphenyl-4-yloxy)-eth)'l]-thiophene-2-carbonyl}-amino)-propionic<br>
acid methyl ester (Isomer 2) as the starting material. MS (ES): 464.2 [M+H]+.<br>
Example 28<br>
3-({S-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyI]-thiophene-2-carbonyl}-<br>
araino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
[ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl) -amino)-<br>
propionic acid methyl ester (Isomer 1) as the starting material. MS (ES): 478.2 [M+H]+.<br>
Example 29<br>
3-({5-(l-(4'-Triftuoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester (Isomer 2) as the starting material. MS (ES): 478.2 [M+Hj+.<br>
Example 30<br>
3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-miophene-2-carbonyl}-arnino)-propionic<br>
acid methyl ester (Isomer 1) as the starting material. MS (ES): 492.2 [M+H]+.<br>
Example 31<br>
3-({5-[l-(4'Trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl)-thiophene-2-carbonyl}-amino)-propionic<br>
acid methyl ester (Isomer 2) as the starting material. MS (ES): 492.2 [M+H]+.<br>
Example 32<br>
3-({5-[2^-Dimethyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-tbiophene-2-<br>
carbonyl]-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
[2,2-dimethyl-l-(4,-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-<br>
arnino)-propionic acid methyl ester (isomer 1) as the starting material. MS (ES): 506.2<br>
[M+Hf.<br>
Example 33<br>
3-({5-[2^-Dimethyl-l-(4'-trifluoromethyl-biphenyI-4-yIoxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
[2,2-dimemyl-l
amino)-propionic acid methyl ester (isomer 2) as the starting material. MS (ES): 506.2<br>
[M+Hf.<br>
Example 34<br>
3-({5-[3,3-Dimethyl-l-(4'-trifluoromethyl-biphenyI-4-yloxy)-butyl]-thiophene-2-<br>
carbonyI}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 26 using 3-({5-<br>
[3,3-dimethyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid metiiyl ester (isomer 1) as the starting material. MS (ES): 520.3<br>
[M+H]+. . . ... . - ~-~ -.----------_._..<br>
Example 35<br>
3-({S-[3^-DimcthyM-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiopherie-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general meUiod as exemplified in Example 26 using 3-({5-<br>
[33-Dimetbyl-l-(4'-trifluorornethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid mediyl ester (isomer 2) as the starting material. MS (ES): 520.3<br>
[M+H]+.<br>
Example 36<br>
3-({5-[2^-Dimethyl-l-(2-methyl-4,-trifluoromethyl-biphenyI-4-yloxy)-propyl]-<br>
thiophcne-2-carbonyl}-amino)-propionic acid, Isomer 1<br><br>
Step A<br>
3-({5-t2^-Dimethyl-l-(2-methyl-4*-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (chiraJ Isomer 1)<br>
(R,S)-3-({5-[2,2-Dimethyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbooyl}-amino)-propionic acid methyl ester (93.4 mg) is separated by<br>
chiral HPLC (column: Chiralpak AD 4.6 x 150 mm; eluent: 10% ethanol in heptane; flow<br>
rate: 1.0 mL/min; UV absorbance wavelength: 225 nm) to provide 3-({5-[2,2-dimethyl-l-<br>
(2-methyl-4'-trifluoromethyl-biphenyl^-yloxy)-propyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester (chiral Isomer 1) (36 mg).<br>
StepB<br>
3-({5-[2^-DimethyH-(2-methyl-4'-trifluoromethyI-bipheDyI-4-yloxy)-propyl]-<br>
thiophene-2-carbonyI}-amino)-propfonic acid (chiral Isomer 1)<br>
A solution of 3-({5-[2,2-dimethyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yIoxy)-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 1) (36<br>
mg, 0.067 mmol) in methanol (1.0 mL) is treated with 5N NaOH (0.067 mL) and shaken<br>
at rt overnight. The reaction is neutralized with IN HC1 (0.068 mL), and extracted into<br>
ethyl acetate (2x). The combined organic layers are dried and concentrated, giving the<br>
title compound (21.6 mg). MS (ES): 520.3 [M+H]+.<br>
The following compounds are made in a substantially similar manner.<br>
Example 37<br>
3-({5-[2^-Dimethyl-l-(2-methyI-4,-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 36 using 3-({5-<br>
[2,2-dimethyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (isomer 2) as the starting material. MS<br>
(ES): 520.4 [M+H]+.<br>
Example 38<br>
3-({S-[l-(4,-tert-Butyl-2-methyI-biphenyl-4-yIoxy)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 36 using 3-({5-<br>
[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-amino&gt;<br>
propionic acid methyl ester (isomer 1) as the starting material. MS (ES): 480.4 [M+H]+.<br>
Example 39<br>
3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 36 using 3-({5-<br>
[l-(4'-tert-butyI-2-methyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester (isomer 2) as the starting material. MS (ES): 480.4 [M+H]+.<br>
Example 40<br>
3-({5-[3^-Dimethyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 36 using 3-({5-<br>
[3,3-dimethyl-l-(2-methyl-4'-trifluoromemyl-biphenyl-4-yloxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (isomer 1) as the starting material. MS<br>
(ES): 534.3 [M+H]+.<br>
Example 41<br>
3-({5-[3,3-Dimethyl-l-(2-methyl-4'-trifluoromethyI-biphenyl-4-yloxy)-butyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 36 using 3-({5-<br>
[33-dimethyl-l
carbonyl}-amino)-propionic acid methyl ester (isomer 2) as the starting material. MS<br>
(ES): 534.3 [M+H]+.<br>
Example 42<br>
3-({5-[3^-Dimethyl-l-(2-methyl-4'-trifluoromethyI-biphenyI-4-yloxy)-butyl]-<br>
thiophene-2-carbonyl)-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the genera] method as exemplified in Example 36 using 3-({5-<br>
[3^-dimemyl-l-(2-memyl-4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (isomer 1) as the starting material. MS<br>
(ES): 534.3 [M+H]+.<br>
Example 43<br>
3-({S-[3^-Dimethyl-l-(2-methyl-4,-trifluoromethyI-biphenyl-4-yloxy)-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 36 using 3-({5-<br>
[33-dimetnyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-<br>
carbonyl)-amino)-propionic acid methyl ester (isomer 2) as the starting material. MS<br>
(ES): 534.3 [M+H]+.<br>
Example 44<br>
S^fS-Il^^-DimethyW-trifluoromethyl-biphenyl^-yloxy^propyU-thiophene^<br>
carbonyI}-amino)-propionic acid, Isomer 1<br>
Step A <br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yIoxy)-prop3'l]-thiophene-2-<br>
carbonyl}-araino)-propionic acid methyl ester (chiral Isomer 1)<br>
To a solution of 3-({5-[l-(4-iodo-3,5-dimethyl-phenoxy)-propyl]-thiophene-2-carbortyl}-<br>
amino)-propionic acid methyl ester (chiral Isomer 1) (187.3 g, 0.347 mmol) in THF (3.7<br>
ml) is added (4-trifiuoromethyl)phenylboronic acid (92,5 g, 0,449 mrnol), potassium<br>
fluoride (53.9 mg, 1.12 mmol), palladium(D) acetate (4,3 mg, 0.019 mmol), and (oxydi-<br>
2,l-phenylene)bis-(diphenylphosphine) (20 mg, 0.037 mmol), The reaction mixture is<br>
heated to reflux overnight. After cooling to rt, the reaction mixture is partitioned between<br>
ethyl acetate and water. The aqueous layer is back-extracted with ethyl acetate, the<br>
combined organic layers are dried and concentrated, then loaded onto Cu and eluted<br>
using acetonitrile with a water gradient from 15% to 100% giving 3-({5-[l-(2,6-dimethyl-<br>
4'-trifluoromethyI-biphenyl-4-yloxy)-propyl]-thiophene-2-crbonyl}-ainino)-propionic<br>
acid methyl ester (chiral Isomer 1) (81.1 mg). MS (ES): 520.4 [M+H]+.<br>
StepB<br>
3-({S-[l-(2,6-Dimethyl-4'-trifluoromethyl-bipheny)-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid (chiral Isomer 1)<br>
A solution of 3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 1) (79.6 mg,<br>
0.153 mmol) in methanol (1.54 mL) is treated with 5N NaOH (0.154 mL) and shaken at rt<br>
overnight. The reaction is neutralized with IN HC1 (0.158 mL), and extracted into ethyl<br>
acetate (2x). The combined organic layers are dried and concentrated, giving the title<br>
compound (76 mg).<br>
MS (ES): 506.4 [M+H]+,<br>
The following compounds are made in a substantially similar manner.<br>
Example 45<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-y]oxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 44 using 3-{{ 5-<br>
ri-(4-iodo-3,5-dimemyl-phenoxy)-propyl]-thiophene-2-carbonyl}-amino)-propionicacid<br>
methyl ester (isomer 1) and (4-trifluoromethyl)phenylboronic acid as the starting<br>
materials. MS (ES): 506.3 [M+H]+. . ....<br>
Example 46<br>
3-({5[l-(4'-tert-Butyl-2,(-dimethyI-biphenyl"4-yloxy&gt;propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 44 using 3-({ 5-<br>
[l-(4-iodo-3,5-dimemyl-phenoxy)-propyl]-uiiophene-2-carbonyl}-amino)-propionicacid<br>
methyl ester (isomer 1) and (4-rm-butyl)phenylboronic acid as the starting materials.<br>
MS (ES): 494.4 [M+Hf.<br>
Example 47<br>
(R,S)-3.({5-[2-Methyl-l-(4'-trifluoromethyI-biphenyI.4-yIoxy)-propylJ-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
To a solution of ()-3-({5-[lK2,6^dimemyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl3-<br>
tbiophene-2-carbonyl}-amino)-propionic acid methyl ester (0.0887 mg, 0.175 mmol) in<br>
THF (2.0 mL) is added lithium hydroxide (IN aqueous, 2.0 mL) at rt and stirred<br>
overnight. The reaction mixture is acidified with 1 N HC1 (2.4 mL), extracted with EtOAc<br>
(3x10 mL), dried over MgS04, filtered, and cone, to provide the title compound (0.0788<br>
gt*fe%). MS (ES): 492.0 [M+H]+.<br>
The following compounds are made in a substantially similar manner:<br>
Example 48<br>
(R^S)-3-({S-[2-MethyH-(4*-trifluoromethyI-biphenyI-4-yIoxy)-propyIl-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using<br>
3-({ 5-[2-methyl-1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl} -<br>
amino)-propionic acid methyl ester (chiral Isomer 1) as the starting material. MS (ES):<br>
492.2 [M+H]+.<br>
Example 49<br>
3-({5-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[2-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (chiral Isomer 2) as the starting material. MS (ES):<br>
492.2 [M+Hf.<br>
Example 50<br>
(R,S)-3-({5-[3-Methyl.l-(4'-trinuoromethyl-biphenyl-4.yloxy)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[3-methyl-lmiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 506.2 [M+H]+.<br>
Example 51<br>
(R,S)-3-({S-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-octyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(4'-1rifluoromethyl-biphenyl-4-yloxy)-octyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester as the starting material. MS (ES): 548.3 [M+H]Example 52<br>
3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-octyl]-thiophene-2-carbonyI}-amino)-<br>
propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l
acid methyl ester (chiral Isomer 1) as the starting material. MS (ES): 548.2 [M+H]+.<br>
Example 53<br>
3-({5-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-octyl]-thiophene-2-carbonyIJ-amino)-<br>
propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-octyI]-thiophene-2-carbonyl}-amino)-propionic<br>
acid methyl ester (chiral Isomer 2) as the starting material. MS (ES): 548.2 [M+H]+.<br>
Example 54<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-3^-dimethyl-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethy]-biphenyl-4-yloxy)-3,3-dimethyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS<br>
(ES): 548.3 [M+H]+.<br>
Example 55<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyI-biphenyl-4-yIoxy)-3^-dimethyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1)<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(2,6-dimethyl-4'-trifluoromeuliyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 1) as the starting material.<br>
MS (ES): 548.3 [M+H]+.<br>
Example 56<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3^-dimcthyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic add, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({ 5-<br>
[l-(2,6-dimemyM'-trifluoromemyl-biphenyM-yloxy)-33-dimethyl-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 2) as the starting material.<br>
MS (ES): 548.3 [M+H]+.<br>
Example 57<br>
(R,S)-3-({3-Chloro-S-[l.(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({3-chloro-5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
caibonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 538.1<br>
[M-H]Example 58<br>
(R,S)-3-({5-[l-(4,-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-4/
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
To a mixture of (R,S)- 3-({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-<br>
trifluoro-butyl]-thiophene-2-carbonyl} -amino)-propionic acid methyl ester (50 mg, 0.09<br>
mmol) in tetrahydrofurari (1.0 mL) is added sodium hydroxide (5N aqueous, 1.0 mL) at<br>
room temperature, and stirred overnight. The reaction mixture is acidified by 5N HC1 (1.0<br>
extracted into ethyl acetate, dried and concentrated, then dried under vacuum, giving<br>
the title compound (45 mg). MS (ES): 562.0 [M-H]*.<br>
Example 59<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-ammo)-propionic acid methyl ester as the starting material. MS (ES): 518.1<br>
[M-H]'.<br>
Example 60<br>
(R^!)-3-({5-[2-MethyM-(2-methyl-4'-trinuoromethyl-biphenyl-4-yloxy)-<br>
propyI]-thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[2-methyl-l-(2-methyl-4,-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 504.1<br>
[M-H]".<br>
Example 61<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'.trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-<br>
2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[1^2,6-dimemyl-4,-trifIuoromemyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
aroino)-propionic acid methyl ester as the starting material. MS (ES): 518.1 [M-H]Example 62<br>
(R^^-CiS-ClK^Methyl^'-trifluoromethyl-biphenyl^-yloxyJ-butylJ-thiophene^-<br>
carbonyl}-amino)-propionic add<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[ 1 -(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-butyl] -thiophene-2-carbonyl} -<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 504.1 [M-H]'.<br>
Example 63<br>
(R^!)-3-({5-[l-(4,-tert-Butyl-2,6-dimethyl-biphenyl-4-yIoxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 506.2<br>
[M-H]Example 64<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[ 1 -(4'-teTt-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 1) as the starting material.<br>
MS (ES): 506,2 [M-H]".<br>
Example 65<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (chiral Isomer 2) as the starting material.<br>
MS (ES): 506.2 [M-H]Example 66<br>
(R3)-3-({5-tl-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 492.2<br>
[M-H]*.<br>
Example 67<br>
3-({5-[l-(4'-tert-ButyI-2-methyl-biphenyl-4-yloxy)-2-methyI-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[ 1 -(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-carbonyl} -<br>
amino)-propionic acid methyl ester (chiral Isomer 1) as the starting material. MS (ES):<br>
492.3 [M-H]Example 68<br>
3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic add, chiral Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-2-methyI-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (chiral Isomer 2) as the starting material. MS (ES):<br>
492.3 [M-H]'.<br>
Example 69<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,<s-dimethyi-biphenyl-4-yloxy></s-dimethyi-biphenyl-4-yloxy>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-.<br>
({5-flK4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 506.3 [M-H]'.<br>
Example 70<br>
XR*S)-3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yIoxy)-buty!l-thiophene-2-<br>
carbonyI}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[ 1 -(4'-tert-butyI-2-methyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl} -amino)-<br>
propionic acid methyl ester as the starting material. MS (ES): 492.3 [M-H]Example 71<br>
(R,S)-3-({5-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-ethy]]-thiophene-<br>
2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 492.0 [M+H]+.<br>
Example 72<br>
(R,S)-3-({S-[l.(4'.tert-ButyN2,6-dimLethyl-biphenyl-4-yIoxy)-ethyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 480.2 [M+H]+.<br>
Example 73<br>
.(R,S)-3.({5-[l-(2,6-Dimethyl-4'-trifIuoromethyl.biphenyl-4-yloxy)-pentyl]-thiophene-<br>
2-carbonyI}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(2,6-dmiethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 534.2<br>
[M+Hf. 9<br>
Example 74<br>
(R,S)-3-({5-[l-(2-Methyl-4'-trifluoromethyI-biphenyI-4-yIoxy)-pentyI]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[ l-(2-methyl-41-trifluoromethyl-biphenyl-4-yloxy)-pentyl] -thiophene-2-carbonyl} -<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 520.0 [M+H]+.<br>
Example 75<br>
(R,S)-3-({5-H-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]-thiophene.2-<br>
carbony]}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 522.2 [M+H]+.<br>
Example 76<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yIoxy)-pentyl].thiophene-2-<br>
carbonyI}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using ()-3-<br>
({5-[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester as the starting material. MS (ES): 508.3 [M+H]+.<br>
Example 77<br>
3-({5-[2-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-l,l-dimethyl-ethyl].<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[2-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-l,l-dimethyl-ethyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 520.0<br>
[M+H]+.<br>
Example 78<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yIoxymethyl)-l-ethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-l-ethyl-propyl]-thiophene-<br>
2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 548.0<br>
[M+H]+.<br>
Example 79<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyI-biphenyl-4-yloxymethyl)-l-propyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(2,6-diinethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-l-propyl-butyl]-thiophene-<br>
2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 576.2<br>
. [M+H]+.<br>
Example 80<br>
3-({5-[l-Allyl-l-(2,6-dimethyl-4'-trifluoromethyl-biphenyI-4-yloxymethyI)-but.3-<br>
enyl]-thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-allyl-l-(2,6-dirnethyl-4'-trifIuoromethyl-biphenyl-4-yloxymethyl)-but-3-enyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS<br>
(ES): 572.0 [M+H]+.<br>
Example 81<br>
3-({5-[l-(2,6-DimethyI-4f-trifluoromethyI-biphenyl-4-yloxymethyI)-cyclopent-3-<br>
enyl]-thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-cyclopent-3-enyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS<br>
(ES): 544.0 [M+H]+.<br>
Example 82<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-cyclopentyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 47 using 3-({5-<br>
[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-cyclopehtyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 546.0<br>
[M+H]+.<br>
Example 83<br>
(R,S)-3-({5-[l-(4-Bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made in a manner substatilly similar to Example 47 starting with ()-3-<br>
({5-[l-(4-bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester MS(ES): 470.2 [M+H]4.<br>
Example 84<br>
(R,S)-3-({S-[l-(3,5-DimethyI-phenoxy)-3-methyl-butyl]-thiophene-2-carbonyl}-<br>
amino)-propioiuc acid<br><br>
This compound is made in a manner substatilly similar to Example 47 starting from ()-3-<br>
({5-[l-(3,5-dimethyl-phenoxy)-3-methyl-butyl]-thiophene-2-carbonyl}-amino)-propionic<br>
acid methyl ester. MS(ES): 390.2 [M+H]+.<br>
Example 85<br>
(R,S)-3-({5-[l-(4-Bromo-3,5-dimethyl-phenylsuIfanyl)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carbonyI}-amino)-propionicacid<br><br>
This compound is made in a manner substatilly similar to Example 47 starting from ()-3-<br>
({5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester. MS(ES): 523.7, 535.8 [M+H]+.<br>
Example 86<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1<br>
Step A <br>
3-({5-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyl-4-yIdxy)-2-methyl-propyI]-<br>
thiophene-2-carbonyI]-amino)-propionic add methyl ester<br>
To a mixture of 3-({5-[1-(4-iodo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl]-amino)-propionic acid methyl ester (chiral Isomer 1) (0.218 g, 0.422 mmol),<br>
(4-trifluoromethyl)phenylboronic acid (0.110 g, 0.536 mmol), and potassium fluoride<br>
(0.0628 g, 1.306 mmol) in THF (4.07 ml) is added palladium(H) acetate (5.5 rag, 0.024<br>
mmol), and (oxydi-2,l-phenylene)bis-(diphenylphosphine) (25.8 mg, 0.0479 mmol). The<br>
reaction mixture is heated to reflux overnight. Additional palladium acetate (13.5 mg,<br>
0.0601 mmol), and (oxydi-2,l-phenylene)bis-(diphenylphosphine) (55.7 mg, 0.103<br>
mmol) and THF (4.0 mL) added. Reaction heated at relux overnight. The reaction<br>
mixture is cooled to rt, cone, loaded onto silica gel and eluted using hexanes with an<br>
ethyl acetate gradient from 0% to 80% giving a mixture of product and starting material,<br>
This material is then loaded onto C18 and eluted using H2O with an MeCN gradient from<br>
35% to 100% giving 3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-<br>
mediyl-propyl]-thiophene-2-carbonyl}-amino)-propionic acid methy] ester (0.0392 g,<br>
17%) as a white foam. MS (ES): 534.4 [M+H]+.<br>
StepB<br>
3-({5-[l-(2,6-Dimethyl-4,-trifluoromethyI-biphenyl-4-yIoxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br>
To a solution of 3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-meuiyl-<br>
propyl]-thiophene-2-carbonyl}-arnino)-propionic acid methyl ester (0.0390 mg, 0.0731<br>
mmol) in THF (2.0 mL) is added lithium hydroxide (IN aqueous, 2.0 mL) at rt and stirred<br>
overnight. The reaction mixture is acidified with 1 N HC1 (2.4 mL), extracted with EtOAc<br>
(3x10 mL), dried over MgSCU, filtered, and cone, to provide the title compound (0.0356<br>
g, 94%). MS (ES): 520.0 [M+H]+.<br>
The following compounds are made in a substantially similar manner:<br>
Example 87<br>
3-({5-[l-(2,6-DimethyJ-4'-trifluoromethyl-biphenyI-4-yloxy)-2-methyI-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 86 using 3-({5-<br>
[ 1 -(4-iodo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-thiophene-2-carbonyl} -amino)-<br>
propionic acid methyl ester (chiral Isomer 2) as the starting material. MS (ES): 520.0<br>
[M+H]+.<br>
Example 88<br>
(R,S)-3-({S-[l-(2,6-Dimethyl-biphenyl-4ryjoxy)-3-methyl-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
Step A<br>
(R,S)-3-({5-[l-(2,6-pimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid ethyl ester,<br>
To a solution of 3-({5-[l-(4-bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (158 mg, 0.330 mmol) in toluene (1.5 mL)<br>
is added potassium fluoride (38.1 mg, 0.660 mmol), phenyl boronic acid (80 mg, 0.66<br>
mmol), and palladium tetrakis triphenyl phosphine (19 mg, 0.02 mmol). Water (1 mL) is<br>
added and the reaction mixture is heated to reflux overnight.. After cooling to it, the<br>
reaction mixture is partitioned between ethyl acetate and water. The aqueous layer is<br>
back-extracted with ethyl acetate, the combined organic layers are dried and concentrated.<br>
The resulting residue is applied to silica gel and eluted using hexanes with an ethyl<br>
acetate gradient to give the title compound (2.06 g). MS (ES): 478.2 [M-H]~.<br>
StepB<br>
(R^l)-3-({5-[l-(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br>
To a mixture of (R,S)-5-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carboxylic acid ethyl ester from die previous step in tetrahydrofuran (1.0 mL) is added<br>
sodium hydroxide (5N aqueous, 1.0 mL) at room temperature, and stirred overnight. The<br>
reaction mixture is acidified by 5N HC1 (1.0 mL), extracted into ethyl acetate, dried and<br>
concentrated, then dried under vacuum, giving the title compound (50 mg). MS (ES);<br>
464.0 [M-H]The following compounds are made in a substantially similar manner.<br>
Example 89<br>
(R,S)-3-({5-[l-(4,-tert-Butyl-2,6-dimethyl-biphenyl-4-yIoxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-r-<br>
Bw-phenyl boronic acid as the reagent in Step A. MS(ES): 522.7 [M+H]+.<br>
Example 90<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-2'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl} -amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 2-<br>
trifluoromethylphenyl boronic acid as the reagent in Step A. MS(ES): 534.2 [M+H]+.<br>
Example 91<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-3'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
Ibis compound is made by the general method as exemplified in Example 88 using 3-<br>
trifluoromethylphenyl boronic acid as the reagent in Step A. MS(ES): 534.2 [M+H]+.<br>
Example 92<br>
(R3)-3-({5-tl-(4,-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyI]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-<br>
ethylphenyl boronic acid as the reagent in Step A. MS(ES): 494.2 [M+H]+.<br>
Example 93<br>
(R,S)-3-({5-[3-Methyl-l-(2,6^'-trimethyI-biphenyl-4-yloxy)-butyl].thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-<br>
methylphenyl boronic acid as the reagent in Step A. MS(ES): 480.0 [M+H]+.<br>
Example 94<br>
(R^-S-QS-tl^'-Isopropyl-Z.fi-dimethyl-biphenyM-yloxyVS-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic add<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-<br>
isopropylphenyl boronic acid as the reagent in Step A. MS(ES): 508.0 [M+H]+.<br>
Example 95<br>
(R,S)-3-({5-[1^2,6-DimethyM^pentyl-biphenyl.4-yloxy)-3-methyl.butyl]-thiophene-<br>
2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-n-<br>
pentylphenyl boronic acid as the reagent in Step A. MS(ES): 536.0 [M+H]+.<br>
Example 96<br>
(R,S)-3-({5-[l-(4'-CycIohexyl-2,6-dimethyI-biphenyl-4-yloxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-<br>
cyclohexylphenyl boronic acid as the reagent in Step A. MS(ES): 548.0 [M+H]+.<br>
Example 97<br>
(R,S)-3-({5-tl-(4'-Cyano-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl].thiophene-<br>
2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-<br>
cyanophenyl boronic acid as the reagent in Step A. MS(ES): 492.1 [M+H]+.<br>
Example 98<br>
(R^S)-3-({5-tl-(2,6-Dimethyl-4'-trifIuoromethoxy-biphenyl-4-yloxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-<br>
trifluoromethoxyphenyl boronic acid as the reagent in Step A. MS(ES): 550.0 [M+H)+.<br>
Example 99<br>
CR^)-3-({5-[l-(4,-Dimethylamino-2,6-dimethyl-biphenyl-4-yIoxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-n-n-<br>
dimethylphenyl boronic acid as the reagent in Step A. MS(ES): 509.2 [M+H]+.<br>
Example 100.<br>
(R,S)-3.[(5-{l-[4-(5-Acetyl-thiophen-2.yl)-3,5-dimethyl-phenoxy]-3-methyl-butyl}-<br>
thiophene-2-carbonyl)-amino]-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 5-<br>
acetyl-2-thiophenyl boronic acid as the reagent in Step A. MS(ES): 514.0 [M+H]+.<br>
Example 101<br>
(R,S)-3-[(5-{l-[4-(5-Cyano-thiophen-2-yl)-3,S-dimethyl-phenoxy]-3-methyl-butyl}-<br>
thiophene-2-carbonyl)-amino]-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 5-<br>
cyano -2-thiophenyl boronic acid as the reagent in Step A. MS(ES): 497.0 [M+H]+.<br>
Example 102<br>
(R,S)-3-({5-[l-(3,5.Dimethyl-4-thiophen-3-yl-phenoxy)-3-methy]-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 88 using 2-<br>
thiophenyl boronic acid as the reagent in Step A. MS(ES): 472.0 [M+H]+.<br>
Example 103<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4,4-trifluoro-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-t-<br>
butylphenyl boronic acid and methyl-3({5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-<br>
4,4,4-trifluoro-butyl]-thiophene-2-carbonyl}-ammo)-propionic acid as the starting<br>
materials in Step A. MS(ES): 578.0 [M+H]+.<br>
Example 104<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'.trifluoromethyl-biphenyl-4.ylsvdfanyl)-4,4,4-<br>
trifluoro-butyl]-thiophene-2-carbouyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 88 using 4-<br>
trifluromethyl boronic acid and methyl-3({5-ll-(4-bromo-3,5-dimethyl-phenylsulfanyl)-<br>
4,4,4-trifluoro-butyl]-miophene-2-carbonyl}-amino)-propionic acid as the starting<br>
materials in Step A. MS(ES): 590.2 [M+H]+.<br>
Example 105<br>
(R,S)-3-({S-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 58 using ()-3-<br>
({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-caibonyl}-amino)-propionic acid methyl ester as the starting material.<br>
MS(ES): 574.0 [M+H]+.<br>
Procedure BB, Chiral Separation<br>
The(R,S)-3-({5-[l-(4,-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester was resolved on a Chiralpak<br>
AD-H column (0.46 x 15.0 cm) with a flow rate of 0.6mL/min. and detection at 270nm.<br>
Eluted with isopropyl alcohol in heptane with 0.2% dimethyl-ethylamine and<br>
concentrated the fractions to provide a pure enantiomer ester (chiral isomer 1,97.3% ee).<br>
Hydrolysis of the pure enantiomer of the ester provided the title compound as a white<br>
solid. MS (ES): 577.34 (M++1), 575.34 (M^l), the structure was also confirmed by<br>
proton NMR.<br>
The following enantiomeric pure compounds were obtained by a chiral separation<br>
procedure similar to Procedure BB, using Chiralcel OD-H column (4.6 x 250 mm),<br>
Chiralpak AD-H column (4.6 x 150 mm), or using Chrralcel OJ column (4.6 x 250 mm):<br>
Example 106<br>
3-({5-[l-(4,-tert-Butyl-2,6-dimethy)-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 58 using 3-({5-<br>
[l-(4,-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, chiral Isomer 1 as the starting material.<br>
MS(ES): 562.0 [M+H]+:<br>
Example 107<br>
3-({5- [l-(4' -tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 58 using 3-({5-<br>
[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, chiral Isomer 2 as the starting material.<br>
MS(ES): 562.0 [M+H]+.<br>
Example 108<br>
3-({5-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 58 using 3-({5-<br>
[l-(2,6-dimethyl-4'-trifluoromemyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, chiral Isomer 1 as the starting material.<br>
MS(ES): 574.0 [M+H]+.<br>
Example 109<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 58 using 3-({5-<br>
[l-(2,6-dimemyM'-trifluoromemyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester, chiral Isomer 2 as the starting material.<br>
MS(ES): 574.0 [M+H]+.<br>
Example 110<br>
3-({5-[l-(2,6-Dimethyl-4'-trifIuoromethoxy-bipheny]-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
To a solution of 3-({5-il-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-2-methyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (Isomer 2) in<br>
tetrahydrofuran (2.0 mL) is added 1 N LiOH (2.0 mL) and stirred overnight. The reaction<br>
mixture is acidified witii 1 N HC1 (2.2 mL) and extracted with EtOAc (3 x 10 mL).<br>
Combined extracts are dried over MgSCU, filtered, and concentrated to provide 3-({5-[l-<br>
(2,6-dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-2-methyI-propyl]-thiophene-2-<br>
carbony]}-amino)-propionic acid (Isomer 2) (0.101 g, 89%) as a white foam. MS (ES):<br>
536.0 [M+H]+.<br>
Example 111<br>
3-({S-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yIoxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (Isomer 2) as the starting material. MS<br>
(ES): 494.2 [M+H]+. ------------------ --------<br>
Example 112<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-blphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-2jR-hydroxy-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-mediyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2-hydroxy-propionic acid methyl ester as the starting material. MS<br>
(ES): 524.3 [M+H]+.<br>
Example 113<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyI}-amino)-2S-hydroxy-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-diiophene-2-<br>
carbonyl}-amino)-2/?-hydroxy-propionic acid methyl ester as the starting material. MS<br>
(ES): 536.0 [M+H]+.<br>
Example 114<br>
(RjS^-CfS^l^'-tert-Butyl^^-dimethyl-biphenyM-yloxyJ^-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-2S-hydroxy-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-25-hydroxy-propionic acid ethyl ester as the starting material. MS<br>
(ES): 524.3 [M+H]+.<br>
Example 115<br>
3-({5-[l-(4'-tert-Butyl-2-methyl-b!phenyl-4-yloxy)-butyi]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2-memyl-biphenyH-yloxy)-butyl]-miophene-2-c^bonyl}-amino)-<br>
propionic acid methyl ester (isomer 1) as the starting material. MS (ES): 494.2 [M+H]+.<br>
Example 116<br>
3-({5-[l-(4'-tert-Butyl-2-methyl-biphenyI-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
yC|5-[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-amino)-<br>
propionic acid methyl ester (isomer 2) as the starting material. MS (ES): 494.2 [M+H]+.<br>
Example 117<br>
3-({5-[l-(4'-tert-ButyI-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[ 1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-emyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (isomer 1) as the starting material. MS (ES): 480.2<br>
[M+H]+.<br>
Example 118<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyI]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (isomer 2) as the starting material. MS (ES): 480.2<br>
[M+H]+.<br>
Example 119<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyJ}-<br>
amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl} -<br>
amino)-propionic acid methyl ester (isomer 1) as the starting material. MS (ES): 508.3<br>
[M+Hf.<br>
Example 120<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yIoxy)-but}'l]-thiophene-2-carbonyl}-<br>
amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (isomer 2) as the starting material. MS (ES): 508.3<br>
[M+H]+.<br>
Example 121<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-<br>
carbony)}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5- [1 -(2,6-dimemyM'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-<br>
,carbonyl}-amino)-propionic acid methyl ester (isomer 1) as the starting material. MS<br>
(ES): 534.2 [M+H]+.<br>
Example 122<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-<br>
carbonyI}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimemyl-4'-trifluoromemyl-biphenyl-4-yloxy)-pentyl]-thiophene-2-<br>
carbonyl) -amino)-propionic acid methyl ester (isomer 2) as the starting material. MS<br>
(ES): 534.0 [M+H]+.<br>
Example 123<br>
3-({5-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yIoxy)-2-methyl-propyI]-<br>
thiophene-2-carbonyl}-amino)- 2R -hydroxy-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethy]-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl)-amino)-2/?-hydroxy-propionic acid methyl ester (isomer 1) as the starting<br>
material. MS (ES): 536.0 [M+H)+.<br>
Example 124<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyI-propyl]-<br>
thiophene-2-carbonyl}-amino)-2R -hydroxy-propionic add, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimemyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2/?-hydroxy-propionic acid methyl ester (isomer 2) as the starting<br>
material. MS (ES): 536.0 [M+H]+.<br>
Example 125<br>
3-({5-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyI-4-yloxy)-2-methyl-propyI]-<br>
thfophene-2-carbonyl}-amino)-2S-hydroxy-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimediyl-4'-trifluoromethyl-bJphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2/J-hydroxy-propionic acid ethyl ester (isomer 1) as the starting<br>
material. MS (ES): 536.0 [M+H]Example 126<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl.4-yloxy)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-25-hydroxy-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2J?-hydroxy-propionic acid ethyl ester (isomer 2) as the starting<br>
material. MS (ES): 536.0 [M+Hf.<br>
Example 127<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2R-hydroxy-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-H-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2tf-hydroxy-propionic acid methyl ester (isomer 1) as the starting<br>
Material. MS (ES): 524.3 [M+HJ+.<br>
Example 128<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyI]-thiophene-2-<br>
carbonyl}-amino)-2Z?-hydroxy-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5- [ 1 -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2/Miydroxy-propionic acid methyl ester (isomer 2) as the starting<br>
material. MS (ES): 524.3 [M+H]+.<br>
Example 129<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-25-hydroxy-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-25-hydroxy-propionic acid ethyl ester (isomer 1) as the starting<br>
material. MS (ES): 524.3 [M+H]+.<br>
Example 130<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-2S-hydroxy-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4,-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-25'-hydroxy-propionic acid ethyl ester (isomer 2) as the starting<br>
material. MS (ES): 524.3 [M+H]+.<br>
Example 131<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-l-ethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyI-2,6-dimethyl-biphenyl-4-yloxymethyl)-l-ethyl-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 536.2<br>
[M+H]+.<br>
Example 132<br>
(R^S)-3-({5-[l.(4'.tert-Butyl.2,6-dimethyl-biphenyl-4-yIoxymetliyl)-propyl]-<br>
thiophene-2-carbonyI}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4-tert-butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 508.3<br>
[M+H]+.<br>
Example 133<br>
^n,S)-3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by me general method as exemplified in Example 110 using 3-<br>
({5^1-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 520.2<br>
[M+H]+.<br>
Example 134<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
carbonylJ-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (isomer 1) as the starting material. MS<br>
(ES): 508.3 [M+H]+.<br>
Example 135<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
((5- [1 -(4'-tert-buty]-2,6-dimethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
carbonyl}-amino)-pTopionic acid methyl ester (isomer 2) as the starting material. MS<br>
(ES): 508.3 [M+HJ+.<br>
Example 136<br>
3-({S-[l-(2,6-Dimthyl-4'-trifluoromethyl-biphcnyl-4-yIoxymethyl)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-tl-(2,6-dimemyM'-trifluoromethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
rarbonyI}-amino)-propionic acid methyl ester (isomer 1) as the starting material. MS<br>
(ES): 520.0 [M+Hf.<br>
Example 137<br>
3-((S-[l-(2,6-Dimethyl-4'-trifluorometbyI-biphenyl-4-yIoxymethyl)-propyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example. 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxymethyl)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (isomer 2) as the starting material. MS<br>
(ES): 520.0 [M+H]+.<br>
Example 138<br>
(R,S)-3-({5.[l-(4'.tert-ButyI-2,6-dimethyl.biphenyl-4.yIoxy)-propyl]-4-chloro-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-propyl]-4-chloro-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 528.0<br>
[M+H]+.<br>
Example 139<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-diniethyl-biphenyl-4-yIsulfanyl)-ethyl].thiophene-2-<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-ethyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 496.3 [M+H]+.<br>
Example 140<br>
(R,S)-3-({5-[l-(4'-tert.Butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-ethyl]-thiophcne-2.<br>
carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-ethyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester as the starting material. MS (ES): 536.0 [M+H]+.<br>
Example 141<br>
(R,S)-3-({S-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yIsulfanyl).2^-dimethyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-2,2-dimethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS<br>
(ES): 550.0 [M+H]+.<br>
Example 142<br>
(R,S)-3-({5-[l-(2,6-DimethyI-4,-trifluoromethyl.biphenyM-ylsulfanyl)-3.methyl-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromediyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS<br>
(ES): 550.0 [M+H]+.<br>
Example 143<br>
3-({5-[l-(4'-tert-Buty]-2,6-dimethyl-biphenyI-4-ylsulfanyl)-ethyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-ethyl]-thiophene-2-carbonyl} -<br>
amino)-propionic acid methyl ester (isomer 1) as the starting material. MS (ES): 536.0<br>
[M+H]+.<br>
Example 144<br>
3-({5-[l-(4'.tert-Butyl-2,6-dimethyl-biphenyl-4-ylsuIfanyl)-ethyl]-thiophene-2.<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-ethyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (isomer 2) as the starting material. MS (ES): 536.0<br>
[M+H]+.<br>
Example 145<br>
3-({5-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yIsulfanyl)-2,2.dimethyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromemyl-biphenyl-4-ylsulfanyl)-2,2-dimethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (isomer 1) as the starting<br>
material. MS (ES): 550.0 [M+H]+.<br>
Example 146<br>
3-({5-[l-(2,6-Dimethyl-4'-trinuoromethyl-biphenyl-4-ylsulfanyl)-2^-dimethyl-<br>
propyI]-thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-2,2-dimethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid-methyl ester (isomer 2) as the starting<br>
material. MS (ES): 550.0 [M+Hf.<br>
Example 147<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3^-dimethyl-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionicacid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l
thiophene-2-carbonyl}-amino)-propionic acid methyl ester as the starting material. MS<br>
(ES): 564.0 [M+H]+.<br>
Example 148<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-pentyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compoimd is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-pentyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 550.0<br>
Fm+H]+.<br>
Example 149<br>
(R,S)-3.({5-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyl-4-ylsulfany])-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester as the starting material. MS (ES): 536.0<br>
[M+H]+.<br>
Example 150<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-y!sulfanyl)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 1<br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-butyl]-thiophene-2-<br>
carbonyl)-amino)-propionic acid methyl ester (isomer 1) as the starting material. MS<br>
(ES): 536.0 [M+H]+.<br>
Example 151<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br><br><br>
This compound is made by the general method as exemplified in Example 110 using 3-<br>
({5-[l-(2,6-dimethyl-4'-ttifluoromethyl-biphenyl-4-ylsulfanyl)-butyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid methyl ester (isomer 2) as the starting material. MS<br>
(ES): 535.8 [M+H]V<br>
Example 152<br>
3-({5-[l-(2,6-Dimethyl-4,.trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 1<br>
Step A <br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyI-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester (Isomer 1)<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4*-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl} -amino)-propionic acid methyl ester (190 mg) is separated by<br>
chiral HPLC (column: Chiralpak AD 4.6 x 150 mm; eluent: 100% 3A ethanol; flow rate:<br>
0.6 mL/min; UV absorbance wavelength: 280 nm) to provide 3-({5-[3-methyI-l-(4'-<br>
trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-carbonyl }-amino)-propionic acid<br>
methyl ester (Isomer 1) (91 mg).<br>
Step B<br>
3-({5-[l.(2,6-Dimethyl-4'-triflnoromethyl-biphenyl-4-yloxy)-3-methyI-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid (Isomer 1)<br>
A solution of 3-({5-[l-(2,6-dimethyl-4'-trifluoromediyl-biphenyl-4-yloxy)-3-methyl-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (Isomer 1) (91 mg,<br>
0.166 mmol) in methanol (1.66 mL) is treated with 5N NaOH (0.166 mL) and shaken at rt<br>
for 2h. The reaction is neutralized with IN HC1 (0.170 mL), and extracted into ethyl<br>
acetate (2x). The combined organic layers are dried and concentrated, giving the title<br>
compound (142 mg). MS (ES): 534.4 [M+H]+<br>
The following compounds are made in a substantially similar manner.<br>
Example 153<br>
3-({5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
MS (ES): 534.4 [M+H]+.<br>
Example 154<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2,2-dimethyl-propyl]-<br>
thiophene-2-carbony]}-amino)-propionic acid, Isomer 1<br><br>
MS (ES): 522.4 [M+H]+.<br>
Example 155<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-y]oxy)-2,2-dimethyl-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
MS (ES): 522.5 [M+H]+.<br>
Example 156<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br>
Step A <br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-y]oxy)-propy]]-thiophene-2.<br>
carbonyl}-amino)-propiomc acid methyl ester, Isomer 2<br>
To a solution of 3-({5-[l-(4-iodo-3,5-dimethyl-phenoxy)-propyl]-thiophene-2-carbonyl}-<br>
amino)-propionic acid methyl ester (Isomer 2) (203,5 mg, 0.406 mmol) in THF (4.1 ml) is<br>
added (4-trifluoromethyl)phenylboronic acid (87 mg, 0.487 mmol), potassium fluoride<br>
(59 mg, 1.22 mmol), palladium(II) acetate (18 mg, 0.081 mmol), and (oxydi-2,1-<br>
phenylene)bis-(diphenylphosphme) (86 mg, 0.16 mmol). The reaction mixture is heated<br>
to reflux overnight. After cooling to rt, the reaction mixture is partitioned between ethyl<br>
acetate and water. The aqueous layer is back-extracted with ethyl acetate, the combined<br>
organic layers are dried and concentrated, then loaded onto C18 and eluted using <br>
acetonitrile with a water gradient from 15% to 100% giving 3-({5-[l-(4'-tert-butyl-2,6-<br>
dimethyl-biphenyl-4-yloxy)-propyl]-thiophene-2-carbonyl) -amino)-propionic acid<br>
methyl ester (Isomer 1) (93 mg).<br>
Step B<br>
3-({5.ll-(4'-tert-BuryI-2,6-dimechyI-biphenyl.4-yloxy)-propyI]-thiophene.2-<br>
carbonyl}-amino)-propionic acid, Isomer 2<br>
A solution of 3-({5-tl-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-propyl]-tbiophene-2-<br>
carbonyl}-amino&gt;propionic acid methyl ester (Isomer 2) (90.2 mg, 0.178 mmol) in<br>
methanol (1.8 mL) is treated with 5N NaOH (0.178 mL) and shaken at rt overnight The<br>
reaction is neutralized with IN HC1 (0.182 mL), and extracted into ethyl acetate (2x).<br>
The combined organic layers are dried and concentrated, giving the title compound (70.5<br>
mg). MS (ES): 494.3 [M+H]+.<br>
The following compounds are made in a substantially similar manner.<br>
Example 157<br>
3-({S-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-thiophene-2-<br>
carbonyl)-amino)-propionic acid, Isomer 2<br><br>
MS (ES): 520.4 [M+H]+.<br>
StepA<br>
(R,S)-3-({54H4'-tert-Butyl-2,6-<ijmeuiyl-biphenyl-4-ytsulfanyi><br>
thtopheoe-2~au-bonyl}-amino)-propiotiic acid methyl ester<br>
A solution of (R,S)-3-{[5-(l-hydioxy-2-inethyl-propyI&gt;-thiophenc-2-carbonyl]-ainino}-<br>
propionic acid methyl ester (3SS.8 mg, 1.25 mmol) and 4-bromo-3,5-dimethyl-<br>
bcnzenethiol (509 mg, 1.88 mmol) in 1,2-dichloroethane (5 mL) is treated with zinc<br>
iodide (399 mg, 1.25 mmol) and stirred overnight at it. The reaction mixture is then<br>
partitioned between water and dichloromethane. The aqueous layer is back-extracted<br>
with dichloromethane, and the combined organic layers are dried, filtered, and<br>
concentrated. The resulting residue is applied to silica gel and eluted using hexanes with<br>
an ethyl acetate gradient from 0% to 70% to give (R^&gt;3-({5-[H4-bromo-3&gt;dimethyl-<br>
phenylsulfanyl)-2-methyl-propyl]-thiophene-2-carbonyl} -amino)-propionic acid methyl<br>
ester (336 nig).<br>
StepB<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6.diinethyI-biphenyl.4-yIsulfanyl)-2-methyl-propyl]-<br>
thiophene-2-carbonyI}-amino)-propionic acid methyl ester<br>
To a solution of (R,S)-3-({5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-2-methyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (244 mg, 0.504 mmol)<br>
in THF (5 ml) is added (4-tert-butyl)phenylboronic acid (269 mg, 1.512 mmol),<br>
potassium fluoride (73 mg, 1.512 mmol), palladium(II) acetate (23 mg, 0.101 mmol), and<br>
(oxydi-2,l-phenylene)bis-(diphenylphosphine) (109 mg, 0.202 mmol). The reaction<br>
mixture is heated to reflux overnight. After cooling to rt the reaction mixture is<br>
partitioned between ethyl acetate and water. The aqueous layer is back-extracted with<br>
ethyl acetate, the combined organic layers are dried and concentrated, then loaded onto C-<br>
18 and eluted using acetonitrile with a water gradient from 15% to 100% giving (R,S)-3-<br>
({5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-2-methyl-propyl]-thiophene-2-<br>
carbonyl]-amino)-propionic acid methyl ester (83 mg).<br>
Step C<br>
(R3)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-2-methyl-propyl]-<br>
thiophene-2-carbonyl}-arnino)-propionicacid<br>
A solution of (R,S)-3-({5-[l-(4'-^r;-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-2-methyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (77.7 mg, 0.144<br>
mmol) in methanol (1.5 mL) is treated with 5N NaOH (0.144 mL) and shaken at rt<br>
overnight. The reaction is neutralized with IN HC1 (0.148 mL), and extracted into emyl<br>
. acetate (2x). The combined organic layers are dried and concentrated, giving the title<br>
compound (74.5 mg). MS (ES): 524.3 [M+H]The following compound is made in a substantially similar manner.<br>
Example 173<br>
(R,S)-3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-2,2-dimethyl-<br>
propyl]-thiophene-2-carbonyl}-amino)-propionic acid<br><br>
MS (ES): 538.3 [M+H]+.<br>
Example 174<br>
(R^D-S-CiS-tl-Ca'-tert-Butyl^jd-dimethyl-biphenyl^-ylsulfanyO-a^-dimethyl-buty]]-<br>
thiophene-2-carbonyl}-amino)-propionic acid<br>
Step A <br>
(R,S)-5-[l-(4-Bromo-3^-dimethyl-phenyIsulfanyl)-3,3-dimethyl-butyl]-thiophene-2-<br>
carboxylic acid ethyl ester<br>
A solution of (R,S)-5-(l-hydroxy-3,3-dimethy]-butyl)-thiophene-2-carboxylic acid ethyl<br>
ester (766.7 mg, 2.99 mmol) and 4-bromo-3,5-dimethyl-benzenethiol (1.2 mg, 4.49<br>
mmol) in 1,2-dichloroethane (12 mL) is treated with zinc iodide (951 mg, 2.99 mmol) and<br>
stirred overnight at rt. The reaction mixture is then partitioned between water and<br>
dichloromethane. The aqueous layer is back-extracted with dichloromethane, and the<br>
combined organic layers are dried, filtered, and concentrated. The resulting residue is<br>
applied to Cjs and eluted using acetonitrile with a water gradient from 15% to 100%<br>
giving to give (R,S)-5-[l-(4-bromo-3,5-dimemyl-phenylsulfanyl)-3,3-dimethyl*butyl]-<br>
thiophene-2-carboxylic acid ethyl ester (1.12 g).<br>
StepB<br>
(R,S)-5-[l-(4.Bromo-3,5-dimethyl-phenylsulfanyl)-3^-dimethyl-butyl]-thiophene-2-<br>
carboxylic acid<br>
To a mixture of (R,S)-5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3,3-dimethyl-butyl]-<br>
thiophene-2-carboxylic acid ethyl ester (1.101 g, 2.42 mmol) in ethanol (24.2 mL) is<br>
added 5N NaOH (2.42 mL) at room temperature, and stirred overnight. The reaction<br>
mixture is acidified by IN HC1 (2.46 mL), extracted into ethyl acetate, dried and<br>
concentrated, then dried under vacuum, giving (R,S)-5-[l-(4-bromo-3,5-dimethyl-<br>
phenylsulfanyl)-3,3-dimethyl-buty]]-thiophene-2-carboxylic acid (896.2 mg).<br>
Step C<br>
(R,S)-3-({5-[l-(4-Bromo-3^-dimethyI-phenyIsuIfanyl}-3^-dimethyl-buty[]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br>
To a mixture of (R,S)-5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3^-dimediyl-butyl]-<br>
thiophene-2-carboxylic acid (886.5 mg, 2.07 mmol) in DMF (21 mL) is added 3-amino-<br>
propionic acid methyl ester hydrochloride^ 46 mg, 2.48 mmol), 1-hydroxybenzotriazole<br>
hydrate (335 mg, 2.48 mmol), and diisopropylethylamine (0.724 mL, 4.14 mmol) at room<br>
temperature, and stirred 10 min. The mixture is then treated with N-(3-<br>
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (794 mg, 4.14 mmol), and<br>
stirred overnight. The reaction mixture is treated with 0.1N HC1 and extracted into ethyl<br>
acetate twice. The combined organic layers are washed with brine, dried and<br>
concentrated, and dried under vacuum to give (R,S)-3-({5-[l-(4-bromo-3,5-dimethyl-<br>
phenylsulfany])-3,3-dimethyl-butyl]-thiophene-2-carbonyl}-amino)-propionicacid<br>
methyl ester (885 mg).<br>
Step D<br>
(R,S)-3-({5-[l-(4,-tert-Butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3^-dimethyl-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br>
To a solution of (R,S)-3-({5-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3,3-dimethyl-<br>
butyl]-thiophene-2-carbonyl}-amino)-propionic acid methyl ester (749.1 mg, 1.46 mmol)<br>
in THF (14.6 ml) is added (4-tert-butyl)phenylboronic acid (780 mg, 4.38 mmol),<br>
potassium fluoride (211 mg, 4.38 mmol), palladium(H) acetate (131 mg, 0.584 mmol),<br>
and (oxydi-2,l-phenylene)bis-(diphenylphosphine) (629 mg, 0.584 mmol). The reaction<br>
mixture is heated to reflux overnight. After cooling to it, the reaction mixture is<br>
partitioned between ethyl acetate and water. The aqueous layer is back-extracted with<br>
ethyl acetate, the combined organic layers are dried and concentrated, then loaded onto C-<br>
ig and eluted using acetonitrile with a water gradient from 15% to 100% giving (R,S)-3-<br>
({5-[^(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3,3-dimethyl-butyl]-thiophene-<br>
2-carbonyl} -amino)-propionic acid methyl ester (274.7 mg).<br>
StepE<br>
(R,S)-3-({5-[lK4'-tert-ButyI.2,6-dimethyl-bipheiiyl-4-ylsuIfaiiyl)-3^-dimethyl-butyl].<br>
thiophene-2-carbonyI}-amino)-propionic acid<br>
To a mixture of (R,S)-3-({ 5-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3,3-<br>
dimethyl-butyl]-thiophene-2-carbonyl} -amino)-propionic acid methyl ester (31 mg, 0.055<br>
mmol) in methanol (0.548 mL) is added 5N NaOH (0.055 mL) at room temperature, and<br>
stirred overnight. The reaction mixture is acidified by IN HC1 (0.056 mL), extracted into<br>
ethyl acetate, dried and concentrated, then dried under vacuum, giving the title compound<br>
(28.8 mg).<br>
MS (ES): 552.2 [M+H]+.<br>
The following compounds are made in a substantially similar manner.<br>
Example 175<br>
(R3)-3-({S-[l-(4,-tert-Butyl-2,
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
MS (ES): 538.3 [M+H]+.<br>
Example 176<br>
3.({5-[l-(4,-tert-ButyI-2,6-dimethyl-biphenyl-4-ylsulfanyl)-l-methyI-ethyl].<br>
thiophene-2-carbonyl}-amino)-propionicadd ...<br><br>
MS (ES): 510.4 [M+H]+.<br>
Example 177<br>
^^-^({S-fl^^-IMmethyl-^-trifluoromethyl-biphenyW-ylsulfan^-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br><br>
Step A<br>
(R,S)-5-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-propyl]-<br>
thiophene-2-carboxylic acid ethyl ester<br>
A solution of (R,S)-5-(l-hydroxy-propyl)-thiophene-2-carboxylic acid ethyl ester (467.6<br>
mg, 2.18 mmol) and 4'-trifluoromethyl-2,6-dimemyl-biphenyl-4-thiol (923 mg, 3.27<br>
mmol) in 1,2-dichloroethane (8.72 mL) is treated with zinc iodide (694 mg, 2.18 mmol)<br>
and stirred overnight at rt. The reaction mixture is then partitioned between water and<br>
dichloromethane. The aqueous layer is back-extracted with dichloromethane, and the<br>
combined organic layers are dried, filtered, and concentrated. The resulting residue is<br>
applied to silica gel and eluted using hexanes with an ethyl acetate gradient from 0% to<br>
40% to give (R,S)-5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-propyl]-<br>
thiophene-2-carboxylic acid ethyl ester (846.8 mg).<br>
StepB<br>
(RyS)-5-tl-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-propyl]-<br>
thiophene-2-carboxylic acid<br>
To a mixture of (R,S)-5-[l-(2,6-dimethyl-4'-trifIuoromethyl-biphenyl-4-ylsulfanyl)-<br>
propyl]-thiophene-2-carboxylic acid ethyl ester (114 mg, 0.238 mmol) in ethanol (2.4<br>
mL) is added 5N NaOH (0.238 mL) at room temperature, and stirred overnight. The<br>
reaction mixture is acidified by IN HC1 (0.242 mL), extracted into ethyl acetate, dried<br>
and concentrated, then dried under vacuum, giving (R,S)-5-[l-(2,6-dimethyl-4'-<br>
trifluoromethyl-biphenyl-4-ylsulfanyI)-propyl]-thiophene-2-carboxylic acid (107 mg).<br>
StepC<br>
(R,S)-3-({5-[l-(2,6.DimethyI.4'-trifluoromethyI-biphenyl-4-yIsulfanyI)-propyI]-<br>
thiophene-2-carbonyl}-amino)-propionic acid methyl ester<br>
To a mixture of (R,S)-5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-<br>
propyl]-thiophene-2-carboxylic acid (107 mg, 0.237 mmol) in DMF (2.4 mL) is added 3-<br>
amino-propionic acid methyl ester hydrochloride(40 mg, 0.284 mmol), 1-<br>
hydroxybenzotriazole hydrate (38.4 mg, 0.284 mmol), and diisopropylethylamine (0.083<br>
mL, 0.474 mmol) at room temperature, and stirred 10 min. The mixture is then treated<br>
with N-(3-dimemylairiuiopropyl)-N*-ethylcarbodiimidehydrochloride (91 mg, 0.284<br>
mmol), and stirred overnight. The reaction mixture is treated with 0.1N HC1 and extracted<br>
into ethyl acetate twice. The combined organic layers are washed with brine, dried and.<br>
concentrated, and dried under vacuum to give (R,S)-3-({ 5-[l-(2,6-dimethyl-4'-<br>
trifluoromemyl-biphenyM-ylsulfanyl)-propyl]-thiophene-2-carbonyl}-amino)-propionic<br>
acid methyl ester (81 mg).<br>
StepD<br>
(R,S)-3-({5-[l-(2,6-Dimethyl-4'.trifluoromethyl-biphenyl-4-ylsulfanyl)-propyl]-<br>
thiophene-2-carbonyl}-amino)-propionicacid<br>
To a mixture of (R,S)-3-({5-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-<br>
propyl]-thiophene-2-carbonyl} -amino)-propionic acid methyl ester (86 mg, 0.161 mmol)<br>
in methanol (1.6 mL) is added 5N NaOH (0.162 mL) at room temperature, and stirred,<br>
overnight The reaction mixture is acidified by IN HC1 (0.166 mL), extracted into ethyl<br>
acetate, dried and concentrated, then dried under vacuum, giving the title compound (75<br>
mg). MS (ES): 522.1 [M+H]+.<br>
The following compounds are made in a substantially similar manner.<br>
Example 178<br>
0R,S)-3-({5-[l-(4,-tert-Butyl-2,6-dimethyI-biphenyl-4-ylsulfanyl)-propyl]-thiophene-<br>
2-carbonyl}-amino)-prop!onic acid<br><br>
MS (ES): 510.2 [M+Hf.<br>
Example 179<br>
(R,S)-3-({5-[l-(4'-tert-ButyI-2,6-dimethyI.biphenyl-4-ylsulfanyl)-4,4-dimethyI-<br>
pentyI]-thiophene-2-carbony]}-amino)-propionicacid<br>
MS(ES): 578.3 [M+H]+.<br>
Example 190<br>
3-({5-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4^-trffluoro-butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2<br><br>
MS(ES):~578.3 [M*H]V---------------------------<br>
The compound of Formulae I-IV is preferably formulated in a unit dosage form<br>
prior to administration. Therefore, yet another embodiment of the present invention is a<br>
pharmaceutical composition comprising a compound of Formulae I-IV and one or more<br>
pharmaceutically acceptable carriers, diluents or excipients.<br>
The present pharmaceutical compositions are prepared by known procedures<br>
using well-known and readily available ingredients. In making the formulations of the<br>
present invention, the active ingredient (Formulae I-IV compound) will usually be mixed<br>
with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the<br>
form of a capsule, sachet, paper or other container. When the carrier serves as a diluent,<br>
it may be a solid, semisolid or liquid material mat acts as a vehicle, excipient, or medium<br>
for the active ingredient. Thus, the compositions can be in the form of tablets, pills,<br>
powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups,<br>
aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories,<br>
sterile injectable solutions and sterile packaged powders.<br>
Some examples of suitable carriers, excipients, and diluents include, lactose,<br>
dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,<br>
tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone,<br>
cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc,<br>
magnesium stearate and mineral oil. The formulations can additionally include<br>
lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents,<br>
sweetening agents or flavoring agents. The compositions of the invention may be<br>
formulated so as to provide quick, sustained or delayed release of the active ingredient<br>
alter administration to the patient.<br>
The compositions of the present invention may be formulated in sustained release<br>
form to provide the rate controlled release of any one or more of the components or active<br>
ingredients to optimize the pharmacological and therapeutic effects. Suitable dosage<br>
forms for sustained release include layered tablets containing layers of varying<br>
disintegration rates or controlled release polymeric matrices impregnated with the active<br>
components and shaped in tablet form or capsules containing such impregnated or<br>
encapsulated porous polymeric matrices.<br>
Liquid form preparations include solutions, suspensions and emulsions. As an<br>
example may be mentioned water or water-propylene glycol solutions for parenteral<br>
injections or addition of sweeteners and opacifiers for oral solutions, suspensions and<br>
emulsions. Liquid form preparations may also include solutions for intranasal<br>
administration.<br>
Aerosol preparations suitable for inhalation may include solutions and solids in<br>
powder form, which may be in combination with a pharmaceutically acceptable carrier<br>
such as inert compressed gas, e.g. nitrogen.<br>
For preparing suppositories, a low melting wax such as a mixture of fatty acid<br>
glycerides such as cocoa butter is first melted, and the active ingredient is dispersed<br>
homogeneously therein by stirring or similar mixing. The molten homogeneous mixture<br>
is then poured into convenient sized molds, allowed to cool and thereby solidify.<br>
Also included are solid form preparations which are intended to be converted,<br>
shortly before use, to liquid form preparations for either oral or parenteral administration,<br>
Such liquid forms include solutions, suspensions and emulsions.<br>
The compounds of the invention may also be deliverable transdermally. The<br>
transdermal compositions may take the form of creams, lotions, aerosols and/or<br>
emulsions and can be included in a transdermal patch of the matrix or reservoir type as a<br>
re conventional in the art for this purpose.<br>
Preferably the compound is administered orally.<br>
Preferably, the pharmaceutical preparation is in a unit dosage form. In such form,<br>
the preparation is subdivided into suitably sized unit doses containing appropriate<br>
quantities of the active components, e.g., an effective amount to achieve the desired<br>
purpose.<br>
The quantity of the inventive active composition in a unit dose of preparation may<br>
be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams,<br>
preferably from about 0.01 to about 950 milligrams, more preferably from about 0.01 to<br>
about 500 milligrams, and typically from about 1 to about 250 milligrams, according to<br>
the particular application. The actual dosage employed may be varied depending upon<br>
the patient's age, sex, weight and severity of the condition being treated. Such techniques<br>
are well known to those skilled in the art. Generally, the human oral dosage form<br>
containing the active ingredients can be administered 1 or 2 times per day.<br>
PHARMACOLOGICAL METHODS<br>
In the following section binding assays as well as functional assays useful for<br>
evaluating the efficiency of the compounds of me invention are described.<br>
Binding of compounds to the glucagon receptor may be determined in a<br>
competition binding assay using the cloned human glucagon receptor. Antagonism may<br>
be determined as the ability of the compounds to inhibit the amount of cAMP formed in<br>
the presence of 5 nM glucagon.<br>
Glucagon Receptor (hGlucR) Binding Assay<br>
The receptor binding assay uses cloned human glucagon receptor (Lok S, Kuijper<br>
JL, Jelinek LI, Kramer IM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs<br>
SH, Rosenberg GB, et al.Gene 140 (2), 203-209 (1994)) isolated from 293HEK<br>
membranes. The hGlucR cDNA is subcloned into the expression plasmid phD (Trans-<br>
activated expression of fully gamma-carboxylated recombinant human protein C, an<br>
antithrombotic factor. GrinneU, B.W., Berg, D.T., Walls, J. and Yan, S.B.<br>
Bio/Technology 5: 1189-1192 (1987)). This plasmid DNA was transfected into 293 HEK<br>
cells and selected with 200 ug/ml Hygromycin.<br>
Crude plasma membranes are prepared using cells from suspension culture. The<br>
cells are lysed on ice in hypotonic buffer containing 25 mM Tris HCL, pH 7.5,1 mM<br>
MgC12, DNAsel, 20 u/ml, and Roche Complete Inhibitors-without EDTA. The cell<br>
suspension is homogenized with a glass dounce homogenizer using a Teflon pestle for 25<br>
strokes. The homogenate is centrifuged at 4 degrees C at 1800 x g for 15 mins. The<br>
supernate is collected and the pellet is resuspended in hypotonic buffer and<br>
rehomogenized. The mixture is centrifuged at 1800 x g for 15 mins. The second<br>
supernate is combined with the first supernate. The combined supernates are<br>
recentrifuged at 1800 x g for 15 mins to clarify. The clarified supernate is transferred to<br>
high speed tubes and centrifuged at 25000 x g for 30 minutes at 4 degrees C. The<br>
membrane pellet is resuspended in homogenization buffer and stored as frozen aliquots at<br>
-80 degree C freezer until needed.<br>
Glucagon is radioiodinated by I-125-lactoperoxidase procedure and purified by<br>
reversed phase HPLC at Perkin-Elmer/NEN (NEX207). The specific activity is 2200<br>
Ci/mmol. Kd determination is performed by homologous competition instead of<br>
saturation binding due to high propanol content in the 1-125 glucagon material. The Kd is<br>
estimated to be 3 nM and is used to calculate Ki values for all compounds tested.<br>
The binding assays are carried out using a Scintillation Proximity Assay<br>
(Amersham) with WGA beads previously blocked with 1% fatty acid free BSA (ICN).<br>
The binding buffer contains 25 mM Hepes, pH 7.4, 2.5 mM CaC12,1 mM MgCl2,0.1%<br>
fatty acid free BSA, (ICN), 0.003% tween-20, and Roche Complete Inhibitors without<br>
EDTA. Glucagon is dissolved in 0.01 N HC1 at 1 mg/ml and immediately frozen at -80<br>
degrees C in 30 ul aliquots. The glucagon aliquot is diluted and used in binding assays<br>
within an hour. Test compounds are dissolved in DMSO and serially diluted in DMSO.<br>
10 ul diluted compounds or DMSO is transferred into Coming 3632, opaque clear bottom<br>
assay plates containing 90 ul assay binding buffer or cold glucagon (NSB at 1 uM final).<br>
50 ul of 1-125 glucagon (0.15 nM final in reaction), 50 ul of membranes (300 ug/well),<br>
and 40 ul of WGA beads (150 ugs/well) are added, covered, and mixed end over end.<br>
Plates are read with a MicroBeta after 14 hours of settling time at room temp.<br>
Results are calculated as a percent of specific I-125-glucagon binding in the<br>
presence of compound. The absolute EC50 dose of compound is derived by non-linear<br>
regression of percent specific binding of I- 125-glucagon vs. the dose of compound added.<br>
The EC50 dose is converted to Ki using the Cheng-Prusoff equation (Cheng Y., Prusoff<br>
W. H., Biochem. Pharmacol. 22,3099-3108,1973).<br>
Glucagon -Like - Peptide 1 (Glpl-R) Receptor Binding Assay<br>
The receptor binding assay uses cloned human glucagon-like peptide 1 receptor<br>
(hGlpl-R) (Graziano MP, Hey PJ, Borkowski D, Chicchi GG, Strader CD, Biochem<br>
Biophys Res Commun. 1993 Oct 15;196(l):141-6) isolated from 293HEK membranes.<br>
The hGlpl-R cDNA is subcloned into the expression plasmid phD (Trans-activated<br>
expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic<br>
factor. Grinnell, B.W., Berg, D.T., Walls, J. and Yan, S.B. Bio/Technology 5: 1189-<br>
1192 (1987)). This plasmid DNA is transfected into 293 HEK cells and selected with 200<br>
ug/ml Hygromycin.<br>
Crude plasma membrane is prepared using cells from suspension culture. The<br>
cells are lysed on ice in hypotonic buffer containing 25 mM Tris HCL, pH 7.5,1 mM<br>
MgC12, DNAse, 20 u/ml, and Roche Complete Inhibitors without EDTA. The cell<br>
suspension is homogenized with a glass dounce homogenizer using a Teflon pestle for 25<br>
strokes. The homogenate is centrifuged at 4 degrees C at 1800 x g for 15 mins. The<br>
supernate is collected and the pellet is resuspended in hypotonic buffer and<br>
rehomogenized. The mixture is centrifuged at 1800 x g for 15 mins. The second<br>
supernate is combined with the first supemate. The combined supernates are<br>
recentrifuged at 1800 x g for 15 mins to clarify. The clarified supernate is transferred to<br>
high speed tubes and centrifuged at 25000 x g for 30 minutes at 4 degrees C. The<br>
membrane pellet is resuspended in homogeniiation buffer and stored as frozen aliquots in<br>
-80 degree C freezer until use.<br>
Glucagaon-like peptide 1 (Glp-1) is radioiodinated by the I-125-lactoperoxidase<br>
procedure and purified by reversed phase HPLC at Perkin-Elmer/NEN (NEX308). The<br>
specific activity is 2200 Ci/mmol. Kd determination is performed by homologous<br>
competition instead of saturation binding due to high propanol content in the 1-125 Glp-1<br>
material. The Kd is estimated to be 3 nM and is used to calculate Ki values for all<br>
compounds tested.<br>
The binding assays are carried out using a Scintillation Proximity Assay<br>
(Amersham) with wheat germ agglutinin (WGA) beads previously blocked with 1% fatty<br>
acid free BSA (ICN). The binding buffer contains 25 mM Hepes, pH 7.4,2.5 mM CaC12,<br>
1 mM MgC12,0.1% fatty acid free BSA, (ICN), 0.003% tween-20, and Roche Complete<br>
Inhibitors without EDTA. Glucagon-like peptide 1 is dissolved in PBS at 1 mg/ml and<br>
immediately frozen at -80 degrees C in 30 ul aliquots. The glucagon-like peptide aliquot<br>
is diluted and used in binding assays within an hour. Test compounds are dissolved in<br>
DMSO and serially diluted in DMSO. 10 ul diluted compounds or DMSO is transferred<br>
into Corning 3632, opaque clear bottom assay plates containing 90 ul assay binding<br>
buffer or cold glucagon-like peptide 1 (NSB at 1 uM final). 50 ul of 1-125 glucagon-like<br>
peptide 1 (0.15 nM final in reaction), 50 ul of membranes (600 ug/well), and 40 ul of<br>
WGA beads (150 ugs/well) are added, covered, and mixed end over end. Plates are read<br>
with a MicroBeta after 14 hours of settling time at room temp.<br>
Results are calculated as a percent of specific I-125-glucagon-like peptide 1<br>
binding in the presence of compound. The absolute EC50 dose of compound isderived<br>
by non-linear regression of percent specific binding of I-125-glucagon-like peptide 1 vs.<br>
the dose of compound added. The EC50 dose is converted to Ki using the Cheng-Prusoff<br>
equation (Cheng Y., Prusoff W. H., Biochem. Pharmacol. 22, 3099-3108,1973).<br>
Glucagon-Stimulated cAMP Functional Antagonist Assay<br>
The cAMP functional assay uses the same cloned human glucagon receptor cell<br>
line isolated for the hGlucR binding assay described above. Cells are stimulated with a<br>
mixture of an EC80 dose of glucagon in the presence of compound. The cAMP generated<br>
within the cell is quantitated using an Amplified Luminescent Proximity Homogeneous<br>
Assay, Alpha Screen, from Perkin Elmer (6760625R). Briefly, cAMP within the cell<br>
competes for binding of biotinylated cAMP from the kit to a coated anti-cAMP antibody<br>
Acceptor bead and a strepavidin coated Donor bead. As the cAMP level within the cell<br>
increases, a disruption of the Acceptor bead-biotinlyated cAMP -Donor bead complex<br>
occurs and decreases the signal.<br>
Glucagon is dissolved in 0.01 N HC1 at 1 mg/ml and immediately frozen at -80<br>
degrees C in 30 ul aliquots. The glucagon aliquot is diluted and used in the functional<br>
assay within an hour. Cells are harvested from sub-confluent tissue culture dishes with<br>
Enzyme-Free Cell.Dissociation Solution, (Specialty Media 5-004-B). The cells are<br>
pelleted at low speed and washed 3 times with assay buffer [25 mM Hepes in HBSS-with<br>
Mg and Ca (GIBCO, 14025-092) with 0.1% Fatty Acid Free BSA (ICN)] then diluted to a<br>
final concentration of 250,000 cells per ml. Compounds are serially diluted into DMSO<br>
then diluted into assay buffer with a 3X concentration of glucagon and 3% DMSO. The<br>
EC80 of glucagon is pre-determined from a full glucagon dose response and represents<br>
the dose at which glucagons produces an 80% of the maximal glucagon response, A<br>
mixture of biotinylated cAMP (1 unit/well final) from the Alpha Screen Kit and 3X<br>
IBMX (1500 uM) is prepared in Assay Buffer.<br>
The functional assay is performed in 96 well, low-volume, white, poylstyrene<br>
Costar Plates (3688). The biotinylated cAMP/IBMX mixture, 0.02 mis, is placed into<br>
each well, followed by addition of 0.02 mis of glucagon dose response, cAMP standard<br>
curve, or compound/glucagon mixtures. The reaction is started by addition of 0.02 mis of<br>
cells (5000/well final). After 60 minutes at room temperature, the reaction is stopped by<br>
the addition of 0.03 mis of Lysis Buffer [10 mM Hepes, pH 7.4,1% NP40, and 0.01%<br>
fatty acid free BSA (ICN) containing 1 unit each/well of Acceptor and Donor beads from<br>
the Alpha Screen Kit]. Lysis Buffer addition is performed under a green light to prevent<br>
bleaching of the detection beads. The plates are wrapped in foil and left to equilibrate<br>
overnight at room temperature. The plates are read on a Packard Fusion-Instrument<br>
Alpha screen units are converted to pmoles cAMP generated per well based upon<br>
the cAMP standard curve. The pmoles cAMP produced in the presence of compound are<br>
converted to % of a maximal response with the EC80 dose of glucagon alone. With each<br>
experiment, the dose of glucagon needed to produce a 50% response of pmoles cAMP is<br>
determined. This EC50 dose is used to normalize results to a Kb using a modified<br>
Cheng-Prusoff equation (Cheng Y., Prusoff W. H., Biochem. Pharmacol. 22,3099-3108,<br>
1973), where Kb = (EC50 compound)/ [1 + (pM glucagon used/ EC50 in pM for<br>
glucagon dose response)].<br>
In general the compounds according to the invention have a Ki value of less than<br>
50M as determined by the Glucagon Receptor (hGlucR) Binding Assay disclosed<br>
herein. The examples provided have Ki values of less than 50M. Preferably the<br>
compounds according to the invention have a Ki value of less than 5uM, and more<br>
preferably of less than 500 nM, and even more preferred of less than 100 nM, as<br>
determined by the Glucagon Receptor (hGlucR) Binding Assay disclosed herein.<br>
Generally, the compounds according to.the invention show a higher affinity for the<br>
glucagon receptor compared to the GLP-1 receptor, and preferably have a 10 to 10000<br>
fold higher binding affinity for the glucagon receptor than for the GLP-1 receptor.<br>
The results are given below for the indicated compound.<br><br>
From the above description, one skilled in the art can ascertain the essential<br>
characteristics of the present invention, and without departing from the spirit and scope<br>
thereof, can make various changes and modifications of the invention to adapt it to<br>
various usages and conditions. Thus, other embodiments are also within the claims.<br>
WE CLAIM:<br>
1. A compound structurally represented by Formula I<br><br>
or a phaiTiiaceulically acceptable salt thereof wherein:<br>
Y is-O-. -S-. or-O-CH2;<br>
Q. D. X and T independently represent carbon or nitrogen, provided that no more than<br>
two of Q. I), X and T are nitrogen:<br>
Rl is -hydrogen. -011. or -halogen:<br>
R2 is -hydrogen, or -((.V('i) alkyl;<br>
R3 and R4 are independently al each occurrence - hydrogen, -halogen. -CN. -(C}-C')<br>
alkoxy. -
R5 and R14 are independently -hydrogen. -(C1-CY) alkyl. -(C;,-C.'i:)c&gt;eloalkvl. -((Y<br>
CYjcycloalkyl-iCYCY.) alky 1. -phenyl, -phenyl-phenyl-(C1-C12)alkyl. -phcrsyl-(( Y<br>
CYJcycloalkyk -aryl. -aryl-{C",-C]^jalkyl. -heteroaryl. -heteroary]-( ('VCp.)alkyl. -((y<br>
("i'lalkenyl. -((yC| .))cyck&gt;alkcnyl. -hetei'ocycloalkyl. -hctcrocyck'ialkyYiCi-CYYilky I. -<br>
anl-((,yCn&gt;) alkenyl. -heteroarsl-KYGo) alkenyl. -((YCYkilkyny 1. -((Y<br>
C.'i.')cycIoalkynyl. -aryl-( (Y( YYilkynyl. -heteroar\I-( IN- LYlalkynyl, and<br>
wherein -((.YCyalky I. -((.A-C.-Oeycloalkyl. -phenyl. -phenyl-phenyY(( Y<br>
(Y'Jalky 1. "phenyl-((VC|,:)cyck&gt;alkyl.-aryl. -aryl-(C|-Ci;i)alkyl. -heteroaryl. -<br>
heteroaryl --('('i-CYOalky], -lieleroeycloalky I. -heterocycIoalkyl-('(a-CY)alkyl. -<br>
(CyC'i.-KiIkenyl. -((Y- CYocydoalkenyl. aryl ((.yCYdalkenyl. -heieroaiy ]-(('&gt;-<br>
C'luJalkenyl. -(C"";-C'|2)alk\ny I. -(Cx-(YY cycloalkynyl. -aryl-((yCY)alk&gt;nv!. or -<br>
heteroaryI-((VCp)aikynyl arc each optionally substituted with from one to three<br>
substituenSs each independently selected from the group consisting of-hydrogen.<br>
- hydroxy, -cyano. -nitro, -halo. -o\o. -(C|-C7)alkvl. -(Ci.C7)alkyl-CO(..)R12. -(LV<br>
C7)alkoxy, -(<.></.>
heterocycloalkyl. -C(())R12, -COOR12. -OC(O)R12. -OS(ObR12. -N(R12K -<br>
\R12C(()jR12. -NRI2S()2R12. -SR12. -S(O)R12. -S(())2R12, and -<br>
S(())&gt;N(R12)2: wherein optionally R5 and RI4 may form a four, live, or six<br>
membered ring with ihe atom to which ihcy arc attached, and the ring so formed<br>
may optionally include one or two double bonds, and optionally may be<br>
substituted with up to four halogens;<br>
R6 and R7 arc independently at each occurrence -hydrogen, -halogen, -hydroxy. -C'N. -<br>
(C1-C-)alkoxy. -(CN-C^lalkenyl. -(Ci.C-)alkyl. -aryl. -hcteroaryl. -(C.;-C7}eycloalkyl. -((.V<br>
CNlheteroeycloalky 1.<br>
wherein -(C '-C^Oalkcnx 1 . -VC.,-C?)alkyL -(C|-C?) alkoxy. -aryl. -hcteroaryl, -((';-<br>
C'7)cycloalkyl. -{C\-Ci )heterocycloalkyL are each optionally substituted with<br>
from one to three suhslituents independently selected from the group consisting of<br>
- hydroxy', -cyano. -nitro. -halo. -oxo. -(C|-C7)alkyl. -(CiX&gt;)alkyl-C()OR12. (CV<br>
C.-7)alkoxy. -fC :-C'7 &gt;cycloa!k\ 1. -aryloxy. -aryl. -aryl-(C|-C7)aIkyl. -hcteroaryl.-<br>
heterocycloalkyl. -C(())R12. -COOR12. -OC(())R12, -OS(O)2R12. -N(R12)2. -<br>
\R12C(())R12. -CK))-NR12R12. \R 12S()2R 12.-SR 12. -S(O)R12. -S(O)2R12.<br>
and-S(ObN(R]2);:-<br>
provided however that wherein I) is nitrogen, then R6 or R7 are not attached to I).<br>
and provided that wherein T is nitrogen, then R6 or R7 are not attached to I. and<br>
provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q. and<br>
provided that wherein X is nitrogen, then R6 or R7 are not attached to X: and<br>
wherein R6 and R7 may optionally form a six membered ring with the atoms to<br>
which they arc attached, and the ring so formed may optionally contain up to two<br>
oxygens, and further the ring so formed may optionally be substituted with up to<br>
four halogens:<br>
R8 and R9 are independently at each occurrence -hydrogen, -hydroxy. -CN. -nitro. -halo.<br>
-(C1-C-)alkyl. -CI7-;. -((.",.Crjalkoxy. -(C;-C7)cycloaIky I. -aryl. -arvl-(C1-C7)alkyl. -<br>
hcteroaryl. -heteroaryl-(( Y('7)alky I. -aryloxy. -C(O)R12. -COOR12. -OC(())RI2. -<br>
OS(O)2R12. -N(R12h. -NR12Q0) R12. -N R.I2S02 R12. -SR12. -S(())R12. -S(O)2 R12.<br>
and-S(O)2N(R12)2:<br>
and wherein -(Ci.C-)alkyl. -(C'|X-)aikoxy. -(CVCYjcycloalkyi. -aryl. -aryl-((V<br>
(2-)alkyl. -heteroaryl. -heleiT&gt;aryl-(C!-(27)alkyl. -aryloxy. are each optionally<br>
substituted with from one to three substituents independently selected from the<br>
group consisting of -hydrogen, -hydroxy, -cyano. -nitro. -halo, -oxo, -((':-<br>
C7)alkyl. -(C|-(;-)alk&gt;l-COORI2. -(C|-C7)alko\yl, -(CMYleycloalkyl. -arylox\. -<br>
aryl. -ar&gt; l-(C iX':?KilkyI. -heteroaryl. -heteroeycloalkyl. -C((.)jR12. -COOR12. -<br>
()C(())R12. -OS(())::R12, -N(R12K -NRI2C(O)R12. -C(O)NR12R12. -NR12S()2<br>
R12. -SR12. -S(O)R 1 2. -S(O)2R 12. and -S(())2N(R12)2;<br>
R10 is independently -hydrogen, -halogen. -(C1-C12) alkyl. -cycloalkyl. -aryl. -aryl-KV<br>
C 7&gt;alky 1. -heteroaryl. -heteroaryl -( Ci-Cvlalkyl. -('C2-C12)alkenyl. -(C.5-C12)cycloalkenyl.<br>
-aryl-{C2-C|(,)aIkenyl, -heleronryl-(C2-C in)alkeny I, -((VC|2/)alkynyl. -(,(V<br>
Ci:)cycloalkyny|. -aryl-(C2-C"i2)alkynyl. -heteroan 1-(C2-C12)alk\nyl.<br>
wherein -(C1-t i:)alk_\ 1. -cycloalkyl. -aryl. -aryl-(C|-C-)alkyl. -heteroaryl. -<br>
heteroaryl -( C|(.."-(alkyl. -(C2-C12)alkenvl. -((.VC12)cy'cloalkenyl. -aryl-(C2-<br>
C]())alkcny!. -hcteroaryl-((.'2-C10)alkenyl. -(C2-C'i2)alkynyi.-fC'x-(.'p.)cycloalkyn\l.<br>
-aryl-{( VCYOalkynyl. -heteroaryl-(C2-C12)alkynyl.<br>
are each optionally substituted with from one to three substituents each<br>
independently selected from the group consisting of-hydrogen, -hydroxy, -cyano.<br>
-nitro. -halo, -oxo, -(C1-CYalkyl, -(C,-C7)alkyl-COOR12. -(C1-C7)alkoxyl. -
(Yjcvcloalkyl, -aryloxy. -aryl. -aryl-C'i-CS alkyl. -heteroaryl, -heteroeycloalkyl. -<br>
C(O)R12. -(.'()()R 12. -()(.'(())R 12. -OS(O):R12. -N(R12K -NR12C(())R1 2, -<br>
NRI2S02 R12. -SRI2. -S(()}RI2. -S(O);&gt;R12. and -S(O)2N(R12)2:<br>
Rl I is independently at. each occurrence hydrogen: or<br>
 . wherein the zig-zag mark represents the point of attachment<br>
to the Rll position in formula I. wherein A. (). and K independently represent carbon or<br>
nitrogen, provided that no more than two of A. G. and f. are nitrogen; provided however<br>
that wherein A is nitrogen, then RK or Rc) are not attached to A. and provided that<br>
wherein G is nitrogen, (hen R8 or \il&gt; are nol attached to G. and provided that wherein H<br>
is nitrogen, then R8 or Rl) are not attached to \i: or<br>
 wherein the zig-zag mark represents the point of<br>
attaehment to the Rll position in formula I. wherein m is an integer off). 1. 2. or 3. and<br>
when m is 0 then (CI Mm is a bond.<br>
provided however that wherein I) is nitrogen, then Rl I is not attached to D. and provided<br>
thai wherein T is nitrogen, then Rll is nol attached to T. and provided that wherein Q is<br>
nitrogen, then Rll is not attached to (). and provided that wherein X is nitrogen, then Rll<br>
is not attached to X:<br>
R12 is independently at each occurrence -hydrogen. -(('1-C7) alky I.<br>
R13 is independently at each occurrence -hydrogen, -halogen. -(C|-C?) alkyl. -CI';. -<br>
OCFi.-fCrCVfalkenyl wherein ((VC?) alkyl, -(CYC^)alkenyl are each optionally<br>
substituted once with substituents independently selected from the group consisting of-<br>
Cf'.,, -OCF3.<br>
2. The compound as claimed in claim 1 is represented by Formula la:<br><br>
or a pharmaceutical!} acceptable salt thereof wherein:<br>
Y is -O-. -S-. or-O-Clh-:<br>
Q. 1). and T independently represent carbon or nitrogen, provided that no more than two<br>
of Q. D, and T are nitrogen:<br>
Rl is -hydrogen, or -011:<br>
R2 is -hydrogen:<br>
R3 and R4 are independent!} at eaeh occurrence -hydrogen, or -halogen;<br>
R5 and R14 arc independently<br>
-hydrogen. -(C;-<... alky i. c>)<br>
alkyl. -((':-C'i;&gt;)alkcnyl. -((YCnJcycloalkenyl. -heterocycloalkyl.<br>
heterocycloalkyl-(G- Cuialkyl. -(C1-C'i^lalkynyl. or -(Cx-C'i &gt;)cycloalkynyl;<br>
wherein -(C1-Ci;) alkyl. -(C;-C;;;)eycloalkyl. -(C\;-C,;&gt;)cycloalky 1 -{C:|-C:,:?.) alky I. -<br>
(CYCn)alkcnyl. -(CYCi?)cy cloalkeny I. -heterocycloalkyl. -heterocycloalky l-( Ci-<br>
C12)alk\l. -(('YYlalkynyl. or -(C8-CY)cycloalkynyl are each optionally<br>
substituted with one to three halogens;<br>
wherein optionally R5 and R14 may form a four, live, or six membered ring with<br>
the atom to which they are attached, and the ring so formed may optional!}<br>
include one or two double bonds, and optionally may be substituted with up to<br>
three halogens;<br>
R6 and R7 are independently<br>
-hydrogen, -halogen, -hydroxy. -C'N. -(C|-('7)alkoxy. -((VCYialkenyL -(("j.<br>
(^)alkyl. -((VC-)cyeloalkyl. or -(CYC?(heterocycloalkyl.<br>
wherein -(C'rC-)alkoxy. -(CYC-)alkenyl. -(C|-C"-Salkyl. -(CYY)cycloalkyl. or -<br>
(C.;-CY)helcrocyeloalkyl, are each optionally substituted with one to three<br>
halogens;<br>
provided however that wherein I) is nitrogen, then R6 or Rl are not attached to 1).<br>
and provided that wherein I is nitrogen, then R6 or R7 are not attached lo I. and<br>
provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q. and<br>
wherein R6 and R7 may optionally form a six membered ring with the atoms to<br>
which they are atniehed. and the ring so formed may optionally contain up to two<br>
oxygens, and further the ring so formed may optionally be substituted with up to<br>
four halogens;<br>
R8 and Rl) are independently at each occurrence<br>
-hydrogen, -hydroxy. -C'N. -nilro. -halo. -(CYYalkyl. -CF3 -((YCYalkoxy. -<br>
(CYYcycloalkyl. -C(O)R12. -COOR12. -
NR12Q0) R12. -N RI2S0: R12. -SRI2. -S(C&gt;)R12. ~S(C)): R12. or -<br>
S(C))2N(RI2)2: wherein -(C1-("7)nlkyl. -(C;-C7)a1koxy. -(C.5-C7)cyck&gt;alkyl. are<br>
each optionally substituted with from one to three halogens:<br>
R10 is independent!) -hydrogen:<br>
Rl 1 is independently at each occurrence -hydrogen: or<br><br>
wherein the zig-zag mark represents the point of attachment to the Rl I position in<br>
formula I: wherein A. G. and H independently represent carbon or nitrogen,<br>
provided that no more than two of A. (}, and H are nitrogen: provided however<br>
that wherein A is nitrogen, then R8 or R9 are not attached to A. and provided that<br>
wherein G is nitrogen, then RS or R9 are not attached to G. and provided that<br>
wherein 1. is nitrogen, then RS or R() are not attached to H: and<br>
R12 is independently at each occurrence -hydrogen or -(C1-C?) alkyl.<br>
3. The compound as claimed in claim 1. represented by formula lb:<br><br>
or a pharmaceutical!} acceptable salt thereof wherein:<br>
Y is-O-. -S-. or-O-CIb-:<br>
Q. D. and T independently represent carbon or nitrogen, provided that no more than two<br>
of O. I). and T are nitrogen:<br>
Rl is -hydrogen, or -011:<br>
R2 is -hydrogen:<br>
R3 and R4 arc -hydrogen:<br>
R5 and R 14 arc independently<br>
-hydrogen. -(C1-C12) alkyl. -(CVCyjcycloalkyl. -((YC^leycloalkyMCj-Co)<br>
alkvl.-(("2-C'i?)alkenyl. -(C;,-C12)cycloa!kcnyl. -helcrocyeloalkyl.<br>
hetcrocycloalk v l-((..'i- C'12.)alky1, -(C2-C 12Jalkyn v 1. or -(C'&amp;-C 12Icycloalkynyl:<br>
wherein -{(.yCY) alkyl. -((ycycyeloalkyl, -(C1-CnjcyeloalkyHCyCY) alky I. -<br>
(Cycyjalkenyl. -(;,-( Ylcycloalkenyh -heterocycloalkyl. -heterocycloalkyl-((..y<br>
Cyalkyl. -(C'2-C' 12 )alkynyl. or -(C,s-C12)cycloalkynyI are each optionally<br>
substituted with one to three halogens:<br>
wherein optionally R5 and R14 may form a four, five, or six meinbered ring with<br>
the atom to which they are attached, and the ring so formed may optionally<br>
include one or two double bonds, and optionally may be substituted with up to<br>
three halogens:<br>
R6 and R7 are independently<br>
-hydrogen, -halogen, -hydroxy. -CN. -(CyCyalkoxy. -((yc7)alkenyl. -KY<br>
C\)alkyl. -(C5-('-)eycloalkyl. or -(C;,-C-)heterocycloalkyl.<br>
wherein -((YCyalkoxy. -((.ytYtalkenyl. -fC'i-CSialkyk -((ycycycloalkyl. or<br>
((y(Y)helcrocveloalkyl. are each optionally substituted with one to three<br>
halogens:<br>
provided however that wherein I) is nitrogen, then R6 or R7 are not attached to 1).<br>
and provided that wherein T is nitrogen, then R6 or R7 are not attached to I. and<br>
provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and<br>
wherein R6 and R7 may optionally form a six membered ring with the atoms to<br>
which they are attached, and the ring so formed may optionally contain up to two<br>
oxygens, and further the ring so formed may optionally be substituted with up to<br>
four halogens:<br>
R8 and R9 are independently at each occurrence<br>
-hydrogen, -hydroxy. -CN. -nilro. -halo, -(C1-C\)alkyl. -CI\, -( Ci-C-)alkoxy. -((&gt;<br>
CMcycloalkyl. -C(())R12. -COOR12. -OC(O)R12. -OS(ObR12, -N(RI2b, - NRI2C(()&gt;<br>
R12. -N R12SO: R12. -SRI 2. -S(O)R 12. -S(())? R12. or -S(ObN(R12)2:<br>
wherein -((ycyalkyl. -((YCyalkoxy. -('C.rCYjcycloalkyl. are each optionally<br>
substituted with from one 10 three halogens:<br>
R10 is independently -hydrogen;<br>
RM is independently tit each occurrenec -hydrogen: or<br><br>
wherein the zig-zag mark represents the point of attachment to the Rll position in<br>
formula I:<br>
wherein A. G. and H independently represent carbon or nitrogen, provided that no more<br>
than two of A. G. and I' arc nitrogen;<br>
provided however thai wherein A is nitrogen, then R8 or R9 are not attached to A. and<br>
provided that wherein G is nitrogen, then R X or R9 are not attached to G, and provided<br>
that wherein 1- is nitrogen, then R8 or R9 are not attached to li; and<br>
R12 is independently at each occurrence -hydrogen or -(C1-C7) alkyl.<br>
4. The compound as claimed in claim 1. represented by formula ic:<br><br>
or a pharmaceulically acceptable sali thereof wherein:<br>
Y is-O-.-S-. or-(.)-(.'[ h-:<br>
0- D- and T are carbon:<br>
Rl is -hydrogen:<br>
R2 is -hydrogen:<br>
R3 and R4 are -hydrogen;<br>
R5 is hydrogen:<br>
R14 is<br>
-(C|-C12) alk% 1. -((.&gt;C|~;)cycloalkyl. -(C^-C11-)cycloalk\ ]-(C,-C, &gt;) alkyl. (("-<br>
C[2)alkcnyl. -((.';,-("i;icycloalkenyl, -helerocycloalkyl. -heieroeycloalky -(C'K'r.)<br>
alkyl. -(C':-Ci:)cilkynyl. or -((VCtj)cyeloalkynyl;<br>
wherein -(C1-('i:) alkyl. -((';-C12)c&gt;cloalky 1. -(C,^-C12)cycloalky]-(C1-C12) alky I.<br>
-(C1-Cn)alkenyl. -((/;-( 1 
C'i:)alkyl. -((.VCi:&gt;)alkyn\ I. or -(C,s-C12)cycloalkynyI are each optionally<br>
substituted with one to three halogens:<br>
R6 and R7 are independently<br>
-hydrogen, -halogen, -hydroxy. -CN. -(C1-CN)alkoxy. -(CVCNialkenyl. -((V<br>
C?)alkyl.-(('3~C-)cyeloalkyl. or -(CVC^heteroeycloalkyl.<br>
wherein -(('i-C-lalkoxy. -((.V(\)alkenyl. -(C1-C'7)alkyl. -((.yCMcycloalkyl. or -<br>
(C1-C;ihcteroeycloalkyl. are each optionally substituted with one to three<br>
halogens:<br>
provided however that wherein I) is nitrogen, then R6 or R7 are not attached to I).<br>
and provided that wherein T is nitrogen, tlien Ro or R7 are not attached to T. and<br>
provided that wherein Q is nitrogen, then R6 or R7 are not attached to (,). and<br>
wherein R6 and R7 may optionally form a six membered ring with the atoms to<br>
which they are attached, and the ring so formed may optionally contain up to two<br>
oxygens, and further the ring so Conned may optionally be substituted with up to<br>
four halogens;<br>
R8 and R9 are independently al each occurrence<br>
-hydrogen, -hydroxy. -CN. -nitro. -halo. -((VCvjalkyl. - I' - -(C1-C.'7)alkoxy. -{('}-<br>
CY)cycIoalkyl. -C(0,)R12. -COOR12. -0('(())R 12. -OS(O):R12. -N(R12K -<br>
NRI2C(()) R12. -K R12S()2 R12. -SR12. -S(O)RI2. -S(())2 R12. or -<br>
S(OhN(R12)2; wherein -(C1-C7)alkyl. -iC|-C7)alkoxy. -(CyCYlcycloalkyl, are<br>
each optionally substituted with from one to three halogens:<br>
R10 is independently -hydrogen:<br>
Rl 1 is independently at each occurrence<br><br>
\\ herein the zig-zag mark represents the point of attachment to the Rl 1 position in<br>
formula 1: wherein A. G. and I:' independently represent carbon or nitrogen,<br>
provided that no more than two of A. G, and h are nitrogen:<br>
provided however that wherein A is nitrogen, then R8 or R are not attached to<br>
A, and provided that wherein Ci is nitrogen, then R8 or Rl) are not attached to (i.<br>
and provided that wherein I: is nitrogen, then R8 or R9 are not attached to I'; and<br>
RI2 is independently at each occurrence -hydrogen or -(.C1-C7) alkyl.<br>
5. The compound as claimed in claims 1-4. wherein D. X. (v) and T are carbon.<br>
6. The compound as claimed in claims 1-5. wherein A, (i. and 1' are carbon.<br>
7. The compound as claimed in claim 1. selected from the group consisting of:<br>
(R.S)-3-(! 5-[ l-(4'-'l"riiluorometh} l-biphenyl-4-yloxy (-propyl |-thiophene-2<br>
carbonylJ-amino)-propionic acid;<br>
(R.S)-3-( f5-| l-(4'-Trifluoromethyl-biphcnyl-4-ylox\ )-butyl |-thiophene-2-carbonyl J -<br>
aminoi-propionic acid:<br>
(R.S)-.l-f [5-fl-(4'-TrinLioromethyl-l'&gt;iphenyl-4-yloxy')-elhvl |-thiophcne-2-carbonylJ-<br>
amino)-propionic acid:<br>
(R.S)-3-( {5-|l-(4'-1 nHiioromethyl-bipheny]-4-yloxy)-hcxyl |-thiophcnc-2-earbonyi;-<br>
amino)-propionic acid:<br>
(R.S)-.!-( ! .v|C"yelohexyl-(4'-lriniioroniethyl-biphenyl-4-yloxy)-nieth\l[- thiophene-2-<br>
carbonyl J -amino)-propionic acid:<br>
(R.S)-3-({5-[2.2-Dinielhyl-l-(4'-tnlliioroniethyl-biphenyl-4-ylo\y-)-propyl|- thiophene-2-<br>
carbonyl j -amino)-propionic acid:<br>
(R.S)-3-( 15-[3.3-Diine4hy l-l-(4'-triJlLK&gt;r()incthy!-biphen\ l-4-yloxy )-hut\ l|-thiophenc--2-<br>
carbonyl }--aniino)-propionie acid:<br>
(R.S)-3-(!5-|4-Methyl-l-(4'4rillLiommethyl-biphcnyl-4-yloxy)-pentyl]-ihiophene-2-<br>
carbonyl J -amino)-propionic acid:<br>
(R.S)-3-(f5-|l-(2.0-I)imethyl-4'-tritluoroniethyl-biplienyl-4-yloxy)-2.2- dimethyl-prop\ 11-<br>
thiophene-2-carbony] J -aminoj-propionic acid:<br>
(R.S)-3H!3-[l-(2ivl)iniclhy|-4'-irilluon)niclhyl-biphcnyl-4-yl()Ny)-3..1- dimctln 'l-bun 11-<br>
Uiiophenc-2-carbonyl { -aminoj-propionic acid;<br>
(R.S)-3-( !5-|3.3-l)imclhy1-l-(2Hncthyl-4'-irinuoroniciliyl-biphonyl-4-yloxy)-butyl]-<br>
lbiophcne-2-carbonyl \ -aminoj-propionic acid;<br>
(R-S)-3-C!5-|l-(4,-tct-t-Buiy]-2MmethyI-bipheiiyl-4-ylo\y)-3,3-dimelhyl-bLitylJ-lhiophcnc-<br>
2-carbony I}-amino (-propionic acid;<br>
(r<.s j></.s>
thiophcne-2-earbonyl)-aniino| -propionic acid:<br>
(R.SJ-3 -|(5- j 1 - |6--(4-tort-I"Ji!lyl-phenyl)-pyndin-3-yloxy| -3 .3 -dimcihyl-butyl | -<br>
tliiophene-2-carbonyl)-amino]-propionic acid;<br>
(R.S)-3-({5-|l-(4,-tcTl-lkil\l-2-nicHhyl-biphcn&gt;l-4-yloxy)-2.2-tlimcHhyl-propyl|-<br>
thiophcne-2-carbonyl \ -aminos-propionic acid;<br>
(R.S)-3-( [5-|2.2-I)irixnh\-|-l-(2-nKnhyl-4'-trinuoromt;lhyl-biphenyl-4-yloxy)-pmpyl|-<br>
thiophcne-2-carbonyl ! -amino(-propionic acid;<br>
(R.S)-3-( [&gt;j l-(4'-tert-Bulyl-2-mcth\ l-biphenyl-4-yloxy)-pi'opyl |-thiophene-2- carbonyl; -<br>
aminoj-propionic acid;<br>
(R.S)-3-(|5-[l-(2-\1cfh&gt;l-4'-triniH)io]ncthyl-biplKMiyl-4-ylox})-propyi|-ihi()phenc-2-<br>
carbonyl J -aminoj-propionic acid;<br>
(R.S)-3-(l5-|l-(2.6-Dimclhyl-4,-lrinuoromcthyl-biplicnyl-4-yioxy)-propyl [-thiophcnc-2-<br>
carbonyl J -aminoj-propionic acid;<br>
(R.S)-3-(!5-[l-(4'-lcrt-lkily]-2/&gt;dinKUhyl-bipiuinyl-4-yloxy)-propy]J-thiophcnc-2-<br>
carbonyl ) -aminoj-propionic acid:<br>
(R.S)-3-({5-|l-(2jv])inicthyl-4,-trinuor(Miictliyl-biphe!iy]-4-yk)xy)-3-riKUhyl- butyl |<br>
tliiophenc-2-carbonyl j -aminoj-propionic acid:<br>
(R.S)-3-(!5-|l-(4'-tcrt-Butyi-2i)-dinKl:hyl-biphenyl-4-yl()xy)-2.2-diiT)cthyl-pr()p\l|-<br>
thiophene-2-carbonvI \ -aminoj-propionic acid:<br>
3-{(5-(4'-lcr!-lkilyl-2J&gt;dinieihyl-biplKaiy]-4-y]ox\iiicthyi)-tbiophcnc-2-carbon&gt;l |-<br>
aininoj -propionic acid:<br>
(R.S)-3-( {5-[3-MclhyI-l-(2-nictliyI-4'-Lri(lucM-omcthy4-biphenyl-4-&gt;loxyj-l-)i]iyl]-<br>
thiophenc-2-carbonyl ) -aminos-propionic acid;<br>
(R.S)-3-(;5-[l-(4,-kMn-IU!tyl-2-nic{liyl-biphcnyl-4-yloxy)-3-nielJiyl-butyl)-tlii()phciK'-2-<br>
carbonyl ] -aminoj-propionic acid:<br>
3-([5-[lM4'-Triiluon&gt;inctIiy|-biphcn)l-4-yl()xy)-cth\l|-lhiophcnc-2-carbonyl}- amino)<br>
propionic acid. Isomer 1:<br>
3-( J 5-| l-(4'-Tlritluoromcthy]-biphon\i-4-yk).\y )-clh&gt; 1 |-lhiophene-2-carbonyl j -amino)-<br>
propionic acid, isomer 2:<br>
3-(\5-| l-(4,-Trinuorometliyl-biphen\i-4-ylo\\ )-propyl |-lhiophene-2-eai'bonyl | -amino)-<br>
propionic acid. Isomer I:<br>
j-({5-|l-(4'-TnnuoixMTicthy]-biplKNiy]-4-yloxy)-propyl|4hi()phenc-2-carlx)nyl)-amino)<br>
propionic acid. Isomer 2:<br>
3-( |5-| l-(4'-1 ri fluoromethy]-biphcnyl-4-yloxy)-bulyl|-thic)phenc-2-carb()nyl}-aniino)-<br>
propionic acid. Isomer 1;'<br>
3-( ;5-|l-(4,-'IYifliR-)n)nKHbyl-biphciiyl-4-yloxy)-bulyl|-ihiophcnc-2-carbunyl}-aiiiin())-<br>
propionic acid. Isomer 2:<br>
3-( |5-|2.2-1 !)inuuhyl-l-(4'-lrinuoroiiicihyl-biphcnyl-4-yloxy)-propyl|-thi(&gt;phcnc-2-<br>
carbonyl !-aniino)-propionic acid. Isomer I:<br>
3-f ;5-[2.2-Dinulhyl4-(4,4rillu(H'()iiiethyl-biphenyl-4-yloxy)-].M'opyl]-l.hiophcnc-2-<br>
carbonyl [-aminoj-propionic acid. Isomer 2:<br>
3-( (5-|3..VDimclhyl4-{4'-trilluon)iiiethyl-biphcnyl-4-yloxy)-butyl|-ihiophcnc-<br>
2-carbonyl)-amino (-propionic acid. Isomer 1:<br>
3-(S5-[3.3-[)imcthyl-l-(4,-trinuoromelh\l-biphenyl-4-ylox} (-butyl ]-thiophenc-<br>
2-carbonyl}-amino)-propionic acid. Isomer 2;<br>
3-({5-|2.24)imelhyl-l-(2-metliyl-4'-trinuoromethyl-biphenyl-4-yloxy)-propyl|-<br>
thiophene-2-carbonyI !-amino)-propionic acid. Isomer 1:<br>
3-( (5-|2,2-Dimetbyl-l42-mclhyl-4'4n11iioromethyl-biphenyl-4-yloxy)-propyl|-<br>
thiophene-2-carbonyl;-aniino)-pi'opionic acid. Isomer 2;<br>
3-( 15-|l-(4'-lerl-f5ulyl-2-nieihyl-biphenyl-4-yloxy (-propyl |-thiophcnc-2-carbonyl{-<br>
amino)-propionic acid. Isomer 1:<br>
3-(,' 5-| l-(4'-terl-Biil\ l-2-mclliyI-biphenyl-4-yloxy(-propyl |-tbiophcne-2-carbony I \ -<br>
amino (-propionic acid. Isomer 2:<br>
3-( {5-|3.3-Dimcthyl-l-(2-i)ielliyI-4'-iritliioroniclh\i-biphciiyl-4-yloxy)-bLil\"l|-tliiopbt,ne-<br>
2-carbonyl |-amino)-propionic acid. Isomer 1:<br>
3-( !5-|3.3-Diniethyl-l-(2-nKlhyU4'-trilliK)n)!nelh&gt;l-bipiKmyl-4-yloxy)-buiyl[-thiophene-<br>
2-carbonylj -aminoj-propionic acid. Isomer 2:<br>
3-( j5-|3.3-Dimelhyl-l-(2-iTielliyl-4'-tnnLi()romcthyl-biplicnyl-4-yioxy)-biityi]- ihiophenc-<br>
2-carbonyl}-amiiio)-propionie acid. Isomer 1:<br>
3-( j5-f3J-Dimctliyl-1^2-iTiothyl-4'-irinuoromctliyl-bipluMiyl-4-yloxy)-bLityi]- thiophene-<br>
2-carbonyl)-amino (-propionic acid. Isomer 2:<br>
3-( i5-| l-(2.6-Dimethyl-4'-tri(luoi\imcthyl-bi phenyl-4-yloxy)-propy I ]-thiophene-2-<br>
carbonyl j-amino)-pi'opionic acid. Isomer 1:<br>
3-( !5-|l-(2.6-Dimctliyl-4'-irillu()nHiiethyl-biphLMiyl-4-yk)xy)-propyl|-tliiophene-2-<br>
carbonyl) -amino(-propionic acid. Isomer 2:<br>
3-( [5-[l-(4'-tert-Fkilyl-2i)-diinclhyl-biphi;nyl-4-ylo\y)-pr()pyl|-lhiophent,-2-carbonyl!-<br>
amino)-propionic acid. Isomer 1;<br>
(R.Sl-3-( J?-[2-Mcthyl-l-(4'-irilluoromelhyl-biphenyl-4-yloxy)-propyl|- thiophcne-2-<br>
carbonyl | -amino)-propionic acid;<br>
(R.S)-3-( |5-|2-Methyl-l-(4'-trilluoronie)liyl-biplien\l-4-yk)xy)-propyl|-lhii)phene-2-<br>
carbonyl \ -amino)-propionie acid:<br>
3-( [5-|2-Meth\l-l-(4'-irinuoromethyl-biphenyl-4-\loxy (-propyl j-thiophene-2- carbonyl |-<br>
amino)-propionic acid. Isomer 1:<br>
(R.S)-3-(!5-[3-Metbyl-l-(4'-triflu(imrnetliyl-biphenyl-4-\U)xy)-biUyl|-thi()phene-2--<br>
carbonyl |-amino)-propionic acid. Isomer 2;<br>
(R.S)-3-( 15-[l-(4,-TianiK&gt;roniclhyl-biphenyl-4-yloxy)-oet\l|-thiopheiie-2-carbonyl J -<br>
amino)-propionic acid;<br>
3-( f5-|l-(4'-'l"t'illiiorometliyl-biphen\ l-4-yloxy)-oct\ l]-thiophene-2-carbonyl j-amino)-<br>
propionic acid. Isomer I:<br>
3-([5-|4-(4'-Tnnu
propionic acid, Isomer 2:<br>
(R.S)-3-({5-|l-(2.6-Dinicthyl-4'-irinu()roiT)ethyl-biphenyl-4-yloxy)-3.3- dimethyl-butyl |-<br>
thiophene-2-carbonyl { -amino(-propionic acid:<br>
3-( j5-[l-(2/)-I.)imetliyl-4'-iriniu&gt;ronielh\l-bipheny1-4-ylo.xy)-3.3-dimcthyl-biityl|-<br>
thiophene-2-carbonyl]-amino (-propionic acid. Isomer 1:<br>
3-( j5-|I-(2,6-DinKUhyl-4'-tiiniioromeihyl-biphenyl-4-yloxy)-3.3-dimetliyl-biityi|-<br>
thiophene-2-carbonyl!-amino)-propionic acid, isomer 2:<br>
(R.S)-3-(i3-Chloro-5-|l-(2,6-(liiiiethyl-4'-trilluoronunhyl-biphenyl-4-yloxy)-pn)pyl|-<br>
lhiophcne-2-carbon) 1! -amino(-propionic acid;<br>
(R.S)o-(i5-|l-(4'-tcrl-But&gt;i-2.6-dinic{liyl-biphenyi-4-ylox\ )-4.4.4-trilluoro-bul\-r]-<br>
thioplic-nc-2-earbonyl \ -aminoj-propionic acid:<br>
(R.S)-3-( {o4,l-(2i&gt;DinuUi\vl-4'4rilluoronictl\v14.iiplK&gt;n\I-4-\1oxy)-2-mcthyl-propyl|-<br>
thioplienc-2-carbonyl J -amino)-propionic acid;<br>
(R.S)-3-( |5-|2-Mcth\l4-(2-!iicthyl-4'4rif]iH)roiiicdiyl-biphcnyl-4-yloxy)-pi'opyi|-<br>
diiophene-2-carbonyl J -amino)-propionic acid:<br>
(R.S)o4I54,lH-^&gt;I5iniclhyl-4'4rilluoromcthyl4iiplKiiyl-4-yloxy)4iutyl|-thioplicnc-2-<br>
carbonyl j -aminoVpropionic acid:<br>
(R.S)-3-( f5-|l-(2-VIclhyl-4'-lrinuon)mcthyi-biphenyl-4-yl()xy)4nut\-| |-lliiophenc-2-<br>
carbonyl J --aminoVpropionic acid:<br>
(R.S)-3-( {5-|l-(4,-icrt-Hulyl-2.6-diinclhyl-biphcny]-4-ylox&gt;-)-2-mctIiyl- propyl]<br>
thiophcne-2-carbonyl \ -amino-propionic acid;<br>
3 4 {5-[144'-teil-fkily10.(vdimolliyl-biplKMiyl-4-yloxy)-2-riioihyl-pr()pyl|-thiophL,iie-2-<br>
carbonyl|-amino)-propionic acid. Isomer I:<br>
3-( (5-f]-(4'-icMn-fiu(y]-2.6-dimoihyl-biplieiiyl-4-yloxy)-2-niethyl-propyl |-ihiophcnc-2-<br>
carbonyl|-aminoVpropionic acid. Isomer 2:<br>
(R.S)-3-(!5-[l-(4'-lcrt-Butyl-2-iriclliyl-bipl)ca)yl-4-yloxy)-2-nK&gt;thyi-propyI|-thioplK&gt;nc-2-<br>
carbonyl J -aminoVpropionic acid:<br>
3-( {5-| l-(4'-tcrl-Buly]-2-mc-th} 'l-biphciu 1-4-vIoxy )-2-mcthyl-prop) I|4hiopbene~2-<br>
carbony] [-aminoVpropionie acid. Isomer 1:<br>
3-( |5-|l-(4,-lert-lkilyl-2-nieth} l-biphcnyi-4-&gt;loxy)-2-mcth_\ 1-prop} l|-thiopbenc-2-<br>
carbony]}-aminoVpropionic acid. Isomer 2:<br>
(R.S)-3-( !5-[l-(4'-!ert-lkilyl-2.6HlinK'th}l4^iphcnyl-4-yl()xy)-butyl]-t.hiophcne-2-carbop,\l<br>
! -amino)-propionic acid;<br>
(R.SV34 (5-| 1 -(4'-tcrt-[k.il:yl-2-niel:hyl-biphcnyl-4-yloxy)-bulyl |-tbiophene-2-carbonyl J -<br>
aminoVpropionic acid:<br>
(R.S)-3-( j5-| l-{2.6-I)imcth\ 1-4-iriiluoromeiliyl-biphciiy 1-4-yloxy )-cthyi |-tliiophcne-2-<br>
carbonyl J -amino)-propionic acid:<br>
(R.S 1-34 [5-[l-(4'-tcn-[kilyl-2.6-diiiiclhyl-biphonyl-4-y](&gt;xy)-et1iyl|4hioplic-ne-2-carbonyl<br>
| -amino)-propionic acid:<br>
(R.S)-3-([5-|l-(2.6-[')imcUiyI-4'-tnIluoi\)rncth\ l-biphenyV4-yloxyj-peniyl|4hiophene-2~<br>
carbonyl } -aminoVpropionic acid:<br>
(R.S)-3-( ;5-[l~f2-Mcihyl-4'-tiiniH)ron]cthyl4iiphcnyl-4-yloxy)-pcnlyl|- thiophcne-2-<br>
carbonyl j -aminoj-propionic acid:<br>
(R.S)-3-( !5-|l-(4'-lcrl-Iiutyl-2.6-dimclhyl-|-iiphcnyi-4-\ lox\ )-penlyl|-lhiophene-2-<br>
carbonyl J -aminoj-propionic acid:<br>
(R.S)-3-([5-|l-(4'-tcrt-liuty]-2-mcthyi-bi|Mienyl-4-yloxy)-pcntyl|-thiophenc-2- carbonyl 1-<br>
aminoj-propionic acid:<br>
3-( [5-l2-(2ivDiinelhyl-4'-liiniH)n.)mcthyl-biphciiyl-4-y]oxy)-lJ-dimethyl-dhyl]-<br>
thiophenc-2-carbonyl J -aminoj-propionic acid:<br>
3-( |5-| 1 -(2.6-I&gt;imc:tliy i-4'-iri nuoroincthyi-bipheny 1-4-y loxymcthy 1 )-l -clhy l-propyl |-<br>
diiophenc-2-earbonyl \ -amino(-propionic acid;<br>
3-( !5-|l-(2/&gt;l)imcihyl-4'-triniioroniclhyl-biplKnyl-4-yloxymethyli-l-propyl- butyl j-<br>
thiophcnc-2-carbonyI]-amino(-propionic acid:<br>
3-( |5-| 1-Ally 1-1 -(2,6-dimcthyl-4'-lritluoromethyl-biphcnyl-4-yloxymcUi_\ l)-but-3-cnyl |-<br>
lhiophcne-2-carbonyl } -aminoj-propionic acid;<br>
3-( (5-[1-(2X)-r)iniclhy1-4'-lrilluoronunhyl-biphcnyl-4-yloxynicthy1)-cycl
Uiiophene-2-carbonyl{-aminoj-propionic acid;<br>
3-(]3-|l-(2i^-l)inKliiyl-4,-trinuoron)cUiyl-biphcnyl-4-yloxyniethyrj-cyclopentyl|-<br>
thiophene-2-carbonyl ]- aminoj-propionic acid;<br>
(R.S)-3-( 15-| l-(4-Bronio-3.5-dimcthyl-phcnoxy)-3-mcthyl-butyl |-tliiophcnc-2-<br>
carbonyl j-aniino)-propionie acid:<br>
(R.S)-3-({5-|l-(3.5-DinK&gt;thyl-phcnoxy)-3-nicdiyl-butyl|-tldophenc-2-carbonyl]-aniinoJ-<br>
propionic acid;<br>
(R.S)-3-( ^5-|l-(4-l}n)ni()-3.5-diniclhyl-phenylsuiranyl)-4.4,4-trifluoro-butyl|- tbiophcne-<br>
2-carbonyl J -aminoj-propionic acid:<br>
3-( (5-[l-(2/vDimcthyl-4'-lriIILumMiictliy1-biphenyl-4-yioxy)-2-mcthyl-propyl |-<br>
thiophcnc-2-carbonyl! -aminoj-propionic acid. Isomer 1;<br>
3-( [5-[l-(2/)-I)imcihyl-4'-trilluoronicdiyl-biphcnyl-4-yloxy)-2-niclhyl-pr(')pyl |-<br>
thiophcnc-2-carbonyl]-aminoj-propionic acid. Isomer 2:<br>
(R.S)-3-( [5-lI-(2.6-Dimethyl-biphcnyl-4-ylox\ )-3-mcthyl-butyl|-diiophcnc-2- carbonyl j-<br>
ami no J- prop ionic acid:<br>
(R.S)-3-({5-[1-('4,-itTt-Hi!tyl-2.o-clinicil\vl-biplionyl-4-ylo\y)-3-nietliy]-buiyl]- ihiophcnc-<br>
2-carbonyl j -aminoj-propionic acid:<br>
(R.S)-3-(!5-|'l-(2.6-DinKnhyl-2'4rillu<iromcthv1-biphcny></iromcthv1-biphcny>
lhiophene-2-carbonyl ] -amino (-propionic acid;<br>
(R.S)-3-( !5-|l-(2.6-l)imothyl-3'-lrinuoroinclhyl-biplKMiyl-4-yloxy )-3-methyUbutyI]-<br>
thiophene-2-carbonyl j -aniino)-propionic acid;<br>
(R.S)-3-(f5-llH4'-I"-Lh\M-2.6-dinic1h&gt;1-biphenyl-4-y]oxy)-3-meLliyl-biily]|-thiophenc-2-<br>
carbonyi j -aminoj-pmpionic acid;<br>
(R.S)-3-(f5-[j-Mclhyl4-(2i^4'4riiiitnhy1-biplK-nyi-4-yio\y)-butyl|-iliioplione-<br>
2-carbon)4 j-amino)-propionic acid:<br>
(R.S)-3-( [5-[l-(4'-Isc)|&gt;i\)py|-2.^&gt;-ciinictli\ l-biplieriyl-4-yl\y)-.3-nielhyl-bviiyI |- thiophcnc-<br>
2-carbonyl; -amino)-propionic acid;<br>
(R.S)-3-( [ 5-| l-(2.6-S)imcthy l-4'-pcnt&gt; l-biphcnyl-4-\ loxy )-3-niclhyl-bul&gt; 11- thiophene-2-<br>
carbonyi ! -amino)-propionic acid.:<br>
(R.S)-3-( [54,l44'-('ycdohcxylO.()<limcthyi4iiphenyl-4-yu></limcthyi4iiphenyl-4-yu>
thiophene-2-carbonyl ! -aminoj-propionic acid;<br>
(R.S)-3-(!54il-(4'-(\vano-2/)-dinicLliy14^iphcny1-4-y1oxy)-3-mclhyNbuiy]|-lhiophcnc-2-<br>
carbonyi j -amino)-propionic acid:<br>
(R.S}-3-( {5-[1-(2.6-[)iniclhy4-4'Mriniioixiniclht&gt;xy-biphcn\,l-4-yloxy)-3-i'ncthy'l-bLity'] |-<br>
lhiophcnc-2-carbonyl J -amino)-propionic acid:<br>
(R.S)-3-( !54,lH;4,4'.)imcth\4aniincv2.6
lhiophene-2-carbonyl J -amino)-propionic acid:<br>
(R.S)-3-[(5- { 14,4H5-Acelyl-thiophcn-2-yl)-3.5-dimcthyl-pheiioxy|-3-mcthyl- butyl; -<br>
tbioplicne-2-cai"bonyl)-amino|-pi'opionic acid:<br>
(R.S)-34,(5-(l4i445-Cyano-thiophcMi-2-yl)-3.5-dimcthyl-phcnoxy|-3-nit,thyl- buiylj<br>
tliiophcnc-2-carboiiyh-ainino|-prc)pi()iiic acid:<br>
(R.S)-3-( [54id-(3.54)imcihyl-4-iliiophon-3-yl-plicno\y)-3-metliyl4Hiiyl|- thiophenc-2-<br>
carbonyl j -aminor-propionic acid;<br>
(R.S)-3-( !5-|l-(4'tcri4iinyl-2.6-dinicihyl-biphcnyl-4-ylsLdi'anyl)-4.4.4- trifhioro-bulyl| -<br>
ihiophcnc-2-carbonyl J -amino(-propionic acid;<br>
(R.S)-34[54,]42/&gt;Dimothy]-4,-triniioroiTKHhyl4jipluNiyl-4^ylsulfaiiyl)-4.4.4- trilliioro-<br>
butyl|-lhiophcnc-2-carbonyl | -amino(-propionic acid;<br>
(R.S)-3-{. (5-f l-f2.6-I )inicth\-1-4'-irifluorome-ihybbiphenyl-4-yloxy)-444- irifluoro-bulyl |-<br>
thiophcne-2-carbonyl J -amino)-propionic acid:<br>
3-( (5-|l-(4'-lcrt-liutyl-2.6-diincthyl-biphcnyl-4-yl()\y)-4.4.4-tvinuoro-bulyl |- thiophcne-<br>
2-carbonyl}-amino)-propionic acid. Isomer 1:<br>
3-( i 5-| l- )-4.4.4-trifluoro-bulN 11- thiophene-<br>
2-carbonyl}-amino (-propionic acid. Isomer 2;<br>
3-(i5-|l-(2.(&gt;l)inielhyl-4'-irinuoix)nielliyl-biphenyl-4-yloxy)-4,4.4-trilluoro- butyl |-<br>
thiophenc-2-carbonyI j -amino)-propionic acid. Isomer 1:<br>
3-( J 5- [ I -(2.6-IJimcMhyl-4'-trinuoronicthyl-biphenyl-4-yloxy)-4.44-trifluoro- butyl |-<br>
thiophcne-2-earbonyl \ -amino (-propionic acid. Isomer 2:<br>
3-( |5-|l-(2/)-I.)initnliyl-4'-txilluoix)niclhoxy-bipheiiyl-4-yloxy)-2-methyl- propyl |-<br>
thiophcne-2-carbon\l] -amino (-propionic acid. Isomer 2;<br>
3 -(' ' 5- | 1 -(4'-lsopropyi-2.6-diniethyl4iiphcnyl-4-yloxy)-2-mcthyl-propyl|- thiophenc-<br>
2--carbonylj-amino (-propionic acid. Isomer 2:<br>
(R.S)-3-( ;5-|l-(4,-teri-lkityl-2.b-dinicthyl-biphenyl-4-ylox})-2-melhyl-propyi|-<br>
thiophenc-2-carhonyl | -amino )-2i'.'-hydroxy-propionic acid:<br>
(R.S)-3-( {5-[l-(2/)-DinKHhyl-4'-lrinuoromelhyl-biphcnyl-4-yloxy)-2-mcthyl-propyl|-<br>
lhiophene-2-carbony! 1 -amino)-25'-hydroxy-propionic acid;<br>
(R.S)-3-(!5-|l-(4'-lert-Butyl-2,()-diiT)ethyl-biphenyl-4-yloxy)-2-melhyl-pn)pyr|-<br>
thiophene-2-carbonyl ] -amino)-2&gt;S'-hydroxy-propionic acid;<br>
3-(! 5-|l-(4'-tcrt-Butyl-2-mcthyl-biphcnyl-4-yloxy)-butyl]-thiophene~2-earbonyl | -amino)-<br>
propionic acid. Isomer 1:<br>
.V({5-[l-(4Mert-lkiLyl-2-metliyl-biphcnyl-4-\"loxy)-butyl|-thiophenc-2-carbonyl j-amino)-<br>
propionic acid. Isomer 2:<br>
3-( !5-| i-(4'-tcrt-Butyl-2.6-dimethyl-biphcnyl-4-yloxy)-ethy] |-thiophcne-2-earbon\ 1| -<br>
amino)-propionic acid. Isomer 1:<br>
3-( ;5-|l-(4,-tert-Bulyl-2.6-diirietliyl-biphen_\il-4-ylo\y)-ethy]|-thi()phene-2-carboii&gt;l1,-<br>
amino)-propionic acid. Isomer 2;<br>
3-( |5-[l-(4'-tert-Butyl-2.6-dinictliyl-hiphenyl-4-yloxy)-butyl|-thiophene-2-carbonyl J-<br>
amino)-propionic acid. Isomer 1:<br>
3-( J 5-[l-(4'-tert-ButyI-2.6-dimethy!-biphenyl-4-yloxy)-but\i |-thiophene-2-carbonyl) -<br>
aminoj-propionic acid. Isomer 2;<br>
3-( [5-|]-(2.6-I)inielliyl-4l-trilluon)nicthyl-biphenyl-4-yloxy)-peniyl|-tliiophcnc-2-<br>
carbonyl]-amino)-propionic acid. Isomer 1:<br>
3-(l5-('l-('2.6-r)imethyl-r-trinuuromclhyl-biphcnvl-4-yl()x\)-pent\ 1 |-thiophene-2-<br>
carbonylj-aniinoj-propionic acid. Isomer 2:<br>
3-( {5-|l-(2.6-I')iincthyl-4'-trinu(&gt;romciliyl-biphcnyl-4-ylo\\ )-2-mothyl-propyl|-<br>
thiophene-2-carbonyl j -amino)-?..'.'-hydroxy-propionic acid. Isomer 1;<br>
3-(f5-|l-(2j&gt;r)imethyi-4'-trinuoi'omcthyI-bipheny]-4-yloxy)-2-niethyl-propy]|-<br>
thiophene-2-carbonyl ;-amino)-2?-hydrox}-propionic acid. Isomer 2;<br>
3-( f5-|l-(2.6-[)iinctliyi-4'-tnnuovomethyi-biphcnyl-4-ylox\ )-2-niethyl-propy]|-<br>
tliiophene-2-earbonyl j -amino)-2.S-hydroxy-propionic acid. Isomer 1;<br>
3-( \5-\ l-(2.6-Dimclhyl-4'-tvinuoromethyl-biphcnyl-4-yloxy)-2-niclhyl-pr(&gt;pyl]-<br>
thiophcne-2-carbonvl] -amino)-2.S'-hydroxy-propionic acid. Isomer 2:<br>
3-! !5~|l~(4'-tert-Buiyl-2.6-dimcdiyl-biphenyl-4-ylox_\ )-2-mcthyl-propyl]-lliiophene-2-<br>
carbonyl j-amino l-2R-hydrox\-propionic acid. Isomer 1:<br>
3-( |5-|l-{4'-tert-Butyl-2ivdimethyl-hiphenyl-4-yloxy)-2-niethyl-propyl|-thiopliene-2-<br>
carbonyl ] -amino)-2/'.'-hydroxy-propionic acid. Isomer 2:<br>
3-f ;5-|l-('4'-tei1-Bulyl-2.6-dinKMhyl-biphcnyl-4-yloxy)-2-nielhyl-propyl|-Uiiophene-2-<br>
carbonyl} -amino i~25'-hydrox\-propionic acid. Isomer 1;<br>
3-( j5-[l-f4'-terl-Butyl-2.6-diniediyl-bi|4ienyI-4-yloxyV2-nieUryl-propyI)-thHiphene-2-<br>
carbonyl]-aniino)-25'-h\droxy-propionic acid. Isomer 2;<br>
3-(f5-|l-(4Mcit-lkityl-2.6-diniclhyl-biphcnyl-4-yloxymcthyi)-l-ctliyl -propyl ]-thiophenc-<br>
2-carbon\ 1 { -aminos-propionic acid:<br>
3-( [5-|l-(4'-tert-lk[ty!-2.6-dimethyl-biphenyl-4-yloxymelhyl)-propylJ-thiophene-2-<br>
carbonyl J -amino)-propionic acid:<br>
3-( [ 5-|l-(2.6-Dimethyl-4'-trinuoromethyl-biphenyl-4-\ loxymethyl (-propyl]- ihiophene-<br>
2-carbony! ] -aminoj-propionic acid:<br>
3-( [5-|l-(4'-iert-I-kily1-2J)-diiiicthyl-biphcnyl-4-yloxynicthyl)-propyl|-llii(&gt;phenc-2-<br>
carbonyl}-amino(-propionic acid. Isomer 1:<br>
3-( j5-|l-(4'-tcrt-Butyl-2.6-dimcdiv!-biphcnyl-4-ylox\ methyl (-propyl |-thiophcne-2-<br>
carbonyl j-aminol-propionic acid. Isomer 2:<br>
3-( J5-| 1-C2.6-1 )imcthyi-4'-triilLioromethy 1-biphcny 1-4-yloxyinclhx I}-pr<.ipx thiophcne-2-></.ipx>
carbonyl]-amino(-propionic acid. Isomer I:<br>
3-( J 5-| l-(2,6-Dimethy 1-4 '-tri 11 iioromei.hyl-hiphenyl-4-yloxy methyl (-propyl)- thiophene-<br>
2-carbonyl J-amino(-propionic acid. Isomer 2:<br>
.?-([5-[l-(4'-leil-Bulyl-2.6-dinicihy]-biphcnyl-4-yU).\y)-paipyl]-4-ch]oro-thiophcnc-2-<br>
carbonyl ] -aminoj-propionic acid:<br>
3-(}5-|l-(4'-lcrl-BLilyl-2.6-cliniclhyl-biplicnyl-4-ylsuUaiiy! )-cthyi|-tliiopheno-2-carb(.&gt;n&gt;"I I<br>
-amino)-propionie acid;<br>
3-( J 5-| l-(4'-tert-Bniyl-2.6-dimeth&gt;i-biphenyl-4-yisiiiranyl )-cth&gt; l|-diiophene-2-carbonv!J-<br>
amino)-propionic acid:<br>
3-( !5-|I-(2/i4)iiiic!hyl-4'-tri!1uoromclliyl4ii|Mieny]-4-ylsulfanyl)-22-dimethyl-propy!|-<br>
tliiophene-2-carhonyl] -amino (-propionic acid:<br>
3-1 [5-f l-(2.640iniclhyl-4'-(iillu
bul\ 1 |'thiophcnc-2-carbonyl \ -amino(-propionic acid:<br>
3-( |5-[l-(4'-tort-IUilyl-2/&gt;-diinclhyl-biplK'nyl-4-yisiiiranyl)-clh&gt;l|-lhiopliciic-<br>
2-earbonyi!-aminoj-propionic acid. Isomer 1:<br>
3-( 1&gt;-| l-(4'-tert-Buty l-2.(vdimethyl~biphen\i-4-y!sulfanyl j-ethyl |-tbiophcnc-<br>
2-carbonyl J-aminoj-propionic acid. Isomer 2:<br>
3-( [5-[]-(2,64')imclh\ l-4'-lri!luuic)niclhy l-biphenyl-4-y lsLiiranyl)-2,2-clinicthyl-propyi |-<br>
lhiophenc-2-carbonyl j-amino (-propionic acid. Isomer I:<br>
3-( !5-|l-(2.64)imelhyl-4'-{iilluc)r(in:ethy!4r&gt;iphonyl-4-ylsuinmyl)-2.2-dinictliyl-propyi |-<br>
thiophene-2-carbonyl! -amino(-propionic acid, Isomer 2:<br>
3-( !5-|l-{2.6-Ii)inicthyl-4'-tiMiluoixiiincthyl-biphcny4-4-ylsiilfanyl)-3.3-dimcthyl-butyl |-<br>
thiophene-2-cai'bonyl j -aminoj-propionic acid:<br>
3-f[5-|i-(2.(v[)imcth)'I-4'-tiMllu()i()mcthyl-bipheiiyl-4-ylsuiranyl)-pentyl|-thiopheiic-2-<br>
carbonyl j -amino)-propionic acid:<br>
3-(!5-|l-(2/vI)imethyd-4[4rinuiMX)niclhyl-bipbcnyl-4-ylsulIanyl}-butyl]-thiophenc-2-<br>
carbonyl J -aminoj-propionic acid:<br>
3-( !5-|l-(2/)-r)imediyl-4,-t:rinui&gt;roniLnbyl-biphenyl-4-ylsuiranyr)4iutyl]-Uiiophcnc-2-<br>
carbonyl J-amino (-propionic acid. Isomer 1:<br>
3-( !5-|l-(2/)4)imediyl-4,4rillLioroniediyl-biphen\l-4-vlsLd!anyl)4ui!yl]-Uiioplicnc-2-<br>
carbonyl J -amino (-propionic acid. Isomer 2:<br>
3-( !5-|l-(2.6-Diniethvl-4,-trinLioronKnl\vl-biphenyl-4-vloxy)-3-metliyl-but\i|- thiophene-<br>
2-carbony] J-aminoj-propionic acid. Isomer 1:<br>
3-( ;5-[1-(2.6-I')imetli\l-4'-lrillLit)r()iricihyl-biphcnyl-4-yloxy)-3-melhyI-bLity]|- ihiophene-<br>
2-carbonyl {-aminoj-propionic acid. Isomer 2:<br>
3-( {5-|l-(4'4cn-Bulyl-2/)-ciinKMliyl-biplKMnyl-4-ylox\0-2.2-dinicthyl-propyl|-thiophcnc-2-<br>
carbonyl]-amino)-propionic acid. Isomer 1:<br>
3-(! 5-| l-(4'-lert-l'kityl-2.6-clinicth\ l-bipluaiyl-4-yloxy)-2.2-di methyl-propyl |-thiophene-2<br>
carbonyl|~amino)-propiome acid. Isomer 2:<br>
3-(!5-|l-(4'-tert4kityI~2.6-diiiicthyl4Tiphenyl-4-ylo\y)-propyl|-thiophene-2- carbonyl |-<br>
aminoVpropionic acid. Isomer 1:<br>
3-([5-|l-(2.6-[timothyl-4'-innu()roniethyl-biphenyi-4-yloxy)-biuyl|-thiophcno-<br>
2-carbonylj-aminoVpropionic acid. Isomer 2:<br>
3-( !5-|l-(2.6-[)inielhyl-4'-i:iMnuoiX)nKM:hyl4iiphenyl-4-yloxy)-butyi|-(hiophene- 2-<br>
carboml [-amino)-propionic acid. Isomer 1:<br>
3-( ;5-|l-(4'-ls()propyl-2.6Hlinieiliyl-biphLNtyl-4-yloxy)-biityi|-thiophene-2-carbi)nylJ-<br>
amino (-propionic acid. Isomer 2;<br>
3-( !5-[l-(4'-lsopropyl-2.6<linieiliyl-bipheny1-4-yloxy>phcne-2-carboiiyl j -<br>
amino)-propionic acid. Isomer 1:<br>
3-( (5-|l-(2i)-r)inicihyl-4'-trinuoronieihoxy-biphenyl-4-yk)xy)-bulyl|-ihiophcnc-2-<br>
carbonyl]-amino)-propionic acid. Isomer 2:<br>
3-({5-|l-(2.6-I.)intelhyl-4'-lril'lu()r()niLHhoxy-biphen\l-4-yloxy)-butyl|-thiophenc-2-<br>
carbonvl)-aminol-propionic acid. Isomer 1:<br>
3-( 15-| 1 -(4'-lerl-lknyl-2.6-diMieih\ l-bipheiiy]-4-ylsu]raiiyl)-2.2-dimelh}']-pi"()pyl |-<br>
lhiophenc-2-carhony];-amino (-propionic acid. Isomer I:<br>
3-(|5-| l-(4'-tei1-Butyl-2.6-dimeUi\l-biplKaiyl-4-ylsullanyl)-2.2-diniethyl-propyl)-<br>
thiophene-2-carbonyI j -amino)-propionic acid. Isomer 2:<br>
3-(^&gt;|I-(4'-1ert-lkityl-2.6-diinetliyl-biphenyl-4-ylsullanyr)-3,3-diinethyl-butyl!-<br>
thiophene-2-earbonyl \ -amino (-propionic acid. Isomer 2:<br>
3-( !5-|l-(4'-tert-F3iityl-2.6-dinKlliyl-bipheny|-4-ylsulianyi)-3-inethyl-but\l|- thiophene-2-<br>
carbonylj-amino(-propionic acid. Isomer 1:<br>
3-( \5-\ l-(4'-lert-lk!tyl-2.6-dinielhyl-biphenyl-4-ylsuiranyl)-3-methyl-but)l|-thiophene-2-<br>
carbonyl j-amino(-propionic acid. Isomer 2:<br>
3-( !5-|l-(4'-Isopropyl-2.6-tliniethyl-biphen\l-4-ylsultanyr)-2-methyl-propyl|-lhiophene-<br>
2-carbonyl j-amino)-propionie acid. Isomer 1:<br>
3-( |5-|l-(4'-Isopn)pyl-2.6-dinK,lhyl-biphenyl-4-ylsull'an\l)-2-melhyl-propyl|-thiophene-<br>
2-carbonylJ-amino)-propionie acid. Isomer 2;<br>
3-(!5-|l-(4'-tcTt-Bulyl-2/)H)inicihyl-biplieiiyl-4-ylsLillaiiyl)-pn)pyl]-ihioplicne-<br>
2-carbonyIj-amino)-propionie acid. Isomer 1:<br>
3-( { 5-f 1 -(4'-tcrt-Ikny 1-2iwiiincthyl-biphcnyl-4-ylsillt'anyii-propy] |-lhiophciic-<br>
2-carbonylj-amino (-propionic acid. Isomer 2:<br>
(R.S)-3-(!5-[l-(4'-lerl-lkuyl-2j&gt;dinieihyl-bipheiiyl-4-ylsu]lkiyl)-2-methyl-propyl|-<br>
thiophenc-2-carbonyl J -amino j-propionic acid:<br>
{R.S)-3-f {5-[l-C-4'-tcrt-Buiyi-2.6-ditnethyl-biphenyl-4-ylsulfanyn-2.2-dmT[Cthvl-propyl |-<br>
thiophcnc-2-carbonyl J -amino (-propionic acid:<br>
(R.S)-3-('f5-|4-(4'-terl-HuLyl-2ivdiiiielhyl-bipheiiy1-4-ylsiillaiiy1)-3.3-diriK'thyl-biityl|-<br>
Lhiophene-2-carbonyl ] -amino)-propionic acid:<br>
(R.S)-3-( ( 5-| l-(4'-lcTt-lkityi-2.6-dimclhyl-biphcnyl-4-ylsiiiranyl)-3-metbyl- butyl ]-<br>
thiophcne-2-carbonyl | -aminos-propionic acid;<br>
3-( J5-|l-(4'-lert-Ikilyl-2.(vdimeihyl-biplic'nyl-4-ylsulianyl)-l-iTiethyl-i.&gt;ihyl|- lhiophene-2-<br>
carbonvl | -aminos-propionic acid;<br>
(R.S)-3-(;5-[l-(2/}-l)iniclliyl-4l-lrinuor()niciliyl-biphcnyl-4-ylsulIanylVpr()pyl|-<br>
lhiophene-2-carbonyl | -amino)-propkmic acid:<br>
(R.S)-3-({5-|1-(4'-lcrt-l-kityl-2.6-climcthyl-biplK,nyl-4-ylsuiranyI)-propyl|- thiophene-2-<br>
carbonyl j -amino)-propionic acid:<br>
(R.S)-3-( j5-|l-(4'-lcrt-lkiiyl-2.()-dimctliyl-biphcnyi-4-ylsuiranyl)-4.4- dimelhybpeniyi j-<br>
lhioplienc-2-carbony! j amino)-propionic acid:<br>
(R.S)-3-( |5-|l-(4'-lsopropy l-2.6-dimeth\ 1-biphcnj i-4-ylsnlfanylJ-2-mcthy 1- propyl]-<br>
thiophene-2-carbony| ; -amino)-propionic acid:<br>
(R.S)-3-( ^5~[l-(4'-tcrt-Bi!lyl-2.6-dinicHhyl~bipheny!-4-\isulfaiiyn-bulyl |- lhiophene-2-<br>
carbonyl J -amino)-propionic acid:<br>
(R.S)-3-((5-|l-(4'-tcr!:-Hulyl-2/)-dinielhyl-biphenyl-4-&gt;lsiillanyl)-pc!ityl|- thiophene-2-<br>
carbonyl J -amiiio)-propionic acid:<br>
3-( [ 5-|444- Trilluoro- 1 -
thiophene-2-carbon\ Ij-aminol-propionic acid. Isomer 1;<br>
3-( |5-[444-Triniioi\i-l-(4'-isopropyl-2.6-dimt:lliyl-biphcnyl-4-yloxy)-bulyl|- thiophenc-<br>
2-carbonylJ-amino)-propionic acid. Isomer 2:<br>
3-( (5-|l-(2.6-l)imc'thyl-4'-trilliion)nu'lho.\y-biphcn\1-4-yloxy)-4.44-lrinuoro- bulvl j-<br>
lhiopliene-2-carbony IJ -amino )-propionic acid. Isomer 1:<br>
3-({5-[l-(2&gt;6-Dini6thyl-4,-trifluoromethoxy-biphenyl-4-yloxy)-4,4,4-trifluoro- butyl]-<br>
thiophene-2-carbonyl}-amino)-propionic acid, Isomer 2;<br>
3-({5-[l-(4'-Etliy[-2.6-dimethyl-biphenyl-4-ylox:y)-4,4,4-triiluoro-butylJ- thiophene-2-<br>
carbonyl]-amino)-propionic acid, Isomer 1;<br>
3-({5-[I-(4'-Ethyl-2.6-dimethyl-biphenyl-4-yloxy)-4,4.4-trifluoro-butyl]- thiophene-2-<br>
carbonyl}-aniino)-propionic acid, Isomer 2;<br>
3-({5-tl-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yls.ilfanyl)-4.4,4-trifluoro-butyl]-<br>
tliiophene-2-carbonyl}-arnino)-propionic acid, Isomer I; and<br>
3-({5-[l-(4'-ten-Butyl-2,6'-dimethyl-biphenyl-4-ylsilfanyl)-4.4,4-(rifluoro- butyl]-<br>
miophene-2-carbonyI}-amino)-propionic acid, Isomer 2;<br>
or a pharmaceutical!}' acceptable sail or solvate thereof.<br>
8. A pharmaceutical composition of compounc.s as claimed in claims 1-7 and a<br>
pharmaceutically acceptable carrier.<br><br><br><br>
A compound structurally represented by Formula 1<br><br>
or a pharmaceutically acceptable salt thereof as glucagon receptor antagonists.<br></linieiliyl-bipheny1-4-yloxy></...></ijmeuiyl-biphenyl-4-ytsulfanyi></llmethyl-biphenyi-4-yloxy></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1mb3JtIDE4LnBkZg==" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1nZmEucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-gfa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1wY3QgcmVxdWVzdCBmb3JtLnBkZg==" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-pct request form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDI4NzYta29sbnAtMjAwNy1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">02876-kolnp-2007-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUFCU1RSQUNUIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-ABSTRACT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUFTU0lHTk1FTlQgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-ASSIGNMENT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUNMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LURFU0NSSVBUSU9OIChDT01QTEVURSkgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-DESCRIPTION (COMPLETE) 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVCBSRVBMWSBSRUNJRVZFRCAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-EXAMINATION REPORT REPLY RECIEVED 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gMSAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 1 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gMTggMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 18 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gMiAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 2 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gMjYucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gMyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 3 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gMyAxLjIucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 3 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gNSAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 5 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUZPUk0gNSAxLjIucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-FORM 5 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LU9USEVSUyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-OTHERS 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LU9USEVSUyAxLjIucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-OTHERS 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-PETITION UNDER RULE 137-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVCAxLjEucGRm" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-REPLY TO EXAMINATION REPORT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mjg3Ni1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">2876-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDI4NzYta29sbnAtMjAwNy5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-02876-kolnp-2007.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="251604-stabilized-unsaturated-polyster-resin-mixtures.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="251606-front-cowl-attaching-structure-in-a-motorcycle.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>251605</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2876/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>13/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>30-Mar-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>26-Mar-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>07-Aug-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ELI LILLY AND COMPANY</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>LILLY CORPORATE CENTER, INDIANAPOLIS, STATE OF INDIANA 46285, UNITED STATES OF AMERICA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CHAPPELL MARK, DONALD</td>
											<td>541 PITNEY DRIVE, NOBLESVILLE, INIDIANA 46062</td>
										</tr>
										<tr>
											<td>2</td>
											<td>TRIPP, ALLIE, EDWARD</td>
											<td>219 BYRKIT STREET, INDIANAPOLIS, INDIANA 46217</td>
										</tr>
										<tr>
											<td>3</td>
											<td>ZHU, GUOXIN</td>
											<td>SHANGHAI CHEMEXPLORE CO. LTD. NO 10 BUILDING, 965 HALEI ROAD, PUDONG NEW AREA, SHANGHAI 201203</td>
										</tr>
										<tr>
											<td>4</td>
											<td>CONNER, SCOTT, EUGENE</td>
											<td>8426 CAREFREE CIRCLE, INDIANAPOLIS, INDIANA 46236</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 333/24</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2006/004461</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2006-02-09</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/652,492</td>
									<td>2005-02-11</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/251605-substituted-thiophenes-as-glucagon-receptor-antagonists by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:49:44 GMT -->
</html>
